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1 Introduction 
1.1 GABA transporters as pharmacological targets 
GABA transporters of the SLC6 gene family 
The solute carrier (SLC) group comprises more than 400 membrane-bound proteins 
that exhibit a pivotal role by carrying soluble molecules such as ions, nutrients and 
signaling molecules across lipid cell membranes in a secondary active transport (that 
is by utilizing an electrochemical gradient of a co-substrate).1 Members of the solute 
carrier 6 (SLC6) gene family are amongst the most important neurotransmitter 
transporters widely expressed in the mammalian brain. These SLC6 transporters 
translocate several substrates including γ-aminobutyric acid (GABA; 1; Figure 1), 
dopamine, glycine, norepinephrine, and serotonin by utilizing a sodium- and chloride-
dependent cotransport trough cell membranes. By removing such neurotransmitters 
from the synaptic cleft, SLC6 transporters can effectively terminate downstream 
neurotransmitter signaling and thus are important regulators of homeostatic processes.  
 
Figure 1: Structure of the neurotransmitter γ-aminobutyric acid (GABA; 1) 
 
The SLC6 gene family can be divided phylogenetically into four subfamilies, i.e. in 
monoamine, GABA, amino acid and amino acid/orphan transporters.2 GABA is the 
most important inhibitory neurotransmitter in the mammalian central nervous system 
(CNS) and amongst the GABA transporters (GATs) from the SCL6 gene family, four 
different subtypes of membrane-bound proteins have been cloned. The GABA 
transporter subtypes are designated as GAT1, BGT1, GAT2 and GAT3 according to 
the Human Genome Organisation (HUGO). However, there is a notable degree of 
inconsistency in the nomenclature in dependence on the species from which the 
transporters are cloned;i for instance, the four subtypes are termed mGAT1 (≙ GAT1), 
mGAT2 (≙ BGT1), mGAT3 (≙ GAT2) and mGAT4 (≙ GAT3), when expressed in mice 
                                                          
i Throughout this thesis the HUGO nomenclature is generally applied for the different GABA transporter 
subtypes except when a GAT subtype from a particular species should be emphasized, e.g. for detailing 
experimental conditions. 
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(see Table 1).3,4 GATs consist of 599–632 amino acids2,5 and, based on sequence 
identity, GAT1 diverges most from other subtypes, while BGT1 and GAT2 are 
phylogenetically most closely related to each other.4  
 
Table 1: Nomenclature of GABA transporters across species with the gene and HUGO nomenclature 
being highlighted 
 Gene name: SLC6A1 SLC6A12 SLC6A13 SLC6A11 
 HUGO: GAT1 BGT1 GAT2 GAT3 
s
p
e
c
ie
s
 Human: hGAT1 hBGT1 hGAT2 hGAT3 
Mouse: mGAT1 mGAT2 mGAT3 mGAT4 
Rat: rGAT1 rBGT1 rGAT2 rGAT3 
 
Affinities of GABA and localizations of the transporters differ distinctly amongst the 
individual GAT subtypes. GAT1, GAT2 and GAT3 bind GABA specifically and with high 
affinity, whereas BGT1 is characterized by a lower affinity and transports also betaine 
as substrate.5 Regarding localization, GAT1 and GAT3 are predominately found in the 
mammalian brain usually in vicinity to GABAergic synapses,2,6,7 where GAT1 is mainly 
located on presynaptic neurons and GAT3 on astrocytes. Hence, GAT1 mediates 
neuronal GABA uptake, while GAT3 is responsible for GABA uptake into glial  
cells.8–10 Conversely, BGT1 and GAT2 are only weakly expressed in most parts of the 
mammalian brain and are currently assumed to have greater physiological importance 
in peripheral organs such as kidney and liver.11 So far, GAT1 is the best studied GABA 
transporter, while the elucidation of the physiological role of other GAT subtypes is 
retarded due to a lack of highly potent and selective inhibitors (see section 1.2).  
 
GABAergic neurotransmission and pathophysiology 
It is estimated that about 30–40% of all neurons in the mammalian CNS utilize GABA 
as their primary neurotransmitter12 and at least 40% of inhibitory processing at 
synapses in the brain is mediated by GABA.13 These numbers doubtlessly 
demonstrate the physiological importance of GABA as inhibitory neurotransmitter. 
In the adult mammalian brain, GABA is principally synthesized from glutamate in a 
single step catalyzed by glutamate decarboxylase (GAD)14 and loaded into synaptic 
vesicles by means of a vesicular neurotransmitter transporters (VGAT) for storage.15 
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After liberation from presynaptic neurons by a calcium-dependent exocytosis into the 
synaptic cleft, GABA can address its corresponding pre- and postsynaptic receptors, 
which can be differentiated into two main types. Ionotropic GABAA receptors, mostly 
located on postsynaptic neurons, represent ligand-gated chloride channels; upon 
activation by GABA they allow an influx of chloride ions, which leads to 
hyperpolarisation and finally deactivation of the postsynaptic neuron. Metabotropic 
GABAB receptors, located on both pre- and postsynaptic neurons, represent G-protein 
coupled receptors (GPCRs) acting in two different mechanisms. Activated presynaptic 
GABAB receptors reduce the calcium current and subsequently decrease 
neurotransmitter exocytosis; thereby these receptors serve as a negative feedback 
mechanism for GABA release. In contrast, activated GABAB receptors with 
postsynaptic localization stimulate potassium outward currents and thus again 
hyperpolarize and deactivate the corresponding neuron.15 The extracellular GABA 
concentration is regulated by the aforementioned GABA transporters (GATs) and 
accordingly GABAergic neurotransmission is terminated by the neurotransmitter 
reuptake into neurons and surrounding glial cells. Finally, GABA can be recycled or 
metabolized by enzymatic degradation catalyzed by GABA transaminase (GABA-T).15 
In principal, this described GABAergic neurotransmission is illustrated in Figure 2. 
 
 
Figure 2: GABAergic neurotransmission according to Owens and Kriegstein.15 GABA is synthesized 
from glutamate (via GAD), loaded into vesicles (via VGAT) and released to the synaptic cleft by 
exocytosis, where it can bind to pre- and postsynaptic GABAA and GABAB receptors. Neurotransmission 
is terminated by neuronal or glial reuptake (via GATs) and recycling or metabolizing (via GABA-T) of 
GABA 
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Given the physiological importance of GABA, it is not surprising that pathologically 
impaired GABAergic neurotransmission is associated with a number of neuronal and 
psychiatric diseases such as epilepsy,16-18 Parkinson’s disease,18,19 Huntington’s 
disease,18,20 Alzheimer’s disease,21 depression22,23 and neuropathic pain.24,25 For 
treatment, reduced GABAergic neurotransmission can be adjusted by two basic 
principles, i.e. by directly stimulating GABA receptor activity or by enhancing GABA 
concentration. Currently approved drugs address several major targets: For instance, 
benzodiazepines such as diazepam (2; Figure 3) and barbiturates such as 
phenobarbital (3) are positive allosteric modulators of ionotropic GABAA receptors, 
while metabotropic GABAB receptors are activated by baclofen (4). Vigabatrin (5) 
prevents the enzymatic degradation of GABA as a suicide inhibitor of GABA-T and 
tiagabine (6) increases the GABA concentration in the synaptic cleft by a selective 
inhibition of GAT1. Novel targets associated with GABAergic neurotransmission and 
diversely more experimental compounds are continuously explored in order to find 
potentially new drugs as recently reviewed by Kowalczyk and Kulig.26  
 
 
Figure 3: Structures of approved drugs targeting the GABAergic system 
 
GAT1-selective tiagabine (6) is the only GAT inhibitor in clinical use. It was approved 
as an anticonvulsant medication for the add-on treatment of partial-onset seizures;27,28 
however, the use of tiagabine (6) is accompanied by a number of side effects including 
dizziness, asthenia, nervousness, tremor, diarrhea, and depression that limit its 
applicability.29,30 By the application of potent and selective inhibitors such as tiagabine 
(6) GAT1 emerged as a well-known target mediating anticonvulsants effects. 
Conversely, the pharmacological potential of non-GAT1 GABA transporter subtypes is 
still less well understood but more recently published evidence implies that particularly 
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BGT1 and GAT3 could be promising new targets for the treatment of epilepsy and 
other neurological disorders such as anxiety and pain.2,3,7 According to the World 
Health Organization (WHO), epilepsy affects about 50 million people worldwide, 
making this disease one of the most prevalent neurological disorders globally.31 
Although there were more than 15 antiepileptic drugs introduced in the last decades, 
about one-third of patients continue to have seizures despite receiving medication and, 
generally, antiepileptic treatment is often associated with several complex psychiatric 
side effects.32 Hence, there is an ongoing need of developing new antiepileptic drugs 
and evaluating novel molecular targets. 
 
1.2 GABA uptake inhibitors 
Development of GABA uptake inhibitors 
Since the discovery of an active transport system for GABA in the late 1960s, there 
have been extensive efforts by medicinal chemists to synthesize and establish 
selective GABA transporter inhibitors.33 In the early development the Amanita 
muscaria mushroom constituent muscimol (7; Figure 4), which can be considered a 3-
isoxazolol bioisostere of GABA (1), was found to inhibit GATs, but it also targets 
GABAA receptors and GABA-T. Due to these multiple effects the use of 7 as a tool 
compound is limited; however, it served as a lead structure for structural variations.4 
Inspired by the structure of muscimol (7), the compounds 4,5,6,7-
tetrahydroisoxazolo[4,5-c]pyridin-3-ol (THPO; 8), and later nipecotic acid (9) and 
guvacine (10) were evaluated as more selective GAT inhibitors and found to exhibit 
moderate potency at defined GAT subtypes without targeting GABAA receptors.4,33 The 
(R)-enantiomere of nipecotic acid [(R)-9], in particular, still represents one of the most 
potent small, substrate-related GAT inhibitors known up to date33 and it is commonly 
utilized as a starting point for the development of more potent, larger GAT inhibitors. 
Nipecotic acid (9) displays inhibitory potencies in a similar order of magnitude at all 
GAT subtypes except BGT1, at which it is distinctly less active. However, due to their 
hydrophilicity nipecotic acid (9) and related small, cyclic amino acids are not capable 
of crossing the blood-brain barrier and thus are nearly inactive in vivo upon peripheral 
administration.34  
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Figure 4: Structures of small substrate-related GAT inhibitors 7–10  
 
The attachment of a bulky, lipophilic 4,4-diphenyl-3-butenyl residue to the cyclic amino 
acid moiety led to the discovery of a new generation of GAT inhibitors, with the 
nipecotic acid derivative SK&F-89976A (11; Figure 5) being one of the first 
representatives of this kind of compounds.35 This new generation of GAT inhibitors is 
characterized by a general amphiphilic structure, that is a lipophilic, aromatic moiety 
attached to a hydrophilic amino acid “head”. The increased lipophilicity allowed these 
compounds to penetrate the blood-brain barrier. Further representatives of this 
generation of GAT inhibitors are the aforementioned tiagabine (6), which is the only 
GAT inhibitor in clinical use (see section 1.1), and the guvacine derivative NO711 (12). 
The lipophilic attachments in these compounds 6, 11 and 12 further enhanced 
potencies at and selectivities for GAT1 over other GABA transporter subtypes 
compared to their unsubstituted parent compounds nipecotic acid (9) and guvacine 
(10). Hence, compounds 6, 11 and 12 represent orally active, selective and potent 
GAT1 inhibitors with inhibitory potencies at this GABA transporter subtype in the upper- 
to mid-nanomolar range.36,37 More recently, guvacine derivative DDPM-2571 (13), a 
new GAT1-selective compound, was synthesized in our group; it was found to exceed 
the inhibitory potency of tiagabine (6) at GAT1 by more than one log unit and mediated 
anticonvulsant, anxiolytic, antidepressant and antinociceptive effects in mouse 
models.38 3-Hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazols (exo-THPO) 
derivative 14 represents an example of a selective GAT1 inhibitor with micromolar 
potency structurally more diverse from aforementioned compounds 6 and 11–13.39 
Conversely, another, closely related exo-THPO derivative, EF1502 (15), is inhibiting 
the two transporter subtypes GAT1 and BGT1 with similar potency40 and this 
compound was found to mediate anticonvulsant effects in vivo with a mechanistic 
profile distinctly different from tiagabine (6).41  
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Figure 5: Structures of GAT1 inhibitors 11–15 
 
Apart from these GAT1-selective and mixed inhibitors several synthetic approaches 
also led to the discovery of compounds with selectivities towards non-GAT1 GABA 
transporters. The nipecotic acid derivative (S)-SNAP-5114 (16; Figure 6) represents 
the first prototypic inhibitor with moderate potency at and selectivity for GAT3.42 Later, 
chemically more stable carba analogs of this trityloxy derivative 16 could be 
synthesized by our group, of which DDPM-1457 (17) displays a similar potency at 
GAT3.43 These compounds 16 and 17, which possess a 4,4’,4’’-trimethoxytrityl residue 
as lipophilic moiety, demonstrate that the choice of the aromatic domain can influence 
the selectivity for the GABA transporter subtypes. Besides such nipecotic acid derived 
compounds, a series of isatin derivatives including compound 18 was more recently 
reported representing a new class of GAT3 inhibitors.44 Furthermore, 
bicyclo[3.1.0]hexane derivative 19 was proposed being the first highly selective BGT1 
inhibitor45 and compound 20 represents a lately published example of a selective BGT1 
inhibitor with micromolar potency.46 
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Figure 6: Structures of non-GAT1-selective inhibitors 16–20 
 
Inhibitory potencies of selected GAT inhibitors, which were already tested in our group 
at the different GABA transporter subtypes, are displayed in Table 2. It is remarkable 
that the inhibitory potencies of best GAT1-selective inhibitors are clearly higher than 
those of GABA transporter inhibitors with selectivities towards other transporter 
subtypes. There is still a lack of highly potent, non-GAT1-selective inhibitors that could 
be employed as pharmacological tools for elucidating the therapeutic potential of these 
GAT subtypes. 
Classical GAT inhibitors with selectivities for either GAT1 or GAT3, which are derived 
from small cyclic amino acids such as nipecotic acid (9) and guvacine (10), typically 
exhibit amphiphilic structures: These compounds possess a hydrophilic amino acid 
“head” and a lipophilic aromatic moiety. The lipophilic residue is connected to the 
hydrophilic domain via a spacer attached to the nitrogen atom of the amino group. 
Hence, nipecotic acid and guvacine derived GAT inhibitors are usually substituted at 
the 1-position of the cyclic amino acid. 
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Table 2: Functional inhibitory potencies of selected GAT inhibitors tested in our group at the different 
GABA transporter subtypes cloned from mice 
 Inhibitory potencies (pIC50±SEM)a 
Compound mGAT1 mGAT2 mGAT3 mGAT4 
Tiagabine (6) 6.88±0.12 50%b 64%b 73%b 
(RS)-Nipecotic acid (9) 4.88±0.07 3.10±0.09 4.64±0.07 4.70±0.07 
(R)-Nipecotic acid [(R)-9] 5.19±0.03 3.39±0.05 4.76±0.05 4.95±0.05 
(S)-Nipecotic acid [(S)-9] 4.24±0.05 3.13±0.14 3.83±0.04 3.63±0.06 
Guvacine (10) 4.87±0.06 3.31±0.03 4.59±0.05 4.59±0.05 
SK&F-89976A (11) 6.16±0.05 3.43±0.07 3.71±0.04 3.56±0.06 
NO711 (12) 6.83±0.06 3.20±0.09 3.62±0.04 3.07±0.05 
DDPM-2571 (13) 7.90±0.09 4.31c 4.35c 4.07c 
(S)-SNAP-5114 (16) 4.07±0.09 63%b 5.29±0.04 5.65±0.02 
DDPM-1457 (17) 4.40±0.05 4.42±0.11 5.47±0.02 5.87±0.08 
18 4.53c 52%b 44%b 4.61c 
rac-24 4.58±0.10 108%b 68%b 76%b 
a For sake of comparability all listed inhibitory potencies derive from the biological tests of our research 
group based on [3H]GABA uptake assays with HEK293 cells stably expressing the different GAT 
subtypes mGAT1–mGAT4. Values are usually given as means±SEM from at least three independently 
performed experiments. 
b In case of low inhibitory potencies percentages are given that represent the remaining [3H]GABA 
uptake in presence of 100 µM test compound. 
c Obtained from less than three experiments and accordingly no SEM value is stated. 
 
Moreover, in the last years several attempts have been made to synthesize analogous 
compounds substituted in different positions of the cyclic amino acid moiety that were 
tested for their potential to inhibit GABA uptake. For instance, 5-substituted arecoline 
derivatives as well as the N-methyl guvacine derivative 21 (Figure 7) were synthesized 
by Müller-Uri et al.47 N’Goka et al.48–50 synthesized 6-substituted nipecotic acid and 
guvacine derivatives of which compound 22 showed an in vitro inhibitory potency of 
the GABA uptake at GAT1 comparable to that of compound 11. In our group, an 
asymmetric route was explored that led to the synthesis of 6-substituted nipecotic acid 
derivatives such as compound 2351 and, more recently, nipecotic acid and N-methyl 
nipecotic acid derivatives substituted in the 4-position (e.g. compound rac-24) were 
synthesized.52 However, in none of these approaches GABA uptake inhibitors as 
effective as N-substituted derivatives could be achieved. Only compound 22 showed 
a biological activity comparable to those of known GAT1-selective inhibitors 6, 11 and 
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12 in in vitro assays, but was nearly inactive in vivo, possibly due to an insufficient 
blood/brain concentration ratio.48 
 
Figure 7: Structures of GAT inhibitor derivatives with different substitution pattern and their inhibitory 
potencies as reported in literature [a) inhibitory effect on [3H]GABA uptake at synaptosomes according 
to reference47; b) inhibitory effect on [3H]GABA uptake at synaptosomes according to reference48; c) 
remaining percentage of [3H]GABA uptake in presence of 100 µM test compound at bovine GAT1 
according to reference51; d) inhibitory effect on [3H]GABA uptake at mGAT1 according to reference52] 
 
Structure of GATs and binding mode of GABA uptake inhibitors 
The elucidation of the binding mode of GABA uptake inhibitors at the corresponding 
transporters requires an understanding of the structure of GAT proteins. As a first 
example of a neurotransmitter-sodium symporter, GAT1, isolated from rat brain, was 
initially sequenced and cloned by Guastella et al.53 Since then, several homologous 
proteins were examined and it became evident that these amino acid and monoamine 
transporters, respectively, are consisting of twelve transmembrane helices (TMs), 
which are connected via both extracellular and intracellular loops.54 Finally, the 
successful crystallization of a bacterial leucine transporter LeuT in presence of its 
substrate leucine and two sodium ions, which was accomplished by Yamashita et al.,55 
revealed the actual three-dimensional structure. Despite having only 20–25% total 
sequence identity, the prokaryotic LeuT is generally considered a good model for 
eukaryotic SLC6 transporters,56 particularly since the sequences in the proximity of the 
substrate binding sites are substantially more highly conserved.57 The structure of this 
bacterial LeuT is illustrated in Figure 8. 
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Figure 8: Structure of LeuT from the bacterium Aquifex aeolicus according to Yamashita et al.55 
 
Amongst the 12 TMs, the first 10 TMs form the essential core of neurotransmitter-
sodium symporters and the region around the helical segments TM1 and TM6, which 
are arranged in an antiparallel orientation, comprises the binding site for the substrate 
and sodium ions.55 Based on these structural insights, Yamashita et al.55 furthermore 
proposed a general transport mechanism following a model of “alternate access”: The 
neurotransmitter-sodium symporters basically possess two “gates”, which can 
alternately allow access to the binding site from either the extracellular or intracellular 
side of the membrane bilayer. The gate towards the extracellular side is primarily 
defined by the amino acid side chains of Tyr108, Phe253, Arg30 and Asp404, of which 
particularly the latter two that can form a charged pair are highly conserved amongst 
neurotransmitter-sodium symporters. Conversely, the gate towards the intracellular 
side is composed of a larger region of the protein in the vicinity of the helical segments 
TM1a, TM6b and TM8. The transporter has to pass several conformations during 
transport and at least three major states can be defined: I) An “outward facing” state, 
at which the extracellular gate is open and the substrate can access the binding site, 
II) a “substrate occluded” state, at which both gates are closed and the substrate is 
trapped at the binding site, and III) an “inward facing” state, at which the intracellular 
gate is open and the substrate can leave the binding site towards the cytoplasm. This 
postulated transport mechanism is illustrated in Figure 9. In the original work of 
Yamashita et al.55 the “substrate occluded” state was crystallized. Meanwhile it was 
achieved to crystallize different states of LeuT basically supporting the proposed 
transport mechanism.58 Furthermore, the general structural resemblance of the 
prokaryotic LeuT with eukaryotic SLC6 transporters has been confirmed recently by 
achieving crystal structures of the dopamine transporter from Drosophila 
melanogaster59 and the human serotonin transporter.60  
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Figure 9: Postulated transport mechanism of LeuT according to Yamashita et al.55 
 
Since its crystallographic elucidation in the year 2005, the structure of LeuT was used 
as the base for homology modeling in several studies in order to create a three-
dimensional model of the human GAT1 (hGAT1). In this context, two investigations 
analyzed the binding of GABA (1) and small inhibitors such as nipecotic acid (9) 
towards hGAT1.61,62 Accordingly, the carboxylic acid function of GABA (1) is bound to 
one sodium atom and additionally fixed in a set of hydrogen bonds mostly mediated by 
the side chain OH group of Tyr140 and the backbone NH of Leu64 and Gly65. 
Furthermore, the GABA (1) amino function is encompassed in a different network of 
hydrogen bonds which includes side chain OH groups of Thr400, Ser396 and Tyr60 
as well as backbone carbonyl functions of Tyr60 and Ser396. The different substrate 
specificity of hGAT1 as compared to LeuT can mostly be explained by three amino 
acid mutations that result in slightly modified interactions, i.e. Ser256 to Gly297 at 
helical segment TM6a, Asn21 to Tyr60 at TM1a and Ile359 to Thr400 at TM8 (LeuT to 
hGAT1).62 Successive studies examined the binding of the larger inhibitor tiagabine (6) 
using homology modeling, docking and molecular dynamics simulations63 and 
compared the binding modes of small and large inhibitors.64 Nipecotic acid (9), as an 
example of a small inhibitor, addresses exactly the same binding site as GABA (1), 
which is termed S1 site, and also adapts a similar pose, in which the amino nitrogen is 
facing towards the intracellular side of the protein interacting again with Tyr60 in 
particular (Figure 10a). Conversely, the bindings of tiagabine (6) and related larger 
inhibitors differ remarkably from the aforementioned due to the presence of the bulky 
lipophilic side chain (Figure 10b): While the orientation of the carboxylic acid function 
is largely retained allowing strong interactions with Tyr140, the pose of the piperidine 
ring of the nipecotic acid moiety is switched with the amino nitrogen and the lipophilic 
residue facing towards the extracellular side of the protein. In this position the amino 
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function only forms hydrogen bonding interactions with the backbone carbonyl function 
of Phe294. The lipophilic aromatic residue, which is linked to the amino group via a 
spacer, is too large to fit in the S1 pocket and accordingly binds to an extracellular 
vestibule that is occasionally designated as S2 site. Hence, the binding of tiagabine (6) 
premises the gate towards the extracellular side to be opened and consequently GAT1 
is constrained in the “outward facing” conformation.63,64  
 
 
Figure 10: Binding of a) nipecotic acid (9; green) and b) tiagabine (6; cyan) towards hGAT1. The amino 
group of nipecotic acid (9) is interacting particularly with the backbone carbonyl function as well as the 
side chain of Tyr60, while the amino group of tiagabine (6) is interacting with the backbone carbonyl 
function of Phe294. The figure was prepared and kindly provided by Dr. Thomas Wein using our in-
house hGAT1 homology model refined by molecular dynamics calculations (see also references62,64) 
 
Based on these insights, a majority of GABA uptake inhibitors can be considered to 
inhibit GABA binding at GAT proteins in a competitive manner. Conversely, more 
recently described GAT inhibitors including compounds 14, 15, 18 and 20 (see above) 
have been proposed to exhibit a noncompetitive interaction mode at the corresponding 
GAT subtypes. For the sake of clarity, the term “noncompetitive” is commonly applied 
phenomenologically based on observed behaviours in functional assays throughout 
the literature without specifying the underlying mechanism. There are different 
mechanisms that can result in such noncompetitive behaviours, including an allosteric 
modulation as well as an inhibition by an irreversible or slow dissociating orthosteric 
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ligand.65 However, at least for some of these noncompetitive GAT inhibitors an 
allosteric modulation could be supported as underlying mechanism. 
For instance, a hypothetical allosteric binding site located between helical segments 
TM10 and TM11 at hGAT3 was revealed by molecular modeling studies for compound 
18, which was proposed as a noncompetitive GAT3 inhibitor.44 Besides, a potential 
allosteric binding site at TM10 of hBGT1 was evaluated for compound 20 by 
experimental studies using chimeric constructs of transporters with different 
pharmacological properties and computational studies based on a homology model of 
hBGT1.46 Still, the physiological role and the pharmacological importance of possible 
allosteric binding sites at the different GAT subtypes have yet to be established in 
future studies, for which noncompetitive GAT inhibitors might emerge as promising tool 
compounds. 
 
1.3  Developments of biological test systems for GAT inhibitors 
General test systems for GAT inhibitors 
The aforementioned, ongoing development of new GAT inhibitors is permanently 
accompanied by advancements of test systems enabling to elucidate the bioactivities 
of synthesized compounds. In this context, computational methodologies increasingly 
gain in importance for structure-activity studies and the rational design of novel 
bioactive compounds in general.66 And as outlined in section 1.2, in silico techniques 
such as homology modeling, docking and molecular dynamics simulations, have 
already been applied, in particular, to facilitate our understanding of GAT inhibitors and 
their interaction modes at the corresponding molecular targets. However, these 
computer-aided approaches are reliant on the input of concrete experimental data from 
appropriate bioassays in order to be able to generate precise predictions. 
Since the 1960s the functional activities of potential GAT inhibitors could be 
determined in uptake assays utilizing tritium-labelled GABA ([3H]GABA) and 
measuring radioactivity by liquid scintillation counting as read-out. In those early 
[3H]GABA uptake assays slices of rat cerebral cortex67 and later synaptosomal 
preparations were used as target materials.68 Though, such preparations were 
gradually replaced as target materials when cell lines transfected with the different 
GAT subtypes became available in the 1990s.69–71 In our group, a [3H]GABA uptake 
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assay was established and described in detail by Kragler et al.72 in 2005 that was 
based on the murine proteins mGAT1–mGAT4 transiently expressed in COS-7 and 
HEK293 cells, respectively. Later, this assay was transferred to a 96-well plate format 
in order to increase throughput and it was furthermore modified by using HEK293 cells 
that are stably expressing the murine GAT proteins.73 This latter assay is still routinely 
used in our group in order to evaluate functional activities and subtype selectivities of 
test compounds. In principle, intact cells expressing the corresponding transporter 
subtype are incubated with [3H]GABA in this kind of assay. If no inhibitor is present, 
GABA can be transported into the cytoplasm of the cells unaffectedly. The uptake is 
terminated by a filtration step and after removing the incubation medium the cells are 
lyzed to liberate the included [3H]GABA. Finally, the radioactivity of this transported 
[3H]GABA is quantified by means of liquid scintillation counting. Conversely, in case of 
an inhibitor being present the amount of transported [3H]GABA and consequently also 
the quantifiable radioactivity is reduced compared to the sample without inhibitor. By 
increasing the inhibitor concentrations, concentration-inhibition curves can be obtained 
from which the inhibitory potencies are calculable as IC50 values. As a more recent 
improvement, this principle concept of measuring GABA transport was transferred to 
a new kind of assay using mass spectrometry (MS) for quantification instead of the 
radiometric read-out in order to be devoid of all the drawbacks that result from using 
radioactive material. These so called MS Transport Assays were originally developed 
for all GAT subtypes in our group and described in detail by Schmitt et al.74,75 In 
contrast to the [3H]GABA uptake assays established in our group, these MS Transport 
Assays utilize the human equivalents of the four GABA transporters hGAT1–hGAT3 
and hBGT1, respectively, stably expressed in COS-7 cells. As native GABA is 
endogenously present in those COS-7 cells employed as the GAT expression system, 
deuterated (2H6)GABA is used as substrate to differentiate transported from 
endogenous GABA. 
In addition to the aforementioned functional assays, affinity-based assays are basically 
applicable to study target-ligand interactions. Due to their suitability to be used in high-
throughput screenings (HTS) they have become important tools in earlier stages of the 
drug discovery process.76,77 MS has emerged as a widely used read-out technique for 
affinity-based assays and several different MS based concepts have been evolved for 
this purpose including affinity selection-mass spectrometry (AS-MS) approaches that 
have a widespread application in drug screening.78 Besides the AS-MS techniques, 
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MS Binding Assays represent another example of affinity-based assays utilizing MS 
as read-out. MS Binding Assays may be considered as an improvement of the 
commonly used radioligand binding assays, as they can be employed analogously but 
without the requirement of a radio-labelled ligand, which is usually associated with an 
expensive production and relatively high safety standards.79 Instead of the radioligand, 
the binding of a native marker (MS marker) is quantified with high sensitivity by LC-
ESI-MS/MS (as a replacement for the scintillation counting). The marker is typically a 
well-known ligand with high affinity and selectivity towards the particular target. Like 
radioligand binding assays, MS Binding Assays are generally applicable for saturation, 
competition and kinetic experiments. The basic workflow of a competitive MS Binding 
Assay is outlined in Figure 11. In short, the test compound is incubated together with 
the target and the MS marker. Incubation is terminated by filtration (or alternatively 
centrifugation) in order to isolate the target-ligand complexes from unbound ligands. 
Then the isolated target-ligand complexes are denatured and eluted with methanol for 
liberation of the bound ligands. Finally, the MS marker formerly bound to the target, 
which among other compounds is present in the eluate, is quantified by LC-ESI-
MS/MS, serving as an indirect measure for the test compounds’ binding affinity towards 
the target (i.e. competitive replacement of the marker from the target by the test 
compound and accordingly a decreased amount of bound marker indicates high 
activity of the test compound and vice versa). Meanwhile, MS Binding Assays have 
been established by our group for several targets such as dopamine receptors80,81 as 
well as SLC6 transporters for serotonin,82–84 dopamine,83,84 norepinephrine,83,84 and 
GABA (i.e. mGAT1), the latter of which uses NO711 (12) as MS marker and membrane 
preparation of HEK293 cells stably expressing mGAT1.85,86  
 
 
Figure 11: Basic workflow of a competitive MS Binding Assay according to Zepperitz et al.85 
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Generation and MS based screening of pseudostatic hydrazone libraries 
More recently, a new kind of approach has been established in our group and 
described in detail by Sindelar and Wanner87 in 2012 that combines the generation of 
libraries by means of dynamic combinatorial chemistry (DCC) with the read-out of their 
binding affinities towards mGAT1 in competitive MS Binding Assays. 
Basically, dynamic combinatorial libraries (DCLs) are generated by a reversible 
combination of molecular building blocks of suitable reactivity to afford potential ligands 
for the corresponding target. Per definition, all DCL components are in a 
thermodynamic equilibrium, which requires the interconversion of library members into 
one another. Typically, simple and efficient chemical reactions are primarily applied for 
DCL generation, including acylhydrazone, disulfide, hydrazone, imine, or oxime 
formations.88,89 In the initial approach established in our group, hydrazone formation 
was utilized as DCC reaction of choice. The building blocks were designed to allow the 
generation of libraries composed of compounds structurally related to known GAT1 
inhibitors such as compounds 6 or 11 (see section 1.2). Accordingly, a nipecotic acid 
moiety was chosen as parent structure and substituted at the 1-postion with a spacer 
containing a terminal hydrazine function (affording compound 25). Reaction of this 
hydrazine building block 25 with diverse, mostly aromatic aldehydes 26 as 
corresponding, more lipophilic building blocks yielded the desired hydrazone libraries 
with general structures 27 (Figure 12). For library generation, the single hydrazine 25, 
which was converted with four individual aldehydes 26 per library, was applied in large 
excess compared to the total aldehyde concentration in order to obtain all library 
constituents in similar amounts (without the need of guaranteeing all components to 
be isoenergetic). In this manner an almost constant hydrazone library composition was 
achieved despite the dynamic nature, i.e. hydrazone libraries were rendered 
pseudostatic.  
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Figure 12: Condensation of hydrazine building block 25 (in excess) with diverse aldehydes 26 yielding 
hydrazones with general structure 27 as described by Sindelar and Wanner87 
 
Libraries were generated in the presence of the target mGAT1 to improve assay 
performance. After incubating the mixture of library building blocks and the target 
proteins for a time period sufficient to allow quantitative hydrazone formation, binding 
affinities of libraries were determined in an MS based screening (Figure 13). The 
screening was adapted from the competitive MS Binding Assays originally developed 
by Zepperitz et al.85,86 for the target mGAT1; however, instead of a single test 
compound hydrazone libraries containing several constituents were analyzed. For 
analysis, MS marker NO711 (12) was added to the incubation mixture and, after 
additional equilibration, the samples were further processed as described above to 
finally quantify the MS marker 12 by LC-ESI-MS/MS. The affinity of a particular library 
towards mGAT1 could be expressed accordingly as percentage of remaining NO711 
(12) binding with low values indicating highly active libraries and vice versa. If a library 
fulfilled the set “activity-criteria”, its most active components were identified by 
deconvolution, i.e. screening experiments were performed with single hydrazones 
instead of libraries containing several hydrazones. Finally, hits from the screening 
experiments were resynthesized in pure form and evaluated in full-scale binding 
experiments to establish their binding affinities as pKi values towards mGAT1. 
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Figure 13: Basic concept of the approach combining the generation of pseudostatic hydrazone libraries 
and analysis of binding affinities by competitive MS Binding Assays, modified from Sindelar and 
Wanner87 
 
In a first application serving as proof of concept study, nine libraries were applied each 
constituted with four individual aldehydes. This study yielded compounds with 
submicromolar affinity towards mGAT1 resembling yet known GAT inhibitors devoid of 
a hydrazone function in the spacer.87 Subsequently, a second application based on the 
same hydrophilic building block 25 converted with focussed aldehyde libraries derived 
from biphenyl-carbaldehydes revealed new compounds with even higher potencies.90 
Later, the concept of an MS based screening of libraries generated by DCC reactions 
was transferred to the application of oxime formation as means of linking building 
blocks.91 Oximes basically display a higher hydrolytic stability than hydrazones;92 
however, their formation requires a longer reaction time. Due to this lower reactivity, 
oxime formation was decoupled from the MS based screening and oxime libraries were 
generated in the absence of the target proteins by preincubating the corresponding 
building blocks for a sufficient time period. Notably, this approach, in which a guvacine 
instead of a nipecotic acid moiety was used as parent structure, revealed compound 
13 that is still one of the most potent GAT1 inhibitors known up to date (see section 
1.2).91 
Hence, the MS based screening of libraries generated by DCC reaction has already 
been proven to represent a powerful tool for structure-activity relationship studies with 
the capability of revealing new, highly potent GAT inhibitors. It enables to screen for 
the binding affinities of a diverse set of compounds without the need of synthesizing, 
isolating and purifying all individual components, thus saving expenditure of time and 
costs. Notably, the amount of individual components per libraries is not restricted to a 
certain number, although in those aforementioned, initial applications only four 
compounds per library were tested. In order to increase throughput, the library size 
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could easily be increased, particularly if it should be exclusively screened for highly 
potent compounds and thus the concentration of individual components is kept low.  
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2 Aims and scope 
In the research group of Prof. Klaus T. Wanner it is continuously aimed to closely 
connect the molecular modeling of ligand-target interactions, the organic synthesis of 
novel compounds and the biological testing of newly synthesized molecules as a 
medicinal chemical approach of developing advanced bioactive compounds. In an 
iterative manner, molecular modeling is used to interpret the structure-activity 
relationship of synthesized and biologically tested compounds in order to be able to 
design novel compounds with optimized potencies, which can then again be 
synthesized and evaluated for their biological activities. 
For an in silico screening, which was conducted previously by Dr. Thomas Wein using 
our in-house hGAT1 homology model, a virtual library derived from 4- and 5-substituted 
nipecotic acid derivatives was built. The hypothetical molecules were equipped with a 
biphenyl or diphenyl residue as lipophilic domain attached to the nipecotic acid moiety 
in the 4- or 5-position of the piperidine ring via a spacer with 3, 4, 5, or 6 carbon atoms 
and bearing a double bond in conjugation with the aromatic moiety. The results of this 
virtual screening at hGAT1 revealed that the substitution of nipecotic acid (9) 
particularly in the 5-position and with a five atom spacer (as in molecule 28; Figure 14) 
represents a possible means of obtaining GAT1 ligands with promising docking scores. 
 
 
Figure 14: Structure of hypothetical molecule 28 
 
Furthermore, docking calculations showed that in this hypothetical molecule 28 and 
related 5-substituted nipecotic acid derivatives the piperidine amino group was able to 
point towards the intracellular side of the binding site and could thus interact with two 
different hydrogen bond acceptors in this position, while the lipophilic residue would 
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point to the extracellular side of the pocket (Figure 15). So the binding pose of the 
piperidine moiety of 5-substituted derivatives would be more similar compared to that 
of the unsubstituted nipecotic acid (9) and opposing to that of tiagabine (6), of which 
the amino group and the attached arylalkyl moiety are facing towards the extracellular 
side (see section 1.2 and Figure 10). 
 
  
Figure 15: Binding of hypothetical molecule 28 towards hGAT1. The amino group of compound 28 is 
interacting particularly with the side chain of Asp396 as well as the backbone carbonyl function of Tyr60. 
The figure was prepared and kindly provided by Dr. Thomas Wein using our in-house hGAT1 homology 
model refined by molecular dynamics calculations 
 
Based on these in silico studies nipecotic acid derivatives substituted in the 5- instead 
of the common 1-position of the core structure were chosen as target structures of this 
thesis. These target compounds possessing a lipophilic residue attached to the 5-
position of the nipecotic acid moiety via a spacer should be evaluated as potential 
GABA uptake inhibitors. In order to be able to achieve a vast and easy to perform 
variety of lipophilic residues it was decided to analyze compound libraries generated 
by DCC following the approach by Sindelar and Wanner87 with mGAT1 as target (see 
section 1.3). Therefore, nipecotic acid derivatives were required as building blocks that 
were equipped with a hydrazine function (i.e. compounds with general structures 29–
31). These hydrazines 29–31 should then be converted with diverse aldehydes 26 to 
afford the corresponding hydrazones with general structures 32–34 (Figure 16). 
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Inspired by the results of the molecular modeling, particularly hydrazones 34 with a 
total spacer length of five atoms were desired as target structures, which required the 
nipecotic acid derived building block to possess a two carbon spacer (C2), at the end 
of which a hydrazine function is attached (i.e. hydrazines 31). However, also the 
shorter chained analogs with a total of four (i.e. 33) and three atoms (i.e. 32), 
respectively, which could be obtained from hydrazine building blocks with C1 (i.e. 30) 
and C0 spacers (i.e. 29), should be included in this thesis in order to allow a more 
comprehensive analysis of the structure-activity relationship of 5-substituted nipecotic 
acid derivatives. Notably, of all those nipecotic acid derived hydrazines 29–31 and 
hydrazones 32–34, respectively, the attached residue in 5-position can be cis- and 
trans-oriented relative to the carboxylic acid function in 3-position of the piperidine 
moiety. If synthetically accessible, the two diastereomeres of each hydrazone should 
be examined. 
 
 
Figure 16: Condensation of hydrazine building blocks 29–31 (in excess) with diverse aldehydes 26 
affording target compounds with general structures 32–34 
 
Besides the syntheses of the hydrazine building blocks 29–31, also new appropriate 
aldehydes 26 should be gathered in order to be able to screen for a greater structural 
diversity of potential GAT1 inhibitors. Thus, the total number of aldehydes 26 
accessible for the screening experiments should be increased as well as the number 
of individual aldehydes 26 per library compared to four aldehydes per library employed 
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in previous approaches using N-substituted nipecotic acid and guvacine derivatives, 
respectively. 
Accordingly, the aims of this thesis were to develop a synthetic concept yielding the 
hydrazine building blocks 29–31, to compile appropriate aldehyde libraries 26, and to 
generate hydrazone libraries 32–34 from the aforementioned building blocks, 26 and 
29–31, which were then intended to be screened for their binding affinities towards 
mGAT1 by means of MS Binding Assays. In case hydrazone libraries 32–34 were 
found to be “active” at mGAT1, the whole procedure would furthermore comprise the 
identification of the most active library components by deconvolution experiments as 
well as the verification of potential hits by resynthesis of individual hydrazones 32–34 
and the evaluation of their binding affinities towards mGAT1 in full-scale competitive 
MS Binding Assays. 
Besides this approach allowing to screen for potential GAT1 inhibitors, it was also 
intended to utilize those hydrazone libraries 32–34 generated by DCC in a new kind a 
screening at mGAT4 (≙ GAT3) by means of functional [3H]GABA uptake assays at this 
GABA transporter subtype. Considering that the nipecotic acid moiety is also present 
as parent structure in prototypic mGAT4/GAT3 inhibitors such as (S)-SNAP-5114 (16) 
and that the hydrazone libraries 32–34 should comprise a vast diversity of different 
compounds, their screening at mGAT4 was hoped to reveal new insights into the 
structure-activity relationship and to yield potentially new mGAT4/GAT3 inhibitors. 
 
Despite several antiepileptic drugs have been developed in the past, not all epilepsy 
patients show a sufficient resolution of symptoms by current medical treatment (see 
section 1.1). In this context, these two screening approaches of 5-substituted nipecotic 
acid derivatives at mGAT1 and mGAT4, whereupon those GABA transporters are 
considered as antiepileptic drug targets, were generally aimed to reveal new structural 
scaffolds of GABA uptake inhibitors, which could then be utilized as starting points to 
increase our understanding of the structure-activity relationship and to develop new 
GABA uptake inhibitors with a different pharmacological profile than previously known 
compounds. 
 
 
SUMMARY OF MANUSCRIPTS AND PUBLISHED RESULTS 25 
___________________________________________________________________ 
 
3 Summary of manuscripts and published results 
3.1 Novel allosteric ligands of γ-aminobutyric acid transporter 1 
(GAT1) by MS based screening of pseudostatic hydrazone libraries 
Molecular modeling studies conducted in our group indicated that substituting the 
nipecotic acid moiety with lipophilic arylalkyl residues in the 5-position instead, as 
common, in the 1-position of the core structure could represent an interesting means 
of obtaining novel GAT1 inhibitors. For proving this in silico based hypothesis, it was 
aimed in this study to develop 5-substituted nipecotic acid derivatives and evaluate 
their binding affinities towards the murine GABA transporter mGAT1. In order to allow 
a vast and easy to perform variation of the lipophilic residues attached to the 5-position 
of the nipecotic acid moiety via a spacer, an approach was chosen that combines the 
generation of dynamic combinatorial hydrazone libraries with the screening of their 
binding affinities towards mGAT1 in competitive MS Binding Assays analogously as 
initially developed by Sindelar and Wanner.87 As hydrophilic building blocks nipecotic 
acid derivatives with a one (C1) and two carbon atom (C2) spacer at the 5-position 
bearing a terminal hydrazine function were synthesized, each in both diastereomeric 
forms, i.e. the spacer in 5-position being either cis- or trans-oriented with respect to the 
carboxylic acid function in 3-position of the piperidine ring. Besides, 224 mostly 
aromatic aldehydes were compiled representing the lipophilic building blocks. These 
aldehydes were grouped in 28 libraries, each containing eight individual compounds. 
For hydrazone library generation, each of the four hydrazine derived building blocks 
was separately incubated with all aldehyde libraries in presence of the target mGAT1 
to yield the hydrazones with a total spacer length of four (derived from C1 hydrazines) 
and five atoms (from C2 hydrazines). Hence, four sets of hydrazone libraries, termed 
as cis-C1, trans-C1, cis-C2 and trans-C2, respectively, to indicate their relative 
configurations and different spacer lengths, were generated comprising a total of 
nearly 900 compounds, which were then screened for their binding affinities towards 
mGAT1 in MS Binding Assays. Libraries found to be “active” were further examined in 
deconvolution experiments using only single hydrazones in order to identify their most 
active components. For hit verification, the most active compounds from the screening 
and deconvolution experiments were resynthesized in pure form and evaluated in full-
scale competitive MS Binding Assays in order to establish their pKi values. Ten 
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exclusively cis-configured hydrazones were found to be potent mGAT1 ligands 
exhibiting pKi values > 6, of which the compound bearing a 5-(1-naphthyl)furan-2-yl 
residue and a four atom spacer showed the highest binding affinity (pKi = 6.67±0.03). 
Surprisingly, the inhibitory potencies (pIC50 values) for these hydrazones at mGAT1 
established in functional [3H]GABA uptake assays were clearly lower than the pKi 
values determined in the MS Binding Assays. This discrepancy of functional activities 
and binding affinities prompted us to perform further experiments in order to examine 
the hydrazones’ interaction mode at mGAT1. MS based saturation experiments at 
mGAT1 with NO711 as reporter ligand in the absence and presence of selected 
hydrazones revealed a noncompetitive inhibition of NO711 binding and further 
experiments indicated an allosteric mode of action. Accordingly, the evaluated 5-
substituted nipecotic acid derived hydrazones display a pharmacological profile 
distinctly different to that of bench mark mGAT1/GAT1 inhibitors such as tiagabine and 
could thus represent interesting novel tool compounds for investigations of 
mGAT1/GAT1 mediated GABA transport. 
The original publication is included in the appendix (chapter 8) at the end of this thesis. 
 
Declaration of contributions: 
The previous in silico studies, which gave the basic idea for this research, were 
conducted by Dr. Thomas Wein. New aldehydes were gathered and aldehyde libraries 
were compiled by Simone Huber and me, supported by Dr. Karuna Bhokare, Hans 
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schemes and tables, assisted by Dr. Thomas Wein and Dr. Georg Höfner. Prof. Klaus 
T. Wanner corrected the manuscript.  
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3.2 MS based screening of 5-substituted nipecotic acid derived 
hydrazone libraries as ligands of the GABA transporter 1 
In the previous study (see section 3.1) 5-substituted nipecotic acid derivatives with 
novel structures were revealed as new ligands for mGAT1 with interesting 
pharmacological characteristics. To this end, dynamic combinatorial hydrazone 
libraries containing nipecotic acid derivatives with a four and five atom spacer between 
the 5-position of the piperidine ring and the lipophilic moiety, with the spacer being 
attached in both cis- and trans-orientation with respect to the carboxylic acid function, 
were examined. Ten hits were found to be potent mGAT1 ligands exhibiting pKi values 
> 6, which exclusively derived from cis-configured hydrazones, and amongst these, 
most were bearing the shorter chained, i.e. including four atoms, spacer. 
In order to complement the aforementioned study, 5-substituted nipecotic acid derived 
hydrazones with a three atom spacer in cis-orientation were intended to be screened 
at mGAT1 by means of MS Binding Assays. As hydrophilic building block, the nipecotic 
acid derivative bearing a hydrazine function directly attached to the 5-position of the 
piperidine ring without any additional carbon spacer (C0) and cis-oriented with respect 
to the carboxylic acid function in 3-position was synthesized. This hydrazine was again 
reacted with the 28 aldehyde libraries, each containing eight individual aldehydes, 
which were already employed in the previous study, to form the corresponding 
hydrazone libraries in the presence of the target mGAT1. Amongst the 28 hydrazone 
libraries, one was found to be “active” by the MS based screening experiments. 
Deconvolution experiments, performed for identifying the most active components of 
this “active” library, revealed one hydrazone with promising binding affinity towards 
mGAT1, which was considered to be the hit of this screening campaign. For hit 
verification, this hydrazone, bearing a 5-(2-phenylethynyl)thiophen-2-yl residue as 
lipophilic domain, was resynthesized in pure form and a submicromolar binding affinity 
(pKi = 6.62±0.04) was established in full-scale competitive MS Binding Assays. Again, 
the functional activity, as determined in [3H]GABA uptake assays, was clearly lower 
and additional MS based saturation experiments revealed a noncompetitive inhibition 
mode. Thus, the novel hydrazone bearing a three-atom spacer attached to the 
nipecotic acid moiety likely follows the same mechanistic rationale as the 5-substituted 
nipecotic acid derived ligands of mGAT1 with longer spacers that had been revealed 
in the previous screening campaign. Thereby, the herein described hydrazone adds 
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new insights into the structure-activity relationship of this novel class of ligands for the 
GABA transporter mGAT1 and could accordingly represent another interesting tool 
compound for future studies. 
The original manuscript is included in the appendix (chapter 8) at the end of this thesis. 
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3.3 Generation and screening of pseudostatic hydrazone libraries 
derived from 5-substituted nipecotic acid derivatives at the GABA 
transporter mGAT4 
The GABA transporter mGAT4 (≙ GAT3) is considered a promising drug target for 
mediating antiepileptic effects. However, due to a lack of highly potent inhibitors for 
this GAT subtype the elucidation of its full pharmacological potential as a drug target 
is still retarded (see section 1.2). In order to screen for a vast diversity of compounds 
aiming to reveal potentially new mGAT4/GAT3 inhibitors, the same pseudostatic 
hydrazone libraries initially generated as described in the previous two studies (see 
sections 3.1 and 3.2) and screened at mGAT1 were intended to be utilized in a new 
kind of screening at mGAT4.  
This study describes the generation and screening of these dynamic combinatorial 
hydrazone libraries at mGAT4. The hydrazone libraries, which included more than 
1,100 compounds, are derived from a nipecotic acid moiety as parent structure that 
was – in contrast to yet known mGAT4 inhibitors – substituted at the 5-position instead 
of the common 1-position of the core structure. After generating the libraries by 
preincubating the hydrazine and aldehyde building blocks, respectively, the libraries 
were screened for their inhibitory potencies in a [3H]GABA uptake assay at mGAT4. 
Accordingly, two notable adjustments for the library screening at mGAT4 in 
comparison with the yet established screening at mGAT1 had to be made, while the 
principle procedure (comprising the steps library generation, library screening, 
deconvolutions experiments and hit verification) remained the same: I) For screening 
a functional assay (i.e. [3H]GABA uptake assay) was utilized instead of an MS Binding 
Assay since due to a lack of a highly potent and selective mGAT4 inhibitors, which 
could be employed as MS marker, an MS Binding Assay for the target mGAT4 is not 
yet available. II) The library generation had to be decoupled from the screening 
experiments since the [3H]GABA uptake assay is based on intact cells expressing the 
corresponding target proteins (instead of membrane fragments employed in the MS 
Binding Assay), which would be impaired by the conditions required for in situ library 
generation. 
By the screening and subsequent, for identifying most active library components, 
deconvolution experiments, two new compounds could be identified with promising 
inhibitory potencies at mGAT4. These two hydrazones were resynthesized in pure form 
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and evaluated for their inhibitory potencies at mGAT4 and additionally at the other 
murine GABA transporter subtypes (mGAT1–mGAT3) using a standardized [3H]GABA 
uptake assay based on HEK cells. Besides, inhibitory potencies at the human 
equivalent of the target GABA transporter mGAT4, i.e. hGAT3, were established in an 
MS Transport Assay more recently developed by our group that uses COS cells. The 
results show that the potencies of the newly synthesized compounds at 
mGAT4/hGAT3 are in the low micromolar range and close to that of bench mark 
mGAT4/hGAT3 inhibitor (S)-SNAP-5114. Notably, the hydrazones comprise novel 
structural scaffolds for inhibitors of this target with respect to both the substitution 
pattern of the nipecotic acid moiety (i.e. in 5-position) and the aromatic residue (i.e. a 
biphenyl residue). Hence, these compounds add new insights into the structure-activity 
of mGAT4/hGAT3 inhibitors and could make interesting candidates for further 
investigation. 
The original publication is included in the appendix (chapter 8) at the end of this thesis. 
 
Declaration of contributions: 
The syntheses of the nipecotic acid derived building blocks containing a hydrazine 
function (as described in the previous two studies), the generation of the hydrazone 
libraries for the screening experiments, the generation of single hydrazones for the 
deconvolutions experiments and the syntheses of “active” hydrazones in pure form for 
hit verification were done by me. Conversely, the biological studies comprising the 
screening experiments, the deconvolution experiments and the full-scale [3H]GABA 
uptake assays as well as MS Transport Assays were accomplished by technical 
assistants of our group under the supervision of Dr. Georg Höfner. I wrote the 
manuscript and prepared the figures, schemes and tables, assisted by Dr. Georg 
Höfner. Prof. Klaus T. Wanner corrected the manuscript. 
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4 Further experiments 
Besides the research covered in the previous listed publications and manuscripts, 
which addressed the main aims of this thesis, some additional experiments were 
performed. Basically, intermediate compounds that were required for the syntheses of 
hydrazines 29–31, the syntheses of which are described in the first publication (see 
section 3.1), served as starting points to synthesize nipecotic acid derivatives bearing 
small substituents in the 5-position, which were intended to be biologically tested on 
their capability to inhibit GAT mediated GABA uptake. These experiments are 
described in the following. 
 
4.1 Synthesis of the (S)-SNAP-5114 derivative rac-35 
Compound rac-35, which can be considered a 5-hydroxy nipecotic acid derivative of 
bench mark GAT3 inhibitor (S)-SNAP-5114 (16), was intended to be synthesized as 
target structure in order to examine which influence a hydrophilic substituent in the 5-
position of the nipecotic acid moiety would have on the inhibitory potency at GAT3. 
The synthesis of rac-35 is outlined in Figure 17. In short, the tert-butyloxycarbonyl 
(Boc) protected, 5-hydroxy nipecotic acid derivative rac-36 (from the first publication, 
see section 3.1) was, after cleaving the Boc group and without isolating the 
intermediate, reacted with the tosylate 37, the latter of which was obtained by the 
reaction of trityl derivative 3893 with 4-toluenesulfonyl chloride and triethylamine (NEt3). 
This yielded the methyl ester derivative of rac-35, rac-39, in a yield of 70%. By 
hydrolyzing the ester function of rac-39 with aqueous sodium hydroxide the target 
compound rac-35 was obtained in a yield of 87%. 
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Figure 17: Synthesis of (S)-SNAP-5114 derivative rac-35. Reagents and conditions: a) 4-
toluenesulfonyl chloride, NEt3, DCM, 0 °Crt, 16 h; b) 2 M etheric HCl, MeOH, rt, 17 h; c) Na2CO3, 
acetone/iso-hexane, reflux, 2 d; d) 2 M aqueous NaOH, MeOH, 0 °Crt, 5 h 
 
4.2 Syntheses of fluorinated nipecotic acid derivatives 
The experiments described in this section 4.2 were performed under my supervision 
by “ERASMUS” student Ronan McShane as well as “Pharmazie-Staatsexamen” 
students Miriam Schulz and Janine Piecek in course of their research internships in 
the research group of Prof. Klaus T. Wanner. 
Small nipecotic acid derivatives bearing one or two fluorine atoms in the 5-position of 
the piperidine moiety were intended to be synthesized and biologically tested for their 
capability to inhibit the different GAT subtypes. To this end, appropriate, 5-substituted 
nipecotic acid derivatives were employed in deoxofluorination reactions using the 
reagents diethylaminosulfur trifluoride (DAST; 40, see Figure 18) or 
diethylaminodifluorosulfinium tetrafluoroborate (XtalFluor-E; 41), the latter of which 
was applied in combination with triethylamine trihydrofluoride (NEt3·3 HF) or 1,8-
diazabicyclo(5.4.0)undec-7-ene (DBU), analogously as described for different 
reactions in literature.94–96  
 
Figure 18: Reagents employed for deoxofluorination reactions 
 
FURTHER EXPERIMENTS  33 
___________________________________________________________________ 
 
The deoxofluorination reactions were initially employed to alcohol rac-36 and yielded 
rac-42 as well as the elimination byproduct 43 (see Figure 19). Notably, the 
stereochemistry of the substituent in 5-position was retained, i.e. the fluoro substituent 
of rac-42 was still cis-oriented after the fluorination reaction with respect to the 
carboxylic acid function in 3-position.  
 
 
Figure 19: Synthesis of fluorination product rac-42 and elimination byproduct 43 from alcohol rac-36 
(reagents and conditions see Table 3) 
 
Based on this synthesis, it was furthermore examined which influence the applied 
reagent (compound 40 and 41, respectively) and other varying reaction conditions 
would have on the yield of rac-42 as well as on the ratio of fluorination (i.e. compound 
rac-42) versus elimination product (i.e. 43). The reagents and conditions as well as the 
results of these experiments are shown in Table 4. In summary, by utilizing DAST (40) 
as fluorination reagent the yields of the desired product rac-42 were in a similar order 
of magnitude as those of the elimination byproduct 43 (Table 3, entries 1–3), while by 
using XtalFluor-E (41) the selectivity towards the formation of rac-42 appeared to be 
increased in most of the attempts (Table 3, entries 4–10, with a notable exception from 
the tendency of an increased selectivity being entry 6, at which additional amounts of 
base, NEt3, were added). However, despite the higher selectivity, the total yield of the 
desired product rac-42 could apparently not be increased by using XtalFluor-E (41). 
Interestingly, the highest nominal yields of both rac-42 (34%) and 43 (32%) were 
obtained by using DAST (40; Table 3, entry 3). 
 
 
 
FURTHER EXPERIMENTS  34 
___________________________________________________________________ 
 
Table 3: Different reagents and conditions employed for the synthesis of fluorination product rac-42 and 
elimination byproduct 43 from alcohol rac-36 according to Figure 19 
entry reagents 
(equivalents) 
solvent temp. atmos-
phere 
time products’ 
ratioa  
yieldb 
rac-42 
yieldb 
43 
1 DAST (1.6 eq.) DCM 0 °C air 18 h 1:1 22% 27% 
2 DAST (1.7 eq.) DCM -78 °C air 16 h 2:3 14% 24% 
3 DAST (1.7 eq.) DCM 0 °Crt air 16 h 1:1 34% 32% 
4 XtalFluor-E (1.5 
eq.), NEt3·3 HF 
(2.1 eq.) 
DCM 0 °C N2 72 h >10:1c 21% 2% 
5 XtalFluor-E (1.7 
eq.), DBU (1.6 
eq.) 
DCM 0 °C N2 16 h 5:2d 1%d 3%d 
6 XtalFluor-E (1.5 
eq.), NEt3·3 HF 
(2.0 eq.), NEt3 
(1.0 eq.) 
DCM 0 °Crt Ar 2.5 h 1:1 31% 32% 
7 XtalFluor-E (2.3 
eq.), NEt3·3 HF 
(3.0 eq.) 
DCM 0 °Crt Ar 17.5 
h 
4:1 33% 9% 
8 XtalFluor-E (1.5 
eq.), NEt3·3 HF 
(1.0 eq.) 
DCE 85 °C Ar 3.5 h 9:1 17% 5% 
9 XtalFluor-E (1.3 
eq.), NEt3·3 HF 
(3.0 eq.) 
DCM 0 °Crt Ar 3 h n.d.e 23% 16% 
10 XtalFluor-E (2.3 
eq.), NEt3·3 HF 
(1.5 eq.) 
DCM 0 °Crt Ar 3 h n.d.e 18% 1% 
a The crude ratio of products rac-42/43 was determined by 1H NMR. 
b The isolated yields were determined after purification by flash column chromatography. 
c Negligible elimination and thus an exact ratio could not be determined. 
d The observed conversion was very low and accordingly the stated numbers are imprecise. 
e Not determined. 
 
Simultaneous removal of the protecting groups of compound rac-42 with hydrochloric 
acid, i.e. cleavage of the Boc group and hydrolysis of the ester function, yielded the 
free amino acid rac-4497 (see Figure 20). 
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Figure 20: Synthesis of compound rac-44 from rac-42. Reagents and conditions: a) 1 M aqueous HCl, 
THF, reflux, 2 h; b) strongly acidic cation exchange chromatography 
 
Besides compound rac-42, the trans-oriented analog of rac-42, that is rac-45, and the 
5,5-difluoro substituted compound 46 were synthesized in analogous reactions from 
alcohol rac-47 and ketone 48, respectively (the syntheses of both starting materials 
are described in the first publication, see section 3.1). While the difluorinated 
compound 46 was obtained in moderate to good yield (66%), the yield of rac-45 was 
rather poor (18%); notably, minor amounts of rac-42 and 43 were observed in the 1H 
NMR of crude rac-45, whereas none of these byproducts, rac-42 and 43, were 
observed during the formation of compound 46. Subsequent deprotection reactions 
again yielded the desired free amino acids rac-49 and 50, respectively (see Figure 21). 
 
 
Figure 21: Syntheses of compounds rac-49 and 50, respectively. Reagents and conditions: a) XtalFluor-
E, NEt3·3 HF, DCM, 0 °C, Ar, 2.3 h (for rac-45) or 3.7 h (for 46); b) 1 M aqueous HCl, THF, reflux, 3 h; 
c) strongly acidic cation exchange chromatography 
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In addition to the aforementioned amino acids rac-44, rac-49 and 50, respectively, the 
N-butyl derivative of rac-44, i.e. rac-51, was synthesized. Therefore, compound rac-
42, after cleaving the Boc group, was successively converted with potassium iodide, 
potassium carbonate and 1-bromobutane to the N-butyl derivative rac-52; finally, by 
hydrolyzing the ester function the desired compound rac-51 was obtained (see Figure 
22). 
 
 
Figure 22: Synthesis of compound rac-51 from rac-42. Reagents and conditions: a) 2 M etheric HCl, 
MeOH, 6.5 h, rt; b) KI, K2CO3, 1-bromobutane, acetone, reflux, 5 d; c) 1 M aqueous HCl, THF, reflux, 1 
h; d) 2 M aqueous NaOH, rt, 23 h; e) strongly acidic cation exchange chromatography [note that after 
step c) minor amounts of starting material remained; so for completing ester hydrolysis, step d) was 
additionally performed]  
 
4.3 Results of the biological testing 
The free amino acids synthesized as described in sections 4.1 and 4.2, i.e. rac-35, rac-
44, rac-49, 50 as well as rac-51, were tested for their inhibitory potencies at the 
different GAT subtypes in functional assays. To this end, the [3H]GABA uptake assays 
routinely used in our group (see section 1.3 and literature reference73) were employed, 
which were accomplished by technical assistants of our group under the supervision 
of Dr. Georg Höfner; the results obtained thereby are summarized in Table 4. 
The structure of compound rac-35 was inspired by bench mark GAT3/mGAT4 inhibitor 
(S)-SNAP-5114 (16); with rac-35 it should be examined what effect a small, polar 
substituent, i.e. a hydroxy group, in the 5-position of the nipecotic acid moiety would 
have on the capability of inhibiting mGAT4. However, the functional activity of rac-35 
at this transporter subtype, mGAT4, is clearly lower than that of (S)-SNAP-5114 (16; 
see section 1.2, Table 2). Although taking into account that rac-35 is racemic and thus 
the eutomer could be slightly more potent, it may be concluded that a hydroxy function 
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in the 5-position of nipecotic acid derived GAT3/mGAT4 inhibitors is not well tolerated 
and reduces the inhibitory potency at this GAT subtype. 
 
Table 4: Functional activities of compounds rac-35, rac-44, rac-49, 50 and rac-51 at the different GAT 
subtypes mGAT1–mGAT4 
 Inhibitory potencies (pIC50)a 
Compound mGAT1 mGAT2 mGAT3 mGAT4 
rac-35 59%b 85%b 4.09c 4.07c 
rac-44 4.71c 82%b 73%b 87%b 
rac-49 4.89±0.12d 67%b 4.07±0.06d 4.15±0.13d 
50 3.48c 87%b 95%b 94%b 
rac-51 3.16c 108%b 101%b 113%b 
a The inhibitory potencies derive from the biological tests of our research group based on [3H]GABA 
uptake assays with HEK293 cells stably expressing the different GAT subtypes mGAT1–mGAT4.  
b In case of low inhibitory potencies percentages are given that represent the remaining [3H]GABA 
uptake in presence of 100 µM test compound. 
c Obtained from less than three experiments and accordingly no SEM value is stated. 
d Values are given as means±SEM from at least three independently performed experiments. 
 
In addition, a series of 5-fluoro substituted nipecotic acid derivatives, rac-44, rac-49, 
50 and rac-51, was synthesized in order to examine what effects one or two fluorine 
atoms would have on the functional activities at the different GAT subtypes. All these 
compounds, rac-44, rac-49, 50 and rac-51, show their highest inhibitory potencies at 
mGAT1, while they appear generally less active at the other GAT subtypes, mGAT2–
mGAT4. Remarkably, compounds rac-44 and rac-49 show approximately the same 
potency at mGAT1 as the unsubstituted, racemic nipecotic acid (9; see section 1.2, 
Table 2), while at the same time the subtype selectivity of the fluorinated compounds 
rac-44 and rac-49 for mGAT1 appears to be increased. The trans-oriented rac-49 
appears nominally more potent at all GAT subtypes than the cis-oriented rac-44, 
although the differences are minor. Conversely, the disubstituted derivative 50 is 
clearly less potent at mGAT1. Thus it may be concluded that one fluorine atom is well 
tolerated in the 5-position of the nipecotic acid moiety, retaining potency at and 
increasing subtype selectivity for mGAT1, while two fluorine atoms in the 5-position 
reduce the inhibitory potency distinctly. Possibly, the latter observation might be due 
to the fact that the fluoro substituents decrease the basicity of the amino group; two 
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fluorine atoms may reduce the basicity to such an extent that the amino group is not 
sufficiently protonated anymore under physiological conditions, thus leading to 
impaired ligand-protein interactions. 
As described by Wein et al.64 not pure but N-butylated amino acids might allow a better 
estimate of the activity at GAT1/mGAT1 when larger arylalkyl residues such as those 
in tiagabine (6) or SK&F-89976A (11) are added. Accordingly, the fluorinated, N-butyl 
derivative rac-51 was synthesized and evaluated for its inhibitory potency at mGAT1. 
The established pIC50 value of rac-51 at mGAT1 (i.e. pIC50 = 3.16) is in a similar order 
of magnitude as that of N-butyl nipecotic acid without fluoro substituent [reference 
values for the R-enantiomer (pIC50 = 3.72) and the S-enantiomer (pIC50 = 3.12) from 
literature reference64], also taking into account that rac-51 is racemic and thus the 
eutomer could be slightly more potent. Hence, nipecotic acid derivatives bearing one 
fluoro substituent in the 5-position of the piperidine ring could be considered as 
interesting starting points for the development of larger, highly potent GAT1/mGAT1 
inhibitors. 
 
4.4 Experimental details and compound characterization data 
General methodologies for the syntheses of compounds listed in sections 4.1–
4.2: Solvents for synthesis, extraction and flash chromatography were distilled before 
use. Anhydrous THF was prepared by drying over benzophenone/Na. Other 
commercially available reagents (by ABCR, Acros, Alfa Aesar, Fisher Scientific, 
Maybridge, Merck, Sigma-Aldrich, TCI and VWR) were used without further 
purification. Thin-layer chromatography was carried out on precoated silica gel F254 
glass plates (Merck) and detected under UV light (λ = 254 and 366 nm) or by staining 
with a ninhydrin solution (0.3 g ninhydrin and 3 mL acetic acid dissolved in 100 mL 1-
butanol).98 Flash column chromatography was performed on silica gel 60 (grading 
0.035–0.070 mm, purchased from Merck and Acros). Strongly acidic cation exchange 
chromatography was performed on Amberlite® IRA-120 (H+ form; Merck) with a 25 % 
aqueous NH3 solution as solvent. NMR spectroscopy was performed on Avance III HD 
Bruker BioSpin (Bruker; 1H NMR: 400 or 500 MHz; 13C NMR: 101 or 126 MHz; 19F 
NMR: 376 MHz) or JNMR-GX (JEOL; 1H NMR: 400 or 500 MHz; 13C NMR: 101 or 126 
MHz) spectrometers. The spectra were processed with the NMR software 
MestReNova, versions 8.1, 10.0 and 12.0 (Mestrelab Research S.L.). Chemical shifts 
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were internally referenced to TMS or MeOH (for samples dissolved in D2O). IR 
spectroscopy was performed on a FT-IR Paragon 1000 (Perkin-Elmer) spectrometer 
and analyzed with the software Spectrum v2.00 (Perkin-Elmer). Samples were either 
pressed in KBr pellets or prepared as films between NaCl plates. Mass spectra were 
measured with a mass spectrometer 59827A with 59980 particle beam LC/MS 
interface (Hewlett Packard) and high-resolution mass spectrometry was performed 
with Jeol MStation sector field mass spectrometer (Jeol), Thermo Finnigan MAT 95 
(ThermoFischer Scientific) (both EI) or Thermo Finnigan LTQ FT Ultra mass 
spectrometer (ThermoFischer Scientific) (ESI). Melting points were determined in open 
capillaries on a BÜCHI 510 melting point apparatus and are uncorrected.  
 
2-[Tris(4-methoxyphenyl)methoxy]ethyl 4-methylbenzene-1-sulfonate (37): 
 
2-[Tris(4-methoxyphenyl)methoxy]ethan-1-ol93 (38; 300 mg; 0.761 mmol) was 
dissolved in DCM (0.8 mL). Under cooling in an ice bath it was successively added 
triethylamine (0.16 mL; 1.1 mmol) and 4-toluenesulfonyl chloride (176 mg; 0.921 
mmol). The mixture was stirred over night (16 h) while it was allowed to reach rt  
(0 °Crt). The reaction was quenched by the addition of H2O (25 mL). It was extracted 
with DCM (4 x 25 mL), the combined organic phases were dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (silica gel; ethyl acetate/iso-hexane = 1:4) to yield 37 as white solid 
(371 mg; 89%). mp: 135 °C. Rf = 0.24 (ethyl acetate/iso-hexane = 1:4). IR (KBr): v~ = 
2953, 2929, 2840, 1736, 1608, 1579, 1509, 1458 cm-1. 1H NMR (500 MHz, CDCl3, 25 
°C, TMS): δ = 2.46 (s, 3 H, CCH3), 3.24–3.29 (m, 2 H, SOCH2CH2O), 3.77 (s, 9 H, 
OCH3), 4.11–4.15 (m, 2 H, SOCH2CH2O), 6.76–6.80 (m, 6 H, CCHCHCOCH3), 7.21–
7.26 (m, 6 H, CCHCHCOCH3), 7.33 (d, J = 8.0 Hz, 2 H, SCCHCHC), 7.82 (d, J = 8.3 
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Hz, 2 H, SCCHCHC) ppm. 13C NMR (125 MHz, CDCl3, 25 °C, TMS): δ = 14.19 (CCH3), 
55.18 (OCH3), 61.26 (SOCH2CH2O), 69.67 (SOCH2CH2O), 85.85 (CH2OC), 113.06 
(CCHCHCOCH3), 127.97 (SCCHCHC), 129.65 (CCHCHCOCH3), 129.82 
(SCCHCHC), 133.06 (SCCHCHC), 136.12 (CCHCHCOCH3), 144.67 (SCCHCHC), 
158.36 (CCHCHCOCH3) ppm. MS (ESI): m/z = 571.2 (40%, [M+Na]+). HRMS (ESI): 
[M+Na]+ calcd. for C31H32O7SNa: 571.1766; found 571.1764. 
 
rac-(3R,5S)-(Methyl 5-hydroxy-1-{2-[tris(4-
methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylate) (rac-39): 
 
Compound rac-36 (163 mg; 0.629 mmol) was dissolved in MeOH (3.0 mL) and a 2 M 
etheric HCl (3.0 mL; 6.0 mmol) was added. The mixture was stirred at rt over night (17 
h). Then the reaction was quenched by the addition of a saturated aqueous NaHCO3 
solution (10 mL) and diluted with H2O (20 mL). The aqueous phase was washed with 
ethyl acetate (1 x 20 mL) and freeze dried. To the residue Na2CO3 (320 mg; 3.02 mmol) 
and subsequently 37 (164 mg; 0.299 mmol), dissolved in acetone (2.0 mL) and iso-
hexane (0.5 mL), were added. Further acetone (3.0 mL) was added and the mixture 
was stirred at room temperature for 5 h and then refluxed for 2 d. The reaction was 
quenched with H2O (30 mL) and extracted with DCM (4 x 25 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced pressure. 
After purification by column chromatography (silica gel; ethyl acetate) rac-39 was 
obtained as white amorphous solid (113 mg; 70%). Rf = 0.30 (ethyl acetate). IR (KBr): 
v
~ = 3429, 2950, 2933, 2835, 1734, 1607, 1508, 1463, 1440 cm-1. 1H NMR (400 MHz, 
CDCl3, 25 °C, TMS): δ = 2.03–2.20 (m, 1 H, NCH2CHCHaxHeq), 2.08 (t, J = 9.7 Hz, 1 
H, NCHaxHeqCHaxOH), 2.15 (d, J = 12.9 Hz, 1 H, NCH2CHCHaxHeq), 2.33 (t, J = 10.5 
Hz, 1 H, NCHaxHeqCHaxC=O), 2.57–2.69 (m, 1 H, NCHaxHeqCHaxC=O), 2.68 (t, J = 5.9 
Hz, 2 H, NCH2CH2O), 2.86 (d, J = 8.8 Hz, 1 H, NCHaxHeqCHaxOH), 2.92 (d, J = 11.2 
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Hz, 1 H, NCHaxHeqCHaxC=O), 3.19 (t, J = 5.9 Hz, 2 H, NCH2CH2O), 3.66 (s, 3 H, 
COOCH3), 3.72–3.77 (m, 1 H, NCHaxHeqCHaxOH), 3.78 (s, 9 H, CCHCHCOCH3), 6.79–
6.84 (m, 6 H, CCHCHCOCH3), 7.29–7.35 (m, 6 H, CCHCHCOCH3) ppm. 13C NMR 
(125 MHz, CDCl3, 25 °C, TMS): δ = 34.85 (NCH2CHCH2), 40.18 (NCH2CHC=O), 51.93 
(COOCH3), 55.04 (NCH2CHC=O), 55.19 (CCHCHCOCH3), 57.83 (NCH2CH2O), 60.94 
(NCH2CHOH), 61.27 (NCH2CH2O), 66.45 (NCH2CHOH), 85.79 (CH2OC), 113.03 
(CCHCHCOCH3), 129.73 (CCHCHCOCH3), 136.79 (CCHCHCOCH3), 158.26 
(CCHCHCOCH3), 174.27 (NCH2CHC=O) ppm. MS (ESI): m/z = 536.3 (20%, [M+H]+). 
HRMS (ESI): [M+H]+ calcd. for C31H38O7N+: 536.2648; found 536.2643. 
 
rac-(3R,5S)-(5-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-
carboxylic acid) (rac-35): 
 
Compound rac-39 (102 mg; 0.190 mmol) was dissolved in MeOH (1.5 mL) and a 2 M 
aqueous NaOH solution (0.25 mL; 0.50 mmol) was added at 0 °C. The mixture was 
stirred at 0 °C for 2 h and at rt for further 3 h, before it was quenched with H2O (25 mL). 
The mixture was neutralized with 2 M HCl, and after adding phosphate buffer (pH 7; 
1.0 mL) the aqueous phase was extracted with DCM (5 x 25 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced pressure. 
The residue was redissolved in DCM and iso-hexane was added to the solution until 
the product precipitated. The solid was filtered off and dried under high vacuum to yield 
rac-35 as white amorphous solid (91 mg; 87%). Rf = 0.15 (DCM + 7.5% MeOH). IR 
(Film): v~ = 3301, 2928, 1606, 1507, 1462 cm-1. 1H NMR (500 MHz, DMSO-d6, 25 °C, 
TMS): δ = 1.08 (q, J = 12.2 Hz, 1 H, NCH2CHCHaxHeq), 1.67 (t, J = 10.2 Hz, 1 H, 
NCHaxHeqCHaxOH), 1.85 (t, J = 11.2 Hz, 1 H, NCHaxHeqCHaxC=O), 2.07 (d, J = 12.3 
Hz, 1 H, NCH2CHCHaxHeq), 2.35–2.47 (m, 1 H, NCHaxHeqCHaxC=O), 2.55 (t, J = 5.8 
Hz, 2 H, NCH2CH2O), 2.85 (dd, J = 10.6/4.3 Hz, 1 H, NCHaxHeqCHaxOH), 2.96 (dd, J = 
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11.0/3.7 Hz, 1 H, NCHaxHeqCHaxC=O), 2.98–3.05 (m, 2 H, NCH2CH2O), 3.47 (ddd, J = 
14.8/9.4/4.2 Hz, 1 H, NCHaxHeqCHaxOH), 3.73 (s, 9 H, CCHCHCOCH3), 6.83–6.90 (m, 
6 H, CCHCHCOCH3), 7.22–7.29 (m, 6 H, CCHCHCOCH3) ppm. 13C NMR (126 MHz, 
DMSO-d6, 25 °C, TMS): δ = 36.09 (NCH2CHCH2), 40.18 (NCH2CHC=O), 54.89 
(CCHCHCOCH3), 55.11 (NCH2CHC=O), 57.11 (NCH2CH2O), 61.16 
(NCH2CH2O/NCH2CHOH), 61.26 (NCH2CH2O/NCH2CHOH), 65.43 (NCH2CHOH), 
85.01 (CH2OC), 112.97 (CCHCHCOCH3), 129.23 (CCHCHCOCH3), 136.36 
(CCHCHCOCH3), 157.75 (CCHCHCOCH3), 174.43 (NCH2CHC=O) ppm. MS (ESI): 
m/z = 520.2 (100%, [M-H]-). HRMS (ESI): [M-H]- calcd. for C30H34O7N-: 520.2341; found 
520.2340. 
 
rac-(3R,5S)-[1-(tert-Butyl) 3-methyl 5-fluoropiperidine-1,3-dicarboxylate] (rac-
42): 
 
Compound rac-36 (955 mg; 3.68 mmol) was dissolved in DCM (15 mL) and cooled to 
0 °C. DAST (40; 0.85 mL; 6.2 mmol) was added and it was stirred over night while the 
mixture was allowed to reach rt (0 °Crt). The reaction was quenched with a 10 % 
Na2CO3 solution in ice water and stirred for further 15 min. Then the mixture was 
extracted with DCM (4 x 30 mL). The combined organic phases were dried over MgSO4 
and concentrated under reduced pressure. After purification by column 
chromatography (silica gel; ethyl acetate/iso-hexane = 1:5) rac-42 was obtained as 
white amorphous solid (327 mg; 34%). Rf = 0.34 (ethyl acetate/iso-hexane = 1:5). IR 
(KBr): v~ = 3008, 2977, 2955, 2873, 1737, 1695, 1475, 1451, 1421 cm-1. 1H NMR (400 
MHz, C2Cl4D2, 80 °C, TMS): δ = 1.45 (s, 9 H, OC(CH3)3), 1.78 (pseudo-quin, J ~ 11 
Hz, 1 H, NCH2CHCHaxHeq), 2.34–2.47 (m, 1 H, NCH2CHCHaxHeq), 2.45–2.58 (m, 1 H, 
NCHaxHeqCHaxC=O), 2.81 (ddd, J = 12.8/9.5/5.5 Hz, 1 H, NCHaxHeqCHaxF), 2.88 (dd, J 
= 13.1/10.4 Hz, 1 H, NCHaxHeqCHaxC=O), 3.69 (s, 3 H, OCH3), 4.05–4.23 (m, 2 H, 
NCHaxHeqCHaxC=O, NCHaxHeqCHaxF), 3.65 (dtt, J = 47.6/9.8/4.6 Hz, 1 H, 
NCHaxHeqCHaxF) ppm. 13C NMR (101 MHz, C2Cl4D2, 80 °C, TMS): δ = 28.37 
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(OC(CH3)3), 33.29 (d, JCF = 20.9 Hz, NCH2CHCH2), 39.65 (d, JCF = 8.9 Hz, 
NCH2CHC=O), 44.86 (NCH2CHC=O), 47.73 (d, JCF = 28.5 Hz, NCH2CHF), 51.90 
(OCH3), 80.45 (OC(CH3)3), 85.86 (d, JCF = 176.5 Hz NCH2CHF), 154.31 (NC=O), 
171.90 (NCH2CHC=O) ppm. 19F {1H} NMR (376 MHz, C2Cl4D2, 80 °C): δ = 180.92 ppm. 
MS (EI, 70 eV): m/z = 261.1 (3%, [M]+•), 205.1 (25%), 188.1 (55%), 174.1 (40%), 160.1 
(40%), 141.2 (100%). HRMS (EI, 70 eV): [M]+• calcd. for C12H20O4NF: 261.1376; found 
261.1380. 
 
rac-(3R)-[1-(tert-Butyl) 3-methyl 3,4-dihydropyridine-1,3(2H)-dicarboxylate] (43): 
 
Compound 43 was obtained as byproduct in the synthesis of rac-42 as colorless oil 
(280 mg; 32%). Rf = 0.47 (ethyl acetate/iso-hexane = 1:5). IR (Film): v~ = 2977, 2954, 
2934, 1739, 1706, 1654, 1476, 1457 cm-1. 1H NMR (400 MHz, C2Cl4D2, 80 °C, TMS): 
δ = 1.47 (s, 9 H, OC(CH3)3), 2.23–2.32 (m, 2 H, NCH2CHCHaxHeq, NCH2CHCHaxHeq), 
2.67–2.82 (m, 1 H, NCHaxHeqCHaxC=O), 3.35 (dd, J = 12.8/9.7 Hz, 1 H, 
NCHaxHeqCHaxC=O), 3.69 (s, 3 H, OCH3), 4.03 (d, J = 12.2 Hz, 1 H, 
NCHaxHeqCHaxC=O), 4.74–4.91 (m, 1 H, NCHCHCH2), 6.77 (d, J = 8.5 Hz, 1 H, 
NCHCHCH2) ppm. 13C NMR (101 MHz, C2Cl4D2, 80 °C, TMS): δ = 24.66 
(NCH2CHCH2), 28.35 (OC(CH3)3), 38.32 (NCH2CHC=O), 43.10 (NCH2CHC=O), 51.79 
(OCH3), 80.94 (OC(CH3)3), 103.45 (NCHCHCH2), 125.73 (NCHCHCH2), 152.14 
(NC=O), 173.35 (NCH2CHC=O) ppm. MS (EI, 70 eV): m/z = 241.1 (20%, [M]+•), 185.1 
(20%), 168.0 (15%), 141.0 (100%). HRMS (EI, 70 eV): [M]+• calcd. for C12H19O4N: 
241.1314; found 241.1319. 
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rac-(3R,5S)-[5-Fluoropiperidine-3-carboxylic acid]97 (rac-44): 
 
Compound rac-42 (112 mg; 0.429 mmol) was dissolved in THF (1.0 mL) and 1 M HCl 
(4.0 mL; 4.0 mmol) was added. The solution was refluxed for 2 h before the reaction 
was quenched with H2O (20 mL). Then the aqueous phase was washed with DCM (3 
x 15 mL) and freeze dried. The residue was purified by strongly acidic cation exchange 
chromatography with a 25 % aqueous NH3 solution as solvent to yield rac-44 as white 
lyophilisate (35 mg; 56%). IR (KBr): v~ = 3434, 3176, 3011, 2965, 2923, 2852, 2679, 
2518, 2377,2346, 2306, 1588, 1565, 1467, 1454 cm-1. 1H NMR (400 MHz, 1 M NaOD 
in D2O, 25 °C, MeOH): δ = 1.79 (quin, J = 10.8 Hz, 1 H, NCH2CHCHaxHeq), 2.27–2.49 
(m, 2 H, NCH2CHCHaxHeq, NCHaxHeqCHaxC=O), 2.49–2.68 (m, 2 H, 
NCHaxHeqCHaxC=O, NCHaxHeqCHaxF), 3.01 (d, J = 12.3 Hz, 1 H, NCHaxHeqCHaxC=O), 
3.17 (t, J = 10.5 Hz, 1 H, NCHaxHeqCHaxF), 4.67 (dm, JHF = 47.7 Hz, 1 H, 
NCHaxHeqCHaxF) ppm. 13C NMR (101 MHz, 1 M NaOD in D2O, 25 °C, MeOH): δ = 
34.85 (d, JCF = 18.8 Hz, NCH2CHCH2), 44.64 (d, JCF = 7.6 Hz, NCH2CHC=O), 47.81 
(NCH2CHC=O), 49.52 (d, JCF = 25.2 Hz, NCH2CHF), 90.20 (d, JCF = 170.1 Hz 
NCH2CHF), 182.60 (NCH2CHC=O) ppm. 19F {1H} NMR (376 MHz, 1 M NaOD in D2O, 
25 °C): δ = 178.78 ppm. MS (ESI): m/z = 148.1 (100%, [M+H]+). HRMS (ESI): [M+H]+ 
calcd. for C6H11O2N: 148.0768; found 148.0768. 
No analytical data is described for compound rac-44 in reference.97 
 
rac-(3R,5R)-[1-(tert-Butyl) 3-methyl 5-fluoropiperidine-1,3-dicarboxylate] (rac-
45): 
 
Compound rac-47 (137 mg; 0.528 mmol) was dissolved in DCM (2.0 mL) and cooled 
to 0 °C under argon atmosphere. Triethylamine trihydrofluoride (256 mg; 1.59 mmol) 
FURTHER EXPERIMENTS  45 
___________________________________________________________________ 
 
and XtalFluor-E (41; 288 mg; 1.23 mmol), dissolved in DCM (1.7 mL), were 
successively added and the mixture was stirred at 0 °C for 140 min. The reaction was 
quenched with a 5 % aqueous Na2CO3 solution (10 mL), stirred at rt for further 15 min 
and then it was extracted with DCM (5 x 15 mL). The combined organic phases were 
dried over Na2SO4 and concentrated under reduced pressure. After purification by 
column chromatography (silica gel; ethyl acetate/iso-hexane = 1:5) rac-45 was 
obtained as white amorphous solid (25 mg; 18%). Rf = 0.20 (ethyl acetate/iso-hexane 
= 1:5). IR (film): v~ = 2976, 2956, 2935, 2868, 1737, 1698, 1478, 1456 cm-1. 1H NMR 
(400 MHz, C2Cl4D2, 80 °C, TMS): δ = 1.44 (s, 9 H, OC(CH3)3), 1.81 (dddd, J = 
38.2/14.1/11.1/2.6 Hz, 1 H, NCH2CHCHaxHeq), 2.22–2.32 (m, 1 H, NCH2CHCHaxHeq), 
2.85 (tt, J = 10.6/3.9 Hz, 1 H, NCHaxHeqCHaxC=O), 2.90–3.10 (m, 2 H, 
NCHaxHeqCHaxC=O, NCHaxHeqCHeqF), 3.68 (s, 3 H, OCH3), 4.06–4.15 (m, 1 H, 
NCHaxHeqCHeqF), 4.18 (d, J = 12.5 Hz, 1 H, NCHaxHeqCHaxC=O), 4.75 (dtt, J = 
46.6/4.4/2.3 Hz, 1 H, NCHaxHeqCHeqF). 13C NMR (101 MHz, C2Cl4D2, 80 °C, TMS): δ 
= 28.38 (OC(CH3)3), 31.83 (d, JCF = 21.5 Hz, NCH2CHCH2), 36.73 (d, JCF = 1.9 Hz, 
NCH2CHC=O), 45.21 (NCH2CHC=O), 47.48 (d, JCF = 22.7 Hz, NCH2CHF), 51.79 
(OCH3), 80.18 (OC(CH3)3), 85.14 (d, JCF = 174.6 Hz NCH2CHF), 154.80 (NC=O), 
173.04 (NCH2CHC=O) ppm. 19F {1H} NMR (376 MHz, C2Cl4D2, 80 °C): δ = 185.42 ppm. 
MS (EI, 70 eV): m/z = 261.1 (1%, [M]+•), 206.1 (9%), 205.1 (12%), 204.1 (14%), 202.1 
(12%), 188.1 (32%), 174.1 (20%), 160.1 (29%), 141.1 (43%), 102.1 (15%), 82.1 (33%), 
57.1 (100%). HRMS (EI, 70 eV): [M]+• calcd. for C12H20O4NF: 261.1376; found 
261.1383. 
 
rac-(3R)-[1-(tert-Butyl) 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate] (46): 
 
XtalFluor-E (41; 617 mg; 2.64 mmol) was dissolved in DCM (2.0 mL) and cooled to 0 
°C under argon atmosphere. Triethylamine trihydrofluoride (545 mg; 3.38 mmol) and 
compound 48 (275 mg; 1.07 mmol), dissolved in DCM (1.7 mL) were successively 
added and the mixture was stirred at 0 °C for 220 min. The reaction was quenched 
with a 5 % aqueous Na2CO3 solution (10 mL), stirred at rt for further 15 min and then 
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it was extracted with DCM (5 x 15 mL). The combined organic phases were dried over 
Na2SO4 and concentrated under reduced pressure. After purification by column 
chromatography (silica gel; ethyl acetate/iso-hexane = 1:5) 46 was obtained as white 
amorphous solid (197 mg; 66%). Rf = 0.32 (ethyl acetate/iso-hexane = 1:5). IR (KBr): 
v
~ = 3028, 3009, 2986, 2972, 1737, 1701, 1465 cm-1. 1H NMR (400 MHz, C2Cl4D2, 80 
°C, TMS): δ = 1.45 (s, 9 H, OC(CH3)3), 1.99 (dddd, J = 31.1/13.8/11.8/5.3 Hz, 1 H, 
NCH2CHCHaxHeq), 2.38–2.50 (m, 1 H, NCH2CHCHaxHeq), 2.72–2.90 (m, 2 H, 
NCHaxHeqCHaxC=O, NCHaxHeqCHaxC=O), 2.99 (dddd, J = 29.1/13.8/1.7 Hz, 1 H, 
NCHaxHeqCF2), 3.70 (s, 3 H, OCH3), 4.17–4.28 (m, 1 H, NCHaxHeqCF2), 4.31 (d, J = 
11.6 Hz, 1 H, NCHaxHeqCHaxC=O) ppm. 13C NMR (101 MHz, C2Cl4D2, 80 °C, TMS): δ 
= 28.30 (OC(CH3)3), 35.09 (t, JCF = 25.0 Hz, NCH2CHCH2), 38.93 (d, JCF = 8.7 Hz, 
NCH2CHC=O), 44.72 (NCH2CHC=O), 49.34 (dd, JCF = 35.8/28.2 Hz, NCH2CF2), 52.07 
(OCH3), 80.94 (OC(CH3)3), 118.80 (t, JCF = 244.3 Hz NCH2CF2), 154.24 (NC=O), 
171.41 (NCH2CHC=O) ppm. 19F {1H} NMR (376 MHz, C2Cl4D2, 80 °C): δ = 101.24 (d, 
JFF = 243.4 Hz), 104.28 (d, JFF = 243.2 Hz) ppm. MS (EI, 70 eV): m/z = 279.1 (2%, 
[M]+•), 206.1 (11%), 159.1 (28%), 97.1 (11%), 83.1 (14%), 81.1 (11%), 71.1 (17%), 
69.1 (19%), 57.1 (100%). HRMS (EI, 70 eV): [M]+• calcd. for C12H19O4NF2: 279.1282; 
found 279.1263. 
 
rac-(3R,5R)-(5-Fluoropiperidine-3-carboxylic acid) (rac-49): 
 
Compound rac-45 (53 mg; 0.20 mmol) was dissolved in THF (2.2 mL) and 1 M HCl 
(2.2 mL; 2.2 mmol) was added. The solution was refluxed for 3 h before the reaction 
was quenched with H2O (20 mL). The aqueous phase was washed with DCM  
(3 x 15 mL) and freeze dried. The residue was purified by strongly acidic cation 
exchange chromatography with a 25 % aq. NH3 solution as solvent to yield rac-49 as 
white lyophilisate (30 mg; quant.). IR (KBr): v~ = 3431, 3008, 2960, 2931, 2822, 2785, 
2723, 2629, 2583, 2529, 2464, 2373, 2134, 1636, 1579, 1464, 1453 cm-1. 1H NMR 
(400 MHz, 1 M NaOD in D2O, 25 °C, MeOH): δ = 1.76 (dddd, J = 45.6/14.5/12.6/2.3 
Hz, 1 H, NCHaxHeqCH(COOH)CHaxHeq), 2.18–2.31 (m, 1 H, 
NCHaxHeqCH(COOH)CHaxHeq), 2.54 (dd, J = 12.6/11.2 Hz, 1 H, NCHaxHeqCHCOOH), 
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2.57–2.67 (m, 1 H, NCHaxHeqCHCOOH), 2.68 (dd, J = 41.3/14.8 Hz, 1 H, 
NCHaxHeqCHF), 3.04–3.15 (m, 2 H, NCHaxHeqCHCOOH, NCHaxHeqCHF), 4.79–4.91 
(m, 1 H, NCHaxHeqCHF) ppm. 13C NMR (101 MHz, 1 M NaOD in D2O, 25 °C, MeOH): 
δ = 32.15 (d, JCF = 22.1 Hz, NCH2CH(COOH)CH2), 40.64 (NCH2CHCOOH), 47.30 
(NCH2CHCOOH), 47.78 (d, JCF = 21.2 Hz, NCH2CHF), 88.16 (d, JCF = 163.8 Hz 
NCH2CHF), 183.06 (COOH) ppm. 19F {1H} NMR (376 MHz, 1 M NaOD in D2O, 25 °C): 
δ = 185.59 ppm. MS (EI, 70 eV): m/z = 147.1 (26%, [M]+•), 127.1 (100%), 101.0 (49%). 
HRMS (EI, 70 eV): [M]+• calcd. for C6H10O2NF: 147.0696; found 147.0688. 
 
rac-(3R)-(5,5-difluoropiperidine-3-carboxylic acid) (50): 
 
Compound 46 (128 mg; 0.458 mmol) was dissolved in THF (5.0 mL) and 1 M HCl  
(5.0 mL; 5.0 mmol) was added to the solution. The mixture was stirred at rt for 30 min 
and refluxed for 3 h, before the reaction was quenched with H2O (25 mL). The aqueous 
phase was washed with DCM (3 x 20 mL) and freeze dried. The residue was purified 
by strongly acidic cation exchange chromatography with a 25 % aq. NH3 solution as 
solvent to yield 50 as white lyophilisate (68 mg; 90%). IR (KBr): v~ = 3430, 3022, 2979, 
2807, 2671, 2528, 1595, 1460 cm-1. 1H NMR (400 MHz, 1 M NaOD in D2O, 25 °C, 
MeOH): δ = 1.93–2.12 (m, 1 H, NCH2CHCHaxHeq), 2.34–2.46 (m, 1 H, 
NCH2CHCHaxHeq), 2.53–2.68 (m, 2 H, NCHaxHeqCHaxC=O, NCHaxHeqCHaxC=O), 2.83 
(ddd, J = 30.4/13.9/1.8 Hz, 1 H, NCHaxHeqCF2), 3.08–3.19 (m, 2 H, NCHaxHeqCHaxC=O, 
NCHaxHeqCF2) ppm. 13C NMR (101 MHz, 1 M NaOD in D2O, 25 °C, MeOH): δ = 36.21 
(dd, JCF = 24.3/22.2 Hz, NCH2CHCH2), 44.75 (d, JCF = 7.3 Hz, NCH2CHC=O), 47.47 
(NCH2CHC=O), 50.48 (dd, JCF = 29.4/26.6 Hz, NCH2CF2), 121.95 (dd, JCF = 
243.5/240.9 Hz, NCH2CF2), 181.53 (NCH2CHC=O) ppm. 19F {1H} NMR (376 MHz, 1 M 
NaOD in D2O, 25 °C): δ = 99.42 (d, JFF = 239.1 Hz), 103.53 (d, JFF = 239.1 Hz) ppm. 
MS (EI, 70 eV): m/z = 165.1 (9%, [M]+•), 146.1 (9%), 145.1 (100%), 120.1 (29%), 119.1 
(24%), 101.0 (18%), 100.1 (39%). HRMS (EI, 70 eV): [M]+• calcd. for C6H9O2NF2: 
165.0601; found 165.0592. 
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rac-(3R,5S)-(1-Butyl 3-methyl 5-fluoropiperidine-3-carboxylate) (rac-52): 
 
Compound rac-42 (155 mg; 0.593 mmol) was dissolved in MeOH (3.0 mL) and 2 M 
etheric HCl (3.0 mL; 6.0 mmol) was added. The mixture was stirred at rt for 6.5 h, 
before it was quenched with K2CO3 (830 mg; 6.01 mmol), dissolved in H2O (25 mL). It 
was extracted with DCM (5 x 20 mL) and the combined organic phases were 
concentrated under reduced pressure. The residue was dissolved in acetone (3.0 mL) 
and KI (39.9 mg; 0.240 mmol), K2CO3 (165 mg; 1.19 mmol) and 1-bromobutane  
(0.057 mL; 0.53 mmol) were successively added. The mixture was stirred at rt for 6 h 
and furthermore refluxed for 5 d. Then the reaction was quenched with H2O (25 mL), 
extracted with DCM (5 x 20 mL) and the combined organic phases were concentrated 
under reduced pressure. After purification by column chromatography (silica gel; ethyl 
acetate/iso-hexane = 1:1 + 2% triethylamine) rac-52 was obtained as colorless oil  
(51 mg; 51%). Rf = 0.27 (ethyl acetate/iso-hexane = 1:1 + 2% triethylamine). IR (film): 
v
~  = 2957, 2934, 2873, 2812, 2778, 1739, 1470, 1457 cm-1. 1H NMR (400 MHz, 
CCl2D2, 25 °C, TMS): δ = 0.90 (t, J = 7.3 Hz, 3 H, NCH2CH2CH2CH3), 1.23–1.37 (m, 2 
H, NCH2CH2CH2CH3), 1.39–1.61 (m, 3 H, NCH2CH2CH2CH3, NCH2CHCHaxHeq), 1.95 
(td, J = 10.0/5.3 Hz, 1 H, NCHaxHeqCHaxF), 2.00 (t, J = 11.1 Hz, 1 H, 
NCHaxHeqCHaxC=O), 2.30–2.48 (m, 3 H, NCH2CHCHaxHeq, NCH2CH2CH2CH3), 2.59 
(ddtd, J = 12.6/10.8/4.0/1.8 Hz, 1 H, NCHaxHeqCHaxC=O), 2.99 (dddt, J = 
11.3/4.2/2.9/1.5 Hz, 1 H, NCHaxHeqCHaxC=O), 3.06–3.17 (m, 1 H, NCHaxHeqCHaxF), 
3.66 (s, 3 H, OCH3), 4.56 (dddt, J = 48.4/10.7/9.6/4.7, 1 H, NCHaxHeqCHaxF) ppm. 13C 
NMR (101 MHz, CCl2D2, 25 °C, TMS): δ = 14.16 (NCH2CH2CH2CH3), 20.89 
(NCH2CH2CH2CH3), 29.34 (NCH2CH2CH2CH3), 33.75 (d, JCF = 20.4 Hz, NCH2CHCH2), 
40.34 (d, JCF = 11.6 Hz, NCH2CHC=O), 52.08 (OCH3), 54.83 (d, JCF = 1.6 Hz, 
NCH2CHC=O), 57.81 (d, JCF = 25.0 Hz, NCH2CHF), 58.08 (NCH2CH2CH2CH3), 88.27 
(d, JCF = 171.3 Hz, NCH2CHF), 173.35 (d, JCF = 2.61 Hz, NCH2CHC=O) ppm. 19F {1H} 
NMR (376 MHz, CCl2D2, 25 °C): δ = 181.64 ppm. MS (EI, 70 eV): m/z = 217.1 (2%, 
[M]+•), 174.1 (100%), 57.1 (13%). HRMS (EI, 70 eV): [M]+• calcd. for C11H20O2NF: 
217.1478; found 217.1473. 
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rac-(3R,5S)-(1-Butyl-5-fluoropiperidine-3-carboxylic acid) (rac-51): 
 
Compound rac-52 (42 mg; 0.19 mmol) was dissolved in THF (2.0 mL) and 1 M HCl 
(2.0 mL; 2.0 mmol) was added to the solution. The mixture was stirred at rt for 50 min 
and refluxed for 1 h, before the reaction was quenched with H2O (25 mL). The aqueous 
phase was washed with DCM (3 x 20 mL) and freeze dried. The residue was dissolved 
in 2 M NaOH (2.0 mL; 4.0 mmol) and stirred at rt for 23 h, before the reaction was 
quenched with H2O (20 mL). The aqueous phase was washed with DCM (1 x 40 mL 
and 1 x 20 mL), acidified with 2 M HCl (5.0 mL; 10.0 mmol), again washed with DCM 
(2 x 20 mL) and freeze dried. The residue was purified by strongly acidic cation 
exchange chromatography with a 25 % aq. NH3 solution as solvent to yield rac-51 as 
white lyophilisate (11 mg; 28%). IR (KBr): v~ = 3429, 2960, 2928, 2872, 1604, 1458 
cm-1. 1H NMR (400 MHz, 1 M NaOD in D2O, 25 °C, MeOH): δ = 0.94 (t, J = 7.3 Hz, 3 
H, NCH2CH2CH2CH3), 1.34 (sext, J = 7.3 Hz, 2 H, NCH2CH2CH2CH3), 1.45–1.61 (m, 
3 H, NCH2CH2CH2CH3, NCH2CHCHaxHeq), 1.98–2.09 (m, 2 H, NCHaxHeqCHaxC=O, 
NCHaxHeqCHaxF), 2.37–2.56 (m, 4 H, NCHaxHeqCHaxC=O, NCH2CHCHaxHeq, 
NCH2CH2CH2CH3), 3.07 (d, J = 11.5 Hz, 1 H, NCHaxHeqCHaxC=O), 3.22–3.30 (m, 1 H, 
NCHaxHeqCHaxF), 4.72 (dm, J = 48.0, 1 H, NCHaxHeqCHaxF) ppm. 13C NMR (101 MHz, 
1 M NaOD in D2O, 25 °C, MeOH): δ = 14.33 (NCH2CH2CH2CH3), 21.27 
(NCH2CH2CH2CH3), 28.72 (NCH2CH2CH2CH3), 35.17 (d, JCF = 18.8 Hz, NCH2CHCH2), 
43.25 (d, JCF = 10.6 Hz, NCH2CHC=O), 55.87 (NCH2CHC=O), 57.16 (d, JCF = 25.9 Hz, 
NCH2CHF), 58.41 (NCH2CH2CH2CH3), 89.65 (d, JCF = 168.1 Hz, NCH2CHF), 182.04 
(NCH2CHC=O) ppm. 19F {1H} NMR (376 MHz, D2O, 25 °C): δ = 181.93 ppm. MS (EI, 
70 eV): m/z = 203.1 (13%, [M]+•), 161.1 (67%), 160.1 (100%), 140.1 (33%). HRMS (EI, 
70 eV): [M]+• calcd. for C10H18O2NF: 203.1322; found 203.1316. 
 
Biological testing: [3H]GABA uptake assays were performed as previously 
described73 by technical assistants of our group under the supervision of Dr. Georg 
Höfner. 
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5 Summary of the thesis 
Epilepsy and several other CNS diseases are associated with an impaired GABAergic 
neurotransmission. By the inhibition of membrane-bound GABA transporters (GATs), 
the GABA (1) concentration available in the synaptic cleft for downstream receptors 
can be enhanced, thus adjusting the reduced inhibitory neurotransmission. Particularly 
the GABA transporter subtype GAT1 (≙ mGAT1) emerged as a well-known drug target 
mediating anticonvulsant effects, while other GAT subtypes including GAT3 (≙ 
mGAT4) are still evaluated for their pharmacological potential as drug targets. 
Prototypic GAT inhibitors such as the GAT1-selective, highly potent tiagabine (6), 
which is the first GAT inhibitor in clinical use, and the GAT3-selective (S)-SNAP-5114 
(16) are typically derivatives of small cyclic amino acids such as nipecotic acid (9), of 
which the 1-position of the piperidine moiety is substituted with a lipophilicity-enhancing 
residue.  
The aim of this thesis was to synthesize nipecotic acid derivatives substituted in the 5-
position of the core structure with a lipophilic residue attached to it via a spacer in order 
to explore this uncommon substitution pattern as possible means of obtaining novel 
GABA uptake inhibitors. The idea for this project was based on previous in silico 
studies in our group, in which hypothetical, 5-substituted nipecotic acid derivatives 
were indicated to exhibit an interesting binding pose at the target GAT1. To be able to 
explore a vast and easy to perform variation of lipophilic residues of the target 
compounds, the aims of this thesis should be addressed in an approach that combines 
the generation of dynamic combinatorial hydrazone libraries and the screening of their 
binding affinities towards mGAT1 by means of MS Binding Assays as initially employed 
to N-substituted nipecotic acid derivatives and described by Sindelar and Wanner.87 
The first two studies of this cumulative thesis comprise the syntheses of appropriate 
hydrazine building blocks 29–31, the compilation of aldehyde libraries 26, the 
generation of hydrazone libraries 32–34, the screening and deconvolution experiments 
of these hydrazone libraries 32–34 at mGAT1 as well as the hit verification and 
examinations on the interaction mode. To this end, a synthetic route had first to be 
developed that yielded the building blocks equipped with different spacer lengths 
containing zero, one or two carbon atoms between the nipecotic acid moiety and the 
hydrazine function as well as with different relative orientations (i.e. cis- or trans-
oriented) of the residue in 5-position with respect the carboxylic acid function in 3-
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position of the piperidine ring; that are cis-C0, cis-C1, trans-C1, cis-C2 and trans-C2 
nipecotic acid derived hydrazines 29–31. Each of the five individual hydrazines 29–31 
was separately reacted with all 28 aldehyde libraries 26 in order to allow the formation 
of the hydrazone libraries 32–34. The generation of the hydrazone libraries 32–34 was 
performed in the presence of the target mGAT1 and competitive MS Binding Assays 
served as read-out for their binding affinities towards this target. Libraries found to be 
active were furthermore examined in deconvolution experiments in order to identify 
their most active components. In total, 17 exclusively cis-oriented hydrazones 32–34 
with promising binding affinities towards mGAT1 were revealed by the screening and 
deconvolution experiments; for hit verification, these 17 compounds were 
resynthesized in pure form and their binding affinities (pKi values) were established in 
full-scale MS binding experiments. Thereby, eleven hydrazones 32–34 were found to 
be potent ligands of mGAT1 with pKi values in the submicromolar range. With respect 
to both the substitution in the 5-position and the lipophilic residues these new 
hydrazones 32–34 comprise structural scaffolds so far unprecedented for 
GAT1/mGAT1 inhibitors. Although exhibiting clearly lower inhibitory potencies (pIC50) 
at mGAT1 (as established by functional [3H]GABA uptake assays and compared to 
their good pKi values determined in MS Binding Assays), these novel hydrazones 
(represented by one C0-derived hydrazone 32 and two C1-derived hydrazones 33 in 
further experiments) are particularly interesting since they were found to exhibit a 
noncompetitive interaction mode at mGAT1 by MS based saturation experiments; 
likely, they address a so far uncharacterized, allosteric binding site at GAT1/mGAT1. 
Thus, the herein introduced 5-substituted nipecotic acid derivatives exhibit a different 
pharmacological profile as bench mark GAT1 inhibitors and could represent interesting 
tool compounds for exploring GAT1 mediating GABA transport. 
In the third study of this cumulative thesis, all the libraries comprising the same 
hydrazones 32–34 as utilized in the previous studies were intended to be examined in 
a new kind of screening at mGAT4. Therefore, hydrazone libraries 32–34 were 
generated by preincubating the hydrazine building blocks 29–31 with the aldehyde 
libraries 26 in the absence of the target mGAT4. The thus generated hydrazone 
libraries 32–34 were successively diluted and examined for their inhibitory potencies 
at mGAT4 in functional [3H]GABA uptake assays. The screening and subsequent 
deconvolution experiments revealed two hydrazones 32 with promising inhibitory 
potencies at mGAT4. For hit verification, both compounds were resynthesized in pure 
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form and their inhibitory potencies (pIC50 values) were established in full-scale 
[3H]GABA uptake assays. These two compounds, which both possess a three-atom 
spacer in cis-orientation with respect to the carboxylic acid function and a lipophilic 
moiety derived from a biphenyl residue, exhibit inhibitory potencies at mGAT4 close to 
that of bench mark GAT3/mGAT4 inhibitor (S)-SNAP-5114 (16). Accordingly, the 
herein introduced compounds comprise new structural scaffolds so far unprecedented 
for GAT3/mGAT4 inhibitors and the substitution in the 5-position of the nipecotic acid 
moiety was again found to represent an interesting means of obtaining potentially novel 
GABA uptake inhibitors. 
Besides the aforementioned approaches addressing the main aims and goals of this 
thesis, some additional nipecotic acid derivatives bearing a hydroxy group or one or 
two fluorine atoms in the 5-position of the piperidine ring were synthesized and tested 
for their functional activities at the different GAT subtypes as structural analogs of 
known GAT inhibitors. Most notably, one fluoro substituent in 5-position of the nipecotic 
acid moiety apparently retains the potency at but increases the subtype selectivity for 
mGAT1, making 5-fluoro substituted nipecotic acid derivatives rac-44 and rac-49 
interesting starting points for the development of potentially new highly potent 
GAT1/mGAT1 inhibitors. 
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6 List of abbreviations 
AS-MS affinity selection-mass spectrometry 
BGT betaine/γ-aminobutyric acid transporter 1   
Boc tert-butyloxycarbonyl  
CNS central nervous system 
DAST diethylaminosulfur trifluoride     
DBU 1,8-diazabicyclo(5.4.0)undec-7-ene 
DCC dynamic combinatorial chemistry   
DCE 1,2-dichloroethane 
DCL dynamic combinatorial library 
DCM dichloromethane 
eq. equivalent  
ESI electrospray ionization 
GABA γ-aminobutyric acid 
GABA-T GABA transaminase 
GAD glutamate decarboxylase  
GAT membrane-bound GABA transporters 
GPCR G-protein coupled receptors 
HTS high-throughput screening 
HUGO Human Genome Organisation 
LC liquid chromatography 
MeOH methanol  
MS mass spectrometry 
NEt3 triethylamine 
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rt room temperature 
SEM standard error of the mean 
SLC solute carrier 
temp. temperature 
THF tetrahydrofuran 
TM transmembrane helix 
VGAT vesicular neurotransmitter transporters 
WHO World Health Organization
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Novel Allosteric Ligands of γ‑Aminobutyric Acid Transporter 1
(GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries
Tobias J. Hauke, Thomas Wein, Georg Höfner, and Klaus T. Wanner*
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ABSTRACT: This study describes the screening of dynamic combinatorial libraries based on nipecotic acid as core structure
with substituents attached to the 5- instead of the common 1-position for the search of novel inhibitors of the GABA transporter
GAT1. The generated pseudostatic hydrazone libraries included a total of nearly 900 compounds and were screened for their
binding affinities toward GAT1 in competitive mass spectrometry (MS) based Binding Assays. Characterization of the
hydrazones with the highest affinities (with cis-configured rac-16gf bearing a 5-(1-naphthyl)furan-2-yl residue and a four atom
spacer being the most potent) in binding and uptake experiments revealed an allosteric interaction at GAT1, which was not
reported for any other nipecotic acid derivative up to now. Therefore, the herein introduced 5-substituted nipecotic acid
derivatives could serve as valuable tools for investigations of allosterically modulated GABA transport mediated by GAT1 and
furthermore as starting point for a new class of GAT1 inhibitors.
■ INTRODUCTION
γ-Aminobutyric acid (GABA; 1; Chart 1) is the most important
inhibitory neurotransmitter in the mammalian central nervous
system (CNS), and pathological abnormalities of the
GABAergic neurotransmission are associated with a number of
neuronal diseases such as epilepsy,1−3 Parkinson’s disease,3,4
depression,4,5 and neuropathic pain.6,7 For the treatment of such
diseases, GABAergic neurotransmission can be enhanced by
agonists of GABA receptors, by targeting metabolic enzymes, or
by inhibiting GABA transport proteins (GATs).8 With
exception of one vesicular GABA transporter, GATs are
membrane bound proteins encoded by the solute carrier 6
gene family (SLC6) that remove GABA from the synaptic cleft
by utilizing a cotransport of sodium and chloride through cell
membranes.9 Among the four different subtypes of membrane
bound transporters designated as GAT1, BGT1, GAT2, and
GAT3 (as suggested by HUGO and corresponding to mGAT1,
mGAT2, mGAT3, and mGAT4 when expressed in mice),10,11
GAT1 is mainly responsible for the neuronal reuptake of GABA
in the CNS and emerged as a drug target, while the
pharmacological role and therapeutic potential of other GAT
subtypes is still less well understood.10−13 Many of the known
GAT inhibitors are derivatives of small cyclic amino acids such
as nipecotic acid (2) and guvacine (3), which already show in
vitro activity as GABA uptake inhibitors by their own.14,15 By
introducing a lipophilic side chain to the cyclic amino acids a
new generation of inhibitors, represented by SK&F-89976A (4),
tiagabine (5), or NO711 (6), was established that has an
increased potency and selectivity toward GAT1 compared to
unsubstituted amino acids.16−19 Furthermore, the increased
lipophilicity of those molecules (4−6) enabled them to cross the
blood−brain barrier in contrast to the more hydrophilic,
unsubstituted amino acids (2,3).20 Tiagabine (5) is well
characterized with respect to its anticonvulsant activity, and it
is the only selective GAT1 inhibitor in clinical use.21 Recently,
DDPM-2571 (7), a new GAT1 selective compound, was found
to exceed the inhibitory potency of tiagabine (5) at GAT1 by
more than one log unit, and it was demonstrated to mediate
anticonvulsant, anxiolytic, antidepressant, and antinociceptive
effects in mouse models.22 All these selective and potent GAT1
inhibitors possess a hydrophilic amino acid “head” and a
lipophilic aromatic moiety that is connected to the amino acid
via a spacer originating from the amino nitrogen of the amino
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acid. There have been extensive efforts23−29 to develop
analogous GAT1 inhibitors with a different substitution pattern
of the cyclic amino acid. For example, 4-substituted nipecotic
acid derivatives including compound rac-829 and 6-substituted
guvacine derivatives including compound 924 were synthesized
and tested for their inhibitory potencies of the GABA transport.
However, among these only compound 9 showed in vitro
activity comparable to N-substituted derivatives but was inactive
in anticonvulsant models in vivo, likely due to an insufficient
blood/brain concentration ratio.24
In 2005, the first crystal structure of a bacterial leucine
transporter (LeuT) was reported,30 which represents a
homologue of the SLC6 GABA transporters. Since then, two
investigations used this structure as a base for homology
modeling and analysis of the binding of small inhibitors toward
GAT1.31,32 Later, the binding of tiagabine (5) and related
compounds was evaluated using homology modeling, docking,
and molecular dynamics simulations,33 and different binding
modes of small and large inhibitors were proposed.34 We have
used our in-house hGAT1 homology model refined by
molecular dynamics calculations and described in detail in
Wein et al.34 to investigate the possibility of attaching the
lipophilic arylalkyl residue to the 4- or 5-position of nipecotic
acid (2). For an in silico screening, we built a virtual library of 4-
and 5-substituted nipecotic acid derivatives, of which the
lipophilic residues were chosen to be biphenyl or diphenyl
residues. For the linker, carbon chains with 3, 4, 5, or 6 atoms
and bearing a double bond in conjugation with the aromatic
moiety were examined (example see hypothetical molecule 10).
The substitution of nipecotic acid (2), particularly in the 5-
position and with a five carbon spacer (as in molecule 10), was
found to achieve the highest docking scores among the
hypothetical compounds. Docking calculations showed for
nipecotic acid derivative 10 and related 5-substituted derivatives
that the nitrogen atom was able to point toward the intracellular
side of the binding cavity and could potentially interact with two
different hydrogen bond acceptors in this position. Thereby, the
lipophilic residue would point to the extracellular side of the
pocket (Figure 1c). So the binding pose of the piperidine ring of
5-substituted derivatives would be more similar compared to
that of the unsubstituted nipecotic acid (2; Figure 1a) and
opposing to that of tiagabine (5), of which the piperidine
nitrogen and the attached arylalkyl moiety are facing toward the
extracellular side (Figure 1b).34
On the basis of these results obtained from in silico studies, we
concluded that nipecotic derivatives bearing a lipophilic moiety
attached to the 5-position via a spacer might possibly represent a
new class of potent GABA uptake inhibitors. For a vast and most
of all easy to perform variation of the structure of the lipophilic
residues attached to the 5-position of the nipecotic acid moiety,
we decided to analyze compound libraries generated by dynamic
combinatorial chemistry (DCC). Hence, we followed an
approach that is based on pseudostatic hydrazone libraries and
uses a competitive mass spectrometry (MS) based Binding
Assay for their analysis as reported from our group, recently.35
MS Binding Assays have the advantage to enable the label-free
determination of binding affinities36 and can be employed
analogous to radioligand Binding Assays but are devoid of the
drawbacks that result from using radioactive material.37 TheMS
Binding Assay for the target murine GAT1 (mGAT1) that is
required for this study and that uses NO711 (6) as a native
marker had already been established by us and employed in
related screening campaigns.38
For the present study, we intended to synthesize nipecotic
acid derivatives substituted at the 5-position with a C1 (rac-11
and rac-12) and a C2 spacer (rac-13 and rac-14) and with a
hydrazine function at the end of the spacer. By reaction with
appropriate aldehydes 15, these nipecotic acid derived
hydrazines should allow generation of libraries with a hydrazone
function containing a total spacer length of four atoms (rac-16
and rac-17, resulting from the conversion of hydrazines rac-11
and rac-12) and five atoms (rac-18 and rac-19, resulting from
hydrazines rac-13 and rac-14) (Scheme 1), which should be
screened for their affinities toward mGAT1 and evaluated as
potential GABA uptake inhibitors. Hence, compounds with a
five atom spacer, as suggested by molecular modeling, as well as
with a four atom spacer, which appeared beneficial in some
previously reported cases when potentially new N-substituted
GAT1 inhibitors were synthesized,39,40 should be examined in
this study.
In addition to the generation and screening of the hydrazone
libraries in competitive Binding Assays the whole screening
process would further comprise deconvolution of the most
potent libraries (testing only single hydrazones) and hit
verification by resynthesis and determination of pKi values.
Finally, the best binders should be tested in [3H]GABA uptake
assays for their functional activity (IC50) and subtype selectivity.
Chart 1. Structures of GABA (1), GAT1 Inhibitors (2−9),
and Hypothetical Molecule 10
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■ RESULTS AND DISCUSSION
Chemistry. Synthesis of Hydrazines. For the synthesis of
the desired hydrazines rac-11−rac-14, a carbon side chain had to
be introduced in the 5-position of nipecotic acid (or derivatives
thereof) exhibiting a terminal function suitable for further
derivatization, i.e., the introduction of a hydrazine moiety. As
common precursors required for all hydrazine derivatives, the
aldehydes rac-20 and rac-21were chosen. These aldehydes were
synthesized from commercially available nicotinate 22 as shown
in Scheme 2. Compounds rac-23 and rac-24 were obtained by a
hydrogenation of nicotinate 22 and a subsequent protection of
the amino function with a tert-butyloxycarbonyl (Boc) group.
To this end, conditions as described in a patent41 were applied
initially. However, under these conditions, the hydrogenation
reaction did not lead to a conversion of the starting material
(22). Accordingly, the procedure was modified by adding
sulfuric acid to the reaction mixture in the hydrogenation step.
With this modified protocol, the two diastereomeres rac-23 and
rac-24 (in 3:1 ratio) were obtained in yields of 55% (rac-23) and
19% (rac-24) after separation by flash chromatography. The
major diastereomere rac-23 was oxidized with Dess−Martin
periodinane analogous to a patent,42 yielding the ketone 25
(74%; the oxidation of the two diastereomeres rac-23 and rac-24
as a mixture afforded 25 in approximately the same yield).
To introduce the side chain in the 5-position of 25, we
performed a Wittig reaction (analogously as it was described in
literature for different compounds)43 with the ylide generated
from methoxymethyl triphenylphosphonium chloride by means
of potassium tert-butoxide, which yielded the enol ether 26
(57%; 1:1 mixture of E- and Z-isomer; isomers not separated).
The hydrolysis of the enol ether group was accomplished by a
modified protocol for an analogous reaction from literature43
using 2MHCl (instead of 4 and 6M) and a higher proportion of
the solvent THF (6:1 instead of 1:1 of THF/acid). That way the
undesired additional hydrolysis of the ester function could be
reduced and diastereomeric aldehydes rac-2044 and rac-21 could
be obtained in a yield of 78% as a 1:1 mixture, the separation of
which appeared to be laborious due to their nearly identical
chromatographic retention.
For the synthesis of the nipecotic acid derived hydrazine
derivatives with a C1 spacer, rac-11 and rac-12, at first a direct
reductive hydrazine formation was attempted by converting the
mixture of aldehydes rac-20 and rac-21 with tert-butyl carbazate
applying different reducing agents (e.g., sodium cyanoborohy-
dride or sodium borohydride). This, however, did not lead to the
desired Boc-protected hydrazine derivatives. As an alternative,
the introduction of the required hydrazine function should be
accomplished by a Mitsunobu reaction following a protocol of
Brosse et al.45−47 Alcohols rac-2744 and rac-2848 required for
this purpose were prepared by reduction of aldehydes rac-20 and
rac-21 (in 1:1 mixture) with sodium borohydride (rac-27 and
rac-28; 1:1 mixture; 76%). The thus obtained 1:1 mixture of rac-
27 and rac-28 (yield 76%) was treated with hydrazine derivative
29,47 triphenylphosphine, and diisopropyl azodicarboxylate
(DIAD) in a Mitsunobu reaction. The formed product was
subsequently freed from the phthalimide protecting group with
methylhydrazine, yielding the hydrazine precursors rac-30 and
rac-31 in good yields (38% and 43%, respectively) after
separation with flash chromatography. Target compound rac-
12 as hydrochloride49 was finally obtained in good yield (87%)
by simultaneous hydrolysis of the ester function and cleavage of
Figure 1. Side view of the hGAT1 model along the membrane plane showing the active site of the transporter. The extracellular side is on the top and
the intracellular side is at the bottom of the picture. Docking poses of (a) nipecotic acid (2; green), (b) tiagabine (5; cyan), and (c) hypothetical
molecule 10 (magenta) in the molecular dynamics refined homology model of hGAT1 are shown. The transmembrane helices TM10, TM11, and
TM12 are not displayed for clarity.
Scheme 1. Condensation of Nipecotic Acid Derived
Hydrazines rac-11−rac-14 with Diverse Aldehydes 15 to
Afford Hydrazones with General Structures rac-16−rac-19
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the Boc group of rac-31 by heating to 60 °C in aqueous HCl and
in a sealed high-pressure tube. The same procedure applied to
rac-30, however, did not lead to the pure product rac-11.
Instead, a mixture of rac-11 with a side product was obtained,
which presumably resulted from an intramolecular cyclization
reaction of the hydrazine moiety with the carboxylic acid ester
function. Hence, the procedure was modified. To avoid the
undesired cyclization reaction, the deprotection of the func-
tional groups was performed in two steps. First, the ester was
hydrolyzed with NaOH to give the free acid rac-32, and then the
Boc groups were cleaved in etheric HCl, giving the desired rac-
11 as hydrochloride49 in good yield (85% over two steps).
For the preparation of nipecotic acid derivatives with the
hydrazine function attached to a C2 spacer, we performed the
Wittig reaction with aldehydes rac-20 and rac-21 analogous as
for the synthesis of the enol ether 26. The two diastereomeric
enol ethers, rac-33 and rac-34, could be isolated by flash
chromatography in pure form (rac-33, 48%; rac-34, 33%). The
enol ether hydrolysis of the individual diastereomeres proceeded
more smoothly than with the analogues with shorter side chains,
giving aldehydes rac-35 and rac-36 in yields of 80% and 88%.
When reacted with tert-butyl carbazate in the presence of
sodium cyanoborohydride and acetic acid following an
analogous literature method,50 the Boc-protected hydrazines
rac-37 and rac-38 were obtained in good yields (85% and 83%,
respectively). The protective groups in rac-37 and rac-38 (Boc
and ester function) could finally be removed in one step by
heating the compounds in hydrochloric acid to 60 °C in a sealed
high-pressure tube. The hydrochlorides of the desired nipecotic
acid derived hydrazines with C2 spacer, rac-13 and rac-14,49
were thus obtained in yields of 85% and 83%, respectively.
Aldehydes. Aldehydes 15a−15hp (Chart 2), required for
library generation, were mostly purchased from commercial
suppliers and some synthesized by literature methods.51,52
Aldehydes 15fd, 15ff, 15fh, 15fi, 15fn, 15fp, 15fs, and 15grwere
synthesized in a Suzuki−Miyaura reaction51,53 (see Supporting
Information). Following previous approaches,35,51,52 preferen-
tially lipophilic, aromatic aldehydes were included in the
libraries taking into account known structure−activity relation-
ships for benchmark GAT inhibitors typically possessing a polar
core structure (mostly an amino acid), a spacer of variable
Scheme 2. Synthesis of Nipecotic Acid Derived Hydrazines with C1 Spacer (rac-11 and rac-12) and C2 Spacer (rac-13 and rac-
14)a
aReagents and conditions: (a) H2 (10 bar), Rh/Al2O3, H2SO4, MeOH, 80 °C, 16 h; (b) Boc2O, NEt3, dioxane, rt, 3 h; (c) separation of
diastereomeres by flash chromatography; (d) Dess−Martin periodinane, DCM, rt, 2.5 h; (e) Ph3PCH2OCH3Cl, t-BuOK, THF, −78 °C → rt, 2 h;
(f) aq HCl (2 M), THF, 0 °C→ rt, 2 d; (g) NaBH4, EtOH, 0 °C, 1 h; (h) PPh3, DIAD, 29,
47 THF, 0 °C, 105 min; (i) CH3NHNH2, THF, 0 °C, 2
h; (j) aq NaOH (1 M), MeOH, 0 °C → rt, 15 h; (k) HCl in Et2O (2 M), rt, 3 d; (l) aq HCl (1 M), H2O, 60 °C (sealed high-pressure tube), 3 h;
(m) Ph3PCH2OCH3Cl, t-BuOK, THF, 0 °C → rt, 1.5 h; (n) aq HCl (2 M), THF, 0 °C → rt, 7−9 h; (o) Boc-NHNH2, NaH3BCN, AcOH,
MeOH, 0 °C → rt, 2.5−3.5 h.
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length, and aromatic moieties (see compounds 4−9). New
aldehydes were added in the order of their availability.
Synthesis of Hydrazones. For the hit verification individual
hydrazones, rac-16 or rac-18 were separately synthesized by
combining 1.0 equiv of hydrazine, rac-11·HCl or rac-13·HCl,
with 1.0 equiv of aldehyde 15 as shown in Scheme 1.
Additionally, stoichiometric amounts of NaOD were added to
neutralize HCl, introduced with the hydrazines.49 For practical
reasons, the reactions were performed in deuterated solvents
Chart 2. Libraries Consisting of Aldehydes 15a−15hp
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(DMSO-d6/D2O = 9:1) to be able to monitor reaction progress
by NMR.54
General Aspects of Library Generation. The generation
and screening of the hydrazone libraries delineated from
hydrazine derivatives rac-11−rac-14, the synthesis of which
was described above, should be accomplished analogous to a
method recently published by us.35
In that case, a nipecotic acid derivative provided with a
hydrazine function attached to the N-atom via a linker was
incubated with aldehyde libraries, each library containing four
constituents. For the sake of simplicity, hydrazone library
formation was performed in the presence of the target, mGAT1.
The incubation time was set to four hours, which was found
sufficient for a complete conversion, and the pH adjusted to 7.1
being compatible with the presence of the proteins. The
hydrazine was applied in excess (100 μM) compared to the
aldehydes (four different aldehydes, concentration of each 10
μM) in order to render composition of the libraries constant,
pseudostatic, although they are still dynamic. To determine the
activity of the libraries, the incubation mixtures were directly
used for competitive MS binding experiments. To this end, the
MS marker NO711 (6) was directly added to the incubation
mixture. After additional 40 min of incubation, the amount of
specifically boundMSmarker 6, which is serving as a measure of
the activity of the library (after liberation from the target), was
quantified by LC-ESI-MS/MS.
Basically, for the present study, the experimental conditions
were analogous to those in the initial approach as well as in a
second subsequent application.35,51 Hence, libraries were
generated in the presence of the target mGAT1 and their
activities were then analyzed by competitive MS Binding Assays
as described above. However, the following changes were made:
The library size was increased from four to eight (aldehydes per
library), and the concentration of individual aldehydes was set to
1.0 μM. Finally, a library containing eight constituents in a
concentration of 1 μM should be considered “active”, if it
reduced the amount of boundMSmarker to <50%. Provided the
activity of a library (i.e., the reduction of MS marker binding to
<50%) was due to a single component, the affinity of this binder
(IC50 value) should be at least 1 μM or lower. Besides, the
concentration of the hydrazine derivatives rac-11−rac-14 was
raised to 200 μM as hydrazine concentrations of 100 μM (as in
previous approaches)35,51 did not lead to a complete hydrazone
formation within the given incubation period (see Supporting
Information). Hence, the 25-fold amount of hydrazines (rac-
11−rac-14) as compared to total aldehyde concentration was
applied for hydrazone library generation in the present study.
Screening and Deconvolution of Hydrazone Libraries.
In the present study, a total of 224 aldehydes grouped in 28
libraries, each containing eight individual aldehydes in a
concentration of 1.0 μM, were used (Chart 2). Each of the 28
aldehyde libraries was converted with all four hydrazines (rac-
11−rac-14, applied as hydrochlorides,49 200 μM) in separate
experiments into the corresponding libraries of hydrazones
(Scheme 3). In the following, hydrazone libraries are termed
“cis-C1”, “trans-C1”, “cis-C2”, and “trans-C2” for hydrazones
derived from rac-16, rac-17, rac-18, and rac-19, respectively,
thus indicating their relative configurations and different spacer
lengths.
The results of the screening experiments for the hydrazone
libraries are shown in Figure 2. Control experiments with the
aldehyde libraries 1−28 (aldehydes 15a−15hp) and hydrazines
rac-11−rac-14 alone were performed to ensure that in the
applied concentrations none of the building blocks affected the
marker binding to a remarkable extent (see Supporting
Information).
Nine cis-C1 hydrazone libraries (rac-16; libraries 1, 3, 6, 10,
23, 24, 25, 27, and 28; Figure 2a) and four cis-C2 hydrazone
libraries (rac-18; libraries 1, 19, 23 and 24; Figure 2c) were
found to reduce the remaining MS marker binding below 50%
(by mean values of four replicates) and thus were considered
active. Interestingly, all active libraries derived from cis-
configured nipecotic acid derivatives, while the trans-C1 (rac-
17, Figure 2b) and trans-C2 hydrazone libraries (rac-19, Figure
Scheme 3. Example for the Conversion of Aldehyde Library 1 with Hydrazine rac-11 into cis-C1 Hydrazone Library 1
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2d) did not show any striking activity toward mGAT1. All of the
13 hydrazone libraries considered active were further examined
in deconvolution experiments in order to identify their most
active components. For these experiments, single hydrazones
were studied in the same way as the libraries except that only
single aldehydes were employed in the test procedure
(incubation of aldehydes in a concentration of 1.0 μM with
hydrazine rac-11 and rac-13, respectively, in a concentration of
200 μM). As summarized in Table 1, 16 hydrazones reducedMS
marker binding below the set limit of 50%, while none of the
corresponding aldehydes alone showed remarkable activity.
Fourteen of the active compounds were represented by the
shorter chained hydrazones rac-16, showing remaining MS
marker binding of 16−49% (rac-16e, rac-16r, rac-16fv, rac-
16fw, rac-16fy, rac-16fz, rac-16ga, rac-16gb, rac-16gc, rac-16ge,
rac-16gf, rac-16gg, rac-16gk, and rac-16ho; Table 1, entries 5,
10, 42−43, 45−49, 51−53, 57, and 79). Among the longer
chained derivatives, only hydrazones rac-18e and rac-18fy
fulfilled the criterion for further analysis by reducing MS marker
binding to 47% and 41%, respectively (Table 1, entries 5 and
45). Asmentioned above, with a reduction of themarker binding
to 50% or lower when applied in a concentration of 1 μM,
“active” test compounds should correspond to a maximum IC50
of∼1 μM. Thus, we considered it worthwhile to subject all these
16 hydrazones to further analysis.
Hit Verification. For hit verification the 16 hydrazones
found most active in deconvolution experiments were
synthesized in pure form, and their binding affinities (pKi
values) were established in full-scale competitive MS binding
experiments.
The pKi values found for the hydrazones are in a range from
5.64 to 6.67 (Table 2). The binding affinities of the best 5-
substituted nipecotic acid derived hydrazones (e.g., rac-16gf,
Table 2, entry 11, or rac-16gg, Table 2, entry 12) are almost as
good as those of yet established potent GAT1 inhibitors such as
tiagabine (5, pKi = 7.56) with the difference in the nominal pKi
values being only about one log unit.
Among the best binders from this study, one possesses a 3-
phenoxyphen-1-yl (rac-16r, pKi = 6.02, Table 2, entry 2),
another a 2-(2-naphthyl)pyrimidin-5-yl (rac-16ho, pKi = 6.03,
Table 2, entry 14) residue. All other compounds are
characterized by the presence of a 5-arylfuran-2-yl residue.
Figure 2. Screening of (a) cis-C1 (rac-16), (b) trans-C1 (rac-17), (c) cis-C2 (rac-18), and (d) trans-C2 hydrazone libraries (rac-19). The bars indicate
the percentage of remaining specific binding of NO711 (6) after an incubation time of 4 h for library generation and 40 min for marker binding to
mGAT1; data represent means ± SD of four replicates. The limit for further analysis of a library was defined as 50% remaining marker binding
(indicated by the dashed line).
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Thereby, the furanyl moiety is linked to differently substituted
phenyl residues or to a naphthyl residue. The hydrazone rac-
16gf (pKi = 6.67, Table 2, entry 11) bearing a 5-(1-
naphthyl)furan-2-yl residue showed the highest binding affinity
toward mGAT1 among all hydrazones in this study. For
compounds with a 5-phenylfuran-2-yl residue monosubstituted
at the phenyl ring, a chlorine atom in ortho-position gives rise to
a binding affinity (rac-16fv, pKi = 5.91, Table 2, entry 3)
nominally slightly superior to that with a chlorine atom in meta-
position (rac-16fw, pKi = 5.73, Table 2, entry 4), while a
trifluoromethyl substituent gives rise to a higher affinity inmeta-
(rac-16gc, pKi = 6.15, Table 2, entry 9) than in ortho-position
(rac-16fz, pKi = 5.64, Table 2, entry 6). Compound rac-16gk
(pKi = 5.84, Table 2, entry 13) with a bromine atom in ortho-
position of the phenyl ring showed a similar binding affinity as its
chloro analogue rac-16fv (pKi = 5.91, Table 2, entry 3). Except
for compounds rac-16gb with an ortho-nitro and a para-chloro
substituted phenyl ring (pKi = 5.83, Table 2, entry 8) and rac-
16ge with a meta-trifluoromethyl and a para-fluoro substitution
(pKi = 5.90, Table 2, entry 10), a second substituent (i.e., chloro
or trifluoromethyl) at the phenyl ring was generally favorable,
leading to pKi values in a range of 6.19−6.61 (for rac-16e, rac-
16fy, rac-16ga, rac-16gg, rac-18e, and rac-18fy). The hydrazone
rac-16gg (pKi = 6.61, Table 2, entry 12) bearing a 3,5-
di(trifluoromethyl)phen-1-ylfuran-2-yl residue was found to be
the best binder among all disubstituted phenyl moieties and in
total second best after naphthylfuranyl derivative rac-16gf
among all hydrazones. The shorter spacer length as in
hydrazones rac-16 (4 atoms) appears to be more favorable
than the longer one in rac-18 (5 atoms), as among cis-C1
hydrazones (rac-16) as compared to cis-C2 hydrazones (rac-
18), more compounds fulfilling the activity criteria were found
with higher affinities (pKi = 6.67 for rac-16gf versus pKi = 6.32
for rac-18fy). Still, with pKi values of 6.21 (rac-18e, Table 2,
entry 15) and 6.32 (rac-18fy, Table 2, entry 16), certain cis-C2
hydrazones (rac-18) also showed good binding affinities toward
mGAT1 and their pKi values are similar to the ones of their
direct (i.e., possessing the same lipophilic moieties) shorter-
spaced analogues rac-16e (pKi = 6.35, Table 2, entry 1) and rac-
16fy (pKi = 6.19, Table 2, entry 5).
Table 1. Results of the Deconvolution Experiments for “Active” Hydrazone Libraries
aPercentage of remaining specific binding of NO711 (6) in the presence of either pure aldehyde 15 or cis-C1 (rac-16) or cis-C2 hydrazones (rac-
18) after an incubation time of 4 h for hydrazone formation and 40 min for marker binding to mGAT1; data represent means ± SD of four
replicates. The limit for further analysis of a hydrazone was defined as 50% remaining marker binding (hydrazones considered active are highlighted
in yellow).
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Interestingly, none of the evaluated hydrazones possesses an
ortho-biphenyl residue as a lipophilic domain which was found
to play a dominant role among the best binders from our
previous library screening approaches focusing on nipecotic acid
derivatives with the lipophilic arylalkyl domain being attached to
the amino funcion.35,51,52 Instead, the described screening of
pseudostatic DCC libraries of 5-substituted nipecotic acid
derivatives revealed mGAT1 ligands with good binding affinities
exhibiting lipophilic aromatic moieties so far unprecedented for
this type of bioactive compounds: The 3-phenoxyphenyl, 2-(2-
naphthyl)pyrimidin-5-yl, 5-(1-naphthyl)furan-2-yl, and 5-phe-
nylfuran-2-yl residue. Notably, the latter showed its highest
binding affinities when the phenyl moiety was substituted with
chloro or trifluoromethyl substituents. In case of the other three
moieties, no corresponding substituted aldehydes were available
that could have been included in the screening process.
After characterization of the binding affinities (pKi values), we
examined the functional activities, i.e., the inhibitory potencies
(pIC50 values), at the four GABA transporter subtypes for the six
best binders, rac-16e, rac-16ga, rac-16gf, rac-16gg, rac-18e, and
rac-18fy. The results obtained in [3H]GABA uptake assays with
HEK cells stably expressing mGAT1-mGAT455 are summarized
Table 2. Binding Affinities (pKi) Determined in Competitive Binding Assays at mGAT1 of Hydrazones Synthesized in Pure Form
aIndividually synthesized from appropriate aldehydes and hydrazines, see also ref 54. bpKi values are given as means ± SEM of three independent
experiments. cTiagabine (5) was used as reference in all experiments, and a pKi of 7.56 ± 0.06 (n = 8) was found for this compound.
Table 3. Comparison of Inhibitory Potencies (pIC50) of Best Binders at mGAT1-mGAT4 from [
3H]GABA Uptake Experiments
pIC50
a
entry compd mGAT1 mGAT2 mGAT3 mGAT4
1 rac-16e 4.38 ± 0.15 65% 59% 53%
2 rac-16ga 4.09 ± 0.07 91% 57% 57%
3 rac-16gf 4.64 ± 0.10 64% 4.48 ± 0.09 4.12 ± 0.08
4 rac-16gg 50% 84% 65% 79%
5 rac-18e 4.35 ± 0.10 4.27 ± 0.09 4.23 ± 0.09 4.38 ± 0.03
6 rac-18fy 4.45 ± 0.10 4.27 ± 0.03 4.59 ± 0.09 4.82 ± 0.012
aResults of [3H]GABA uptake assays performed with HEK cells stably expressing mGAT1-mGAT4; pIC50 values are given as means ± SEM of
three independent experiments. In the case of low inhibitory potencies, percentages are given that represent remaining [3H]GABA uptake in the
presence of 100 μM test compound.
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in Table 3. The pIC50 values at mGAT1 are in a range from 4.09
to 4.64 except for compound rac-16gg, which did not show an
inhibitory potency high enough for reliable determination of a
pIC50 value in concentrations up to 100 μM (Table 3, entry 4).
Compound rac-16gf, which showed the highest affinity in the
Binding Assays (pKi = 6.67; Table 2, entry 11), also displayed
the highest inhibitory potency of this series of hydrazones in the
uptake assays at mGAT1 (pIC50 = 4.64; Table 3, entry 3). The
observed subtype selectivities for the investigated compounds
toward mGAT1 are considerably low and rac-18fy even showed
its highest potency towardmGAT4 (pIC50 = 4.82, Table 3, entry
6).
The pIC50 values at mGAT1 from the uptake experiments are
surprisingly low compared to the pKi values from the binding
experiments and the nominal differences of the values (pIC50
and pKi) obtained in the two different test systems amounts to
almost two log units. For comparison, for tiagabine (5) a pIC50
of 6.88 ± 0.12 was established in [3H]GABA uptake assays at
mGAT1,55 which is less than about 0.7 log units lower than its
nominal pKi value from the MS binding experiments. To verify
this unexpected outcome, i.e., the large difference between the
binding affinities (pKi) and the inhibitory potencies (pIC50) at
mGAT1, we characterizedGAT1mediatedGABA uptake also at
hGAT1 (i.e., the human equivalent of this GABA transporter
subtype). The results obtained from these experiments (see
Supporting Information) were, however, essentially the same as
those obtained in the [3H]GABA uptake assays for mGAT1.
So far, several hundreds of derivatives of nipecotic acid (2),
guvacine (3), and related heterocyclic amino acids function-
alized at the nitrogen atomwith lipophilic arylalkyl residues have
been characterized in our group in binding and uptake
assays.34,39,40,51,52,56 For all these compounds, pKi values
(from Binding Assays) were observed that are typically higher
than the pIC50 values (from uptake experiments) but no more
than about one log unit. Possibly, this discrepancy is due to
differences in experimental parameters of the two test systems
such as the target material (i.e., whole cells versus membrane
fragments), the buffer constituents or the incubation protocol.
Furthermore, it is worth mentioning that this phenomenon was
reported by others also for monoamine transporter inhibitors
characterized in binding and uptake assays (e.g., at the serotonin
transporter).57
Hence, the disappointingly low inhibitory potencies of the
synthesized hydrazones determined in mGAT1 uptake assays
(pIC50) as compared to the binding affinities (pKi) were rather
surprising. Even taking into account that there is a certain degree
of uncertainty in the stated values, it could be concluded that this
extent of discrepancy between affinity and inhibitory potency
was remarkably higher than that observed by us for other GAT1
inhibitors so far. A possible instability of the hydrazones in the
“Krebs” incubation buffer of the uptake experiments (containing
glucose and Tris)55 as explanation of this phenomenon could be
ruled out by control experiments (see Supporting Information).
Thus, the question arose if the synthesized hydrazones address
the predicted binding site of known bench mark GAT1
inhibitors such as tiagabine (5) and NO711 (6).
Mode of Interaction. To shed light on the mode of
interaction of the herein introduced hydrazones, rac-16gf
(chosen as the most potent compound of the described series
of hydrazones) and rac-16gg (chosen as the compound showing
the highest difference between affinity in Binding Assays and
inhibitory potency in uptake assays) were exemplarily examined,
whether they inhibit the binding of NO711 (6) at mGAT1 in a
competitive or noncompetitive manner. For this purpose,
saturation experiments with NO711 (6) at mGAT1 in the
presence of fixed concentrations of rac-16gf, rac-16gg, and
tiagabine (5) were performed. The latter was applied as a GAT1
ligand generally assumed to inhibit NO711 (6) binding in a
competitive way. Finally, the resulting saturation isotherms were
compared with those obtained in the absence of these
compounds (for experimental details, see Experimental
Section).
In the presence of 100 nM and 1 μM tiagabine (5; the applied
concentrations are about 0.6 and 1.6 log units higher than its
corresponding pKi value), the obtained saturation isotherms
showed that the density of binding sites (Bmax) for NO711 (6)
remained unchanged, whereas the “apparent” equilibrium
dissociation constants (Kd_app) of 6 were significantly enhanced
(see Figure 3 and Table 4). Both results are completely in line
with a competitive inhibition of NO711 (6) binding by tiagabine
(5). According to Hulme and Trevethick,58 a competitive
binding interaction in this kind of saturation experiment can also
be proven with a Schild-like plot. In a Schild-like plot, the
logarithm of the term ( )1KKd appd −
_ , whereby Kd_app is the
“apparent” Kd (in the presence of the test compound) and Kd is
the “true” Kd (in the absence of test compounds), is displayed as
a function of the concentration of the test compound. In the
present case, a slope (here for the sake of simplicity referred to as
Schild-like coefficient, see Table 4) of 1.05 ± 0.05 was found
which further demonstrates the competitive character of the
interaction between tiagabine (5) and NO711 (6) at mGAT1.
The saturation isotherms obtained in the presence of rac-16gf
and rac-16gg in concentrations of 1 and 10 μM (i.e.,
concentrations about 0.6 and 1.7 log units higher than their
corresponding pKi values) were distinctly different as compared
to those obtained in the presence of tiagabine (5). Both
compounds, rac-16gf and rac-16gg, led to a significant decrease
of Bmax, indicating a noncompetitive interaction with respect to
binding of NO711 (6) and the investigated hydrazones at
mGAT1. The “apparent” Kd values in the presence of rac-16gf
and rac-16gg are increased as well, but in this case in contrast to
tiagabine (5), the calculated Schild-like coefficients amounted to
only 0.49 ± 0.10 and 0.57 ± 0.12 for rac-16gf and rac-16gg,
respectively (Table 4), arguing for a negative cooperativity
according to Hulme and Trevethick.58 Taken together, these
results indicate that inhibition of NO711 (6) binding at mGAT1
by the investigated hydrazones rac-16gf and rac-16gg is
noncompetitive and possibly not due to binding at the same
site addressed by the reporter ligand 6 as well as by tiagabine (5).
For the sake of clarity, it should be pointed out that the term
“noncompetitive” is used only phenomenologically, both in
literature59−62 and herein, to indicate that interactions of ligands
with GAT1 give rise to altered saturation isotherms (with
respect to GABA uptake and NO711 (6) binding experiments,
respectively). Hence and as commonly accepted, the term “non-
competitive” does not specify the underlying mechanism by
which a ligand interacts with its target, in the present case
mGAT1. For instance, noncompetitive inhibition modes can be
the result of an allosteric modulation or be caused by an
irreversible binding or very slow dissociating orthosteric
ligand.63 To our knowledge, no studies have been published
so far that experimentally verified the localization of an allosteric
binding site at GAT1 (e.g., by site-directed mutagenesis
experiments). To rule out the aforementioned kinetic
phenomena (i.e., inhibition by irreversibly binding or very
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slow dissociating orthosteric ligands) as cause for the non-
competitive inhibition mode of the hydrazones under
discussion, the inhibitory potencies (pIC50) of these compounds
were determined in additional GABA uptake experiments using
different time periods for preincubation, i.e., in one set of
experiments 0min instead of the commonly applied 25min. The
experimental details as well as the results obtained thereby are
included in the Supporting Information. In short, the inhibitory
potencies of the six hydrazones, rac-16e, rac-16ga, rac-16gf, rac-
16gg, rac-18e, and rac-18fy, obtained when the preincubation
time amounted to 0 min, are in a similar order of magnitude (i.e.,
pIC50 values in a range from 3.77 to 4.57) as those recorded for
the previous experiments (i.e., with the preincubation time
amounting to 25 min, pIC50 values in a range from 3.87 to 4.51
were obtained) with the nominal differences obtained for the
two different incubation periods being minor and insignificant
(nominal differences between 0 and 25 min preincubation
amounting to only 0.1−0.4 log units). According to these results,
a kinetic phenomenon as explanation for the observed
noncompetitive behavior appears highly unlikely, thus support-
ing an allosteric mode of action at GAT1.
To gain insights in the functional consequences (i.e.,
regarding the inhibition of the GABA transport) associated
with the noncompetitive interaction of the hydrazones rac-16gf
and rac-16gg with GAT1, further GABA uptake experiments
were performed in which either no inhibitor was applied, or
hydrazones rac-16gf and rac-16gg, or finally tiagabine (5) as an
example for a competitively acting compound. These experi-
ments were carried out in form of MS based GABA uptake
saturation experiments with (2H6)GABA as substrate using COS
cells stably expressing hGAT1 as previously reported.64,65 The
saturation curves obtained from the saturation experiments in
presence of the hydrazones rac-16gf and rac-16gg as well as
tiagabine (5), which were applied in concentrations of about or
below their pIC50 values, together with those from the control
experiments (i.e., saturation curves obtained in the absence of
GAT inhibitors) are exemplarily depicted in Figure 4. The Km
and Km_app (“apparent” Michaelis−Menten constants in the
presence of GAT inhibitors) as well as Vmax values calculated
from the data of these saturation experiments are shown in Table
5. As can be seen from these data, in the presence of tiagabine
(5), the maximum velocities for (2H6)GABA transport at
hGAT1 (i.e., Vmax) are slightly decreased while the “apparent”
Michaelis−Menten constants (Km_app) are distinctly increased
(see Table 5). The higherKm_app values effected by tiagabine (5)
are in line with a competitive inhibition mode, whereas the
reduced Vmax values are atypical for a competitive inhibitor,
which is a result, however, that has already been reported before
in literature for this compound (referred to as mixed
competitive/noncompetitive inhibition mode).66 Given that
tiagabine (5) is commonly considered to competitively address
the substrate binding site at GAT1,33,34 we assume that the
slightly decreased Vmax values are at least partly due to the
experimental conditions of the uptake experiment (with a 25
min preincubation period for preequilibration of the test
compound with the target). Conversely, the observed behavior
of the hydrazones rac-16gf and rac-16gg appeared to be
completely different: both the Vmax values and the Km_app values
are substantially decreased (see Table 5), again indicating a
noncompetitive behavior of the hydrazones rac-16gf and rac-
16gg, this time affecting the inhibition of the GABA transport at
hGAT1 (while in the initial experiments described above a
noncompetitive inhibition of theNO711 (6) binding at mGAT1
was observed).
Most notably, the herein introduced hydrazones lead to an
increase of the affinity for the substrate GABA (1) toward its
particular transporter, given the fact that the “apparent”
Michaelis−Menten constants (Km_app, see Table 5) for the
GABA uptake at GAT1 are distinctly reduced in the presence of
rac-16gf and rac-16gg. This observation, as well as the
aforementioned results of the experiments using different
incubation periods, clearly indicate an allosteric mode of action
as explanation for the noncompetitive interaction between the
aforementioned hydrazones and GAT1.
As noted above molecular modeling had indicated that
nipecotic acid derivatives with lipophilic residues attached to the
5-position via an appropriate spacer might represent a new class
Figure 3. Saturation isotherms for NO711 (6) as reporter ligand
addressing mGAT1. Data points represent specific binding (means
from triplicates) obtained in the presence of (a) rac-16gf, (b) rac-16gg,
and (c) tiagabine (5) (in different fixed concentrations as indicated)
and for control also in the absence of any additional test compound.
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of GAT1 inhibitors. Being designed for the binding region
representing the putative binding site of competitive GAT1
inhibitors such as tiagabine (5), these compounds had to be
expected to show the same mode of action, in other words, to be
competitive GAT1 inhibitors as well. Hence, it can be
considered as a matter of serendipity that though the design
aimed at competitive inhibitors, allosteric inhibitors most likely
addressing a different binding site have been identified.
The distinct numerical differences observed between the pKi
values from the binding experiments and the pIC50 values from
uptake experiments can hardly be explained by the allosteric
mode of action of the hydrazone inhibitors alone. A conceivable
explanation could be that binding of ligands or just different
experimental conditions (including target material and buffer
composition as alreadymentioned in the previous section) cause
differences in the GAT1 conformation and the structure of the
allosteric and the substrate binding site, which influence affinity
and potency of investigated test compounds in the way observed
in this study. Although such phenomena are well-known for
neurotransmitter receptors such as the nicotinic acetylcholine
receptor,67 they have not yet been reported for GABA
transporters so far. Hence, further investigations are required
to elucidate this issue and also to improve the understanding of
GAT1 mediated GABA transport in general.
The identified hydrazine inhibitors will be valuable tool
compounds for mechanistic and pharmacological studies,
although their pKi and pIC50 values are lower than those for
common competitive GAT1 inhibitors such as tiagabine (5), to
which, however, they cannot be compared, as they address a
different, namely, an allosteric instead of the competitive binding
site (though it is generally desirable to have benchmark
inhibitors as reference compounds in the assays used to
characterize biological activities in a medicinal chemistry
study−as we did with tiagabine herein).
Potential of the Identified Hydrazone Hits Allosteri-
cally Interactingwith GAT1.Up to now, only few examples of
noncompetitive inhibitors of GAT1 are known, for most of
which the mechanistic rationale (e.g., allosteric modulation or
irreversible binding) for their noncompetitive behaviors has still
to be elucidated. Sarup et al.59 described different N-substituted
3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazols of
which some, such as compound 39 (see Chart 3, pIC50 ∼5.7
for inhibition of GABA uptake at mGAT1), were revealed as
GAT1 inhibitors with noncompetitive mode of inhibition
(based on reduced Vmax values in GABA uptake saturation
experiments). A structurally related compound of 39, referred to
as EF1502 (40), was shown to inhibit both mGAT1 and
mGAT2 (≙ BGT1 according to HUGO) noncompetitively
(pIC50∼5.4 at mGAT1 and pIC50∼4.7 at mGAT2, data refer to
the more potent (R)-enantiomer of 40).60,61 Timple et al.62
described the lignan derivative 41 as a noncompetitive inhibitor
of several neurotransmitter transporters of the SLC6 family
including the dopamine and the norepinephrine transporters as
well as GAT1 (pIC50 ∼4.7 at hGAT1). For the latter target, an
allosteric modulation of the GABA (1) transport was proposed
(based on reduced Vmax and Km_app values in GABA uptake
saturation experiments). Remarkably, none of the aforemen-
tioned noncompetitive inhibitors, 39−41, contains a free amino
acid moiety let alone a nipecotic acid (2) subunit. Only
compounds 39 and 40 can be considered to display a subunit
analogous to an amino acid by accounting the 3-hydroxyisoxazol
moiety as a bioisosteric replacement for a carboxylic acid.68,69
Still, the hydrazones described herein represent a new class of
allosteric GAT1 inhibitors differing substantially from the
noncompetitive inhibitors known so far.
Interestingly, the (R)-enantiomer of EF1502 (40), despite
being clearly less potent than tiagabine (5) at GAT1 in vitro, has
already been shown to exhibit potent anticonvulsant effects in
different in vivo models and, furthermore, to interact synergisti-
cally with tiagabine (5), while potential adverse effects were only
additive.61 Although the pharmacological profile of the
hydrazones rac-16gf and rac-16gg is not sufficiently evaluated
so far, it can be assumed that these compounds could also
mediate promising pharmacological effects, as these compounds
share several common features with EF1502 (40), i.e., they
interact noncompetitively at GAT1, address other GAT
subtypes apart from GAT1, and have inhibitory potencies in a
similar range. However, the herein introduced hydrazones also
display noteworthy differences in the biological activities as
compared to EF1502 (40), making hydrazones rac-16gf and rac-
16gg highly interesting complementary compounds. For
instance, they exhibit a different profile of subtype selectivities:
While EF1502 (40) inhibits both mGAT1 and mGAT2 (≙
BGT1) with similar potencies, hydrazones rac-16gf and rac-
16gg are less potent at mGAT2 but show potencies at mGAT3
and mGAT4, respectively, almost as high as at mGAT1 (see
Table 4. Characterization of theMode of Interaction between the Reporter Ligand (6) andCompounds rac-16gf, rac-16gg, and 5a
inhibitorb
compd parameters 100 nM 1 μM 10 μM absent coefficientc conclusion
rac-16gf Bmax [pmol/mg] 48.4 ± 3.9** 28.3 ± 4.1** 0.49 ± 0.10 noncompetitive
Kd_app [nM] 56.0 ± 7.1 111.9 ± 11.9*
rac-16gg Bmax [pmol/mg] 57.1 ± 3.6* 38.9 ± 1.9** 0.57 ± 0.12 noncompetitive
Kd_app [nM] 57.7 ± 3.8** 154.2 ± 45.9
5 Bmax [pmol/mg] 79.9 ± 4.3 81.0 ± 7.2 1.05 ± 0.05 competitive
Kd_app [nM] 40.5 ± 1.0** 146.8 ± 7.7**
control Bmax [pmol/mg] 79.5 ± 5.0
Kd [nM] 28.3 ± 1.5
aDetermined in saturation experiments using NO711 (6) as reporter ligand for mGAT1. bSaturation experiments were performed in the presence
and absence (control) of rac-16gf, rac-16gg, and 5 (in different fixed concentrations as indicated). cSchild-like coefficients calculated according to
Hulme and Trevethick.58 All results are presented as means ± SEM from three independently performed experiments. Statistically significant
differences from control values are indicated by asterisks (*P < 0.025, **P < 0.01 according to two-tailed Student’s t-tests).
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Table 3). Furthermore, and possibly even more important, the
capability of compounds rac-16gf and rac-16gg to increase the
affinity for the substrate at GAT1 (i.e., reducing the “apparent”
Michaelis−Menten constants, Km_app) and at the same time to
reduce the maximum velocity (Vmax) of GABA transport
provides a pharmacological potential that has not been explored
up to date. To our knowledge, only the lignan derivative 41 has
so far been reported to reduce the “apparent” Michaelis−
Menten constants (Km_app) for the substrate at GAT1 similarly
as it is shown here for the hydrazones rac-16gf and rac-16gg.
Conversely, this compound, 41, was more active at dopamine
and norepinephrine transporters than at GAT1 and was thus
published in the context of a potential drug therapy for the
attention deficit hyperactivity disorder.62 Hydrazone rac-16gf is
about equally potent at GAT1 as lignan derivative 41 (with
respect to the nominal pIC50 values), and in this context it is
worth mentioning that the hydrazones are, in contrast to
compound 41, still racemic, therefore providing the possibility
that the corresponding eutomers could be even slightly more
potent.
Hence, the herein introduced 5-substituted nipecotic acid
derivatives represent valuable new tools for investigation of
allosteric modulation of GAT1 mediated GABA uptake in vitro.
These compounds may also exert a promising new pharmaco-
logical profile by their specific mode of GAT inhibition and be a
helpful starting point for the development of distinctly more
affine and potent GAT1 inhibitors addressing the allosteric
binding site under discussion. Finally, on the basis of experiences
with analogous compounds,51 it appears reasonable to assume
that the hydrazone function within the spacer of this class of
synthesized compounds can be replaced by a corresponding
propenyl group, leading to stable carba analogues without
Figure 4. Saturation isotherms for the (2H6)GABA uptake at hGAT1.
Data points represent specific uptake (means from triplicates) obtained
in the presence of (a) rac-16gf, (b) rac-16gg, and (c) tiagabine (5) (in
different fixed concentrations as indicated) and for control (i.e., in the
absence of any GAT inhibitor).
Table 5. Characterization of the Mode of GABA Uptake Inhibition at GAT1 by Compounds rac-16gf, rac-16gg, and 5a
inhibitorc
compd pIC50
b (hGAT1) parameters 100 nM 300 nM 10 μM 30 μM absent conclusion
rac-16gf 4.37 ± 0.06 Vmax
d 332 ± 56** 165 ± 27** noncompetitive
Km_app
d 10.1 ± 4.0 5.7 ± 1.1**
rac-16gg 3.87 ± 0.03 Vmax
d 341 ± 26** 183 ± 26** noncompetitive
Km_app
d 8.2 ± 1.2* 5.1 ± 0.6**
5 6.81 ± 0.15e Vmax
d 491 ± 61* 419 ± 59** mixedf
Km_app
d 19.7 ± 5.5 29.4 ± 5.8*
control Vmax
d 570 ± 53
Km
d 12.0 ± 1.2
aDetermined in saturation experiments based on MS Transport Assays at hGAT1. bThe inhibitory potencies (pIC50) at hGAT1 were determined
in competition experiments based on MS Transport Assays. cSaturation experiments were performed in the presence and absence (control) of rac-
16gf, rac-16gg, and 5 (in different fixed concentrations as indicated). All results are presented as means ± SEM from three independently
performed experiments. dVmax values are given in [amol/cell·min], Km values in [μM]. Statistically significant differences from control values are
indicated by asterisks (*P < 0.05, **P < 0.01 according to paired, one-tailed Student’s t-tests). eValue from ref 64. fMixed competitive/
noncompetitive, see discussions in the text.
Chart 3. Compounds Proposed As Noncompetitive GAT1
Inhibitors (39−41) in Literature
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remarkable loss of functional activity that should be well suitable
for future in vivo experiments.
■ CONCLUSION
In summary, nipecotic acid derivatives with a novel substitution
pattern were explored with the aim of finding new GABA uptake
inhibitors. Therefore, the 5-substituted nipecotic acid deriva-
tives rac-11−rac-14 possessing a hydrazine function were
synthesized and applied as building blocks in DCC reactions
with appropriate aldehydes for the generation of pseudostatic
hydrazone libraries, which were screened for their affinities
toward mGAT1 by means of MS Binding Assays.35,51 This
approach, i.e., the combined generation and screening of
pseudostatic hydrazone libraries by means of MS Binding
Assays, was again found to represent a powerful tool for
structure−activity relationship studies of ligands for mGAT1,
and it finally revealed new lipophilic moieties for 5-substituted
nipecotic acid derivatives as GAT1 ligands. A total of nearly 900
hydrazones could be screened toward mGAT1, of which the 16
most active were selected for further evaluation of their binding
affinities. The six best binders, rac-16e, rac-16ga, rac-16gf, rac-
16gg, rac-18e, and rac-18fy, with pKi values of 6.21−6.67, are
cis-configured with respect to the substituents of the piperidine
ring and are characterized by 5-arylfuran-2-yl residues as
lipophilic domains, a moiety that is not known so far in GABA
uptake inhibitors. With a pKi value of 6.67 compound rac-16gf
bearing a 5-(1-naphthyl)furan-2-yl residue and a four atom
spacer showed the highest binding affinity within the series of
hydrazones described in this study. Furthermore, the six best
binders were subjected to functional characterization at the
different GABA transporter subtypes, at which, however, they
displayed rather low to moderate inhibitory potencies (pIC50
values up to 4.64 at mGAT1) and low subtype selectivities. In
MS binding experiments with NO711 (6) as a reporter ligand
addressing mGAT1 and compound rac-16gf as well as rac-16gg,
a noncompetitive mode of interaction between the binding of
the evaluated hydrazones and the reporter ligand could be
demonstrated. Additional uptake experiments furthermore
suggested an allosteric mode of action of the GABA (1)
transport at GAT1.
Hence, it can be concluded that substitution of the 5-position
of nipecotic acid represents an interesting structural variation
leading to new GAT1 inhibitors with an interaction mode that
differs distinctly from that of well-known GAT1 inhibitors such
as tiagabine (5). And, more notably, those hydrazones, which
represent the first allosteric modulators of GAT1 derived from
nipecotic acid (2), might emerge as valuable tools for
investigations with the aim to gain more insights in the
physiological relevance of allosteric modulation of GAT1.
■ EXPERIMENTAL SECTION
Chemistry. Solvents for synthesis, extraction, and flash chromatog-
raphy were distilled before use. Anhydrous THF was prepared by
drying over benzophenone/Na. Other commercially available reagents
(by ABCR, Acros, Alfa Aesar, Fisher Scientific, Maybridge, Merck,
Sigma-Aldrich, TCI, and VWR) were used without further purification.
TLC was carried out on precoated silica gel F254 glass plates (Merck)
and detected under UV light (λ = 254 and 366 nm) or by staining with a
ninhydrin solution (0.3 g of ninhydrin and 3 mL of acetic acid dissolved
in 100 mL 1-butanol).70 Flash column chromatography was performed
on silica gel 60 (grading 0.035−0.070 mm, purchased from Merck and
Acros). NMR spectroscopy was performed on Avance III HD Bruker
BioSpin (Bruker: 1H NMR, 400 or 500 MHz; 13C NMR, 101 or 126
MHz; 19FNMR, 376MHz) or JNMR-GX (JEOL: 1HNMR, 400 or 500
MHz; 13C NMR, 101 or 126 MHz) spectrometers. The spectra were
processed with the NMR software MestReNova, versions 8.1, 10.0, and
12.0 (Mestrelab Research SL). Chemical shifts were internally
referenced to TMS or MeOH (for samples dissolved in D2O), except
for hydrazones, which were referenced to DMSO solvent signals (1H
NMR, 2.53 ppm; 13C NMR, 39.13 ppm). IR spectroscopy was
performed on a FT-IR Paragon 1000 (PerkinElmer) spectrometer and
analyzed with the software Spectrum v2.00 (PerkinElmer). Samples
were either pressed in KBr pellets or prepared as films between NaCl
plates. High-resolution mass spectrometry was performed with Jeol
MStation sector field mass spectrometer (Jeol), Thermo Finnigan
MAT 95 (ThermoFischer Scientific) (both EI), or Thermo Finnigan
LTQ FT Ultra mass spectrometer (ThermoFischer Scientific) (ESI).
Elemental analysis for hydrazines rac-11−rac-14 was performed with a
Vario Micro Cube or Vario EL Cube (Elementar) and an 888 Titrando
(Metrohm) in order to determine the corresponding amounts of
hydrogen chloride and water of hydration.49 Melting points were
determined in open capillaries on a Büchi 510 melting point apparatus
and are uncorrected. For purity testing, quantitative NMR spectroscopy
(qNMR) was performed in accordance to the journal protocol71,72 on a
Avance III HD Bruker BioSpin (Bruker: 1H NMR, 400 MHz)
spectrometer. As internal calibrants (IC) dimethyl sulfone (Trace-
CERT certified reference compound, lot no. BCBH9813V, purity:
99.73%) or maleic acid (TraceCERT certified reference compound, lot
no. BCBM8127V, purity: 99.94%) purchased from Sigma-Aldrich were
used. The purity was calculated with the NMR software MestReNova,
versions 10.0 and 12.0 (Mestrelab Research SL). The newly synthesized
aldehydes and hydrazines were ≥95% pure. The metastable
hydrazones54 were used without purity determination but were
synthesized from ≥95% pure building blocks in a 1:1 mixture, and
completeness of the reaction was monitored by NMR. All individually
synthesized hydrazones were checked for PAINS73 with ZINC (http://
zinc15.docking.org/patterns/home/);74 no potential PAINS liabilities
were identified with this in silico tool.
General Procedure for the Simultaneous Hydrolysis of Ester
and Cleavage of Boc Protecting Groups (GP1). The correspond-
ing hydrazine precursor (1.0 equiv) was suspended in a 1 M aqueous
HCl (30 equiv, 30mL/mmol), and themixture was heated to 60 °C in a
sealed high-pressure tube for 3 h. Then the reaction was cooled to rt,
diluted with H2O (15 mL), and washed with DCM (3 × 15 mL). The
aqueous solution was freeze-dried.
General Procedure for the Hydrolysis of Enol Ethers (GP2).
The corresponding enol ether (1.0 equiv) was dissolved in THF (11
mL/mmol), cooled to 0 °C, and a 2 M aqueous HCl (3.7 equiv) was
added. The reaction was stirred at 0 °C for 2 h and at rt for further 5−7
h. Then the reaction was quenched with NaHCO3 (4.6 equiv) and
dissolved in H2O (20 mL). iso-Hexane (5 mL) was added, the phases
were separated, and the aqueous phase was further extracted with DCM
(4 × 25 mL). The combined organic phases were dried over Na2SO4
and concentrated under reduced pressure. The crude product was
purified by flash chromatography on silica gel (EtOAc/iso-hexane =
1:3).
General Procedure for the Reductive Hydrazine Formation
(GP3). The corresponding aldehyde (1.0 equiv) and tert-butyl
carbazate (1.6 equiv) were dissolved in MeOH (33 mL/mmol)
under Ar and stirred at rt for 1 h. Then the mixture was cooled to 0 °C,
AcOH (2.5 equiv), and subsequently NaBH3CN (4.0 equiv, in
portions) were added. It was stirred at 0 °C for 2 h and at rt for
further 80 min. Then the mixture was concentrated under reduced
pressure, quenched with an aqueous NaHCO3 solution (20 mL), and
extracted with DCM (5 × 20 mL). The combined organic phases were
dried over Na2SO4 and concentrated under reduced pressure. The
crude product was purified by flash chromatography on silica gel
(EtOAc/iso-hexane = 1:1).
General Procedure for the Preparation of Hydrazones (GP4).
The reactions were performed in sealed 1.5 mL tubes under Ar. To 850
μL of DMSO-d6, a 200 mM stock solution of the corresponding
hydrazine hydrochloride49 in D2O (50 μL, 1.0 equiv, 0.010 mmol), a 1
M solution of NaOD in D2O (20 μL, 2.0 equiv, 0.020 mmol for rac-11·
HCl and 30 μL, 3.0 equiv, 0.030 mmol for rac-13·HCl) and D2O (30 or
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20 μL) were added to reach a total volume of 950 μL. The reaction was
started by the addition of a 200 mM stock solution of the appropriate
aldehyde in DMSO-d6 (50 μL, 1.0 equiv, 0.010 mmol). The mixture
was sonicated for 5−15 min and stored at rt overnight. All NMR and
HRMS measurements as well as the MS Binding Assays and GABA
uptake assays were performed using this 10 mM solution without
further purification.54 Analysis of the 1HNMR spectra showed that the
reaction equilibriumwas≥96% on the side of the products (determined
by integration of the remaining signal of the aldehyde proton) and the
hydrazones existed to ≥83% as E-isomers.
rac-(3R,5S)-[5-(Hydrazinylmethyl)piperidine-3-carboxylic
Acid]−Hydrogen Chloride−Water (1/2/1) (rac-11·HCl). rac-32
(53 mg; 0.14 mmol) was dissolved in a 2 M etheric HCl (4.8 mL, 9.6
mmol). The solution was stirred under Ar at rt for 3 d. Then themixture
was concentrated under reduced pressure, diluted with H2O (15 mL),
and washed with DCM (3 × 15 mL). The aqueous solution was freeze-
dried, and rac-11·HCl was obtained as white solid (36 mg, 85%); mp
130 °C (decomposition). 1HNMR (500 MHz, 1 M NaOD in D2O, 25
°C): δ 1.14 (q, J = 12.4 Hz, 1 H), 1.65−1.77 (m, 1 H), 2.02 (d, J = 12.8
Hz, 1 H), 2.14 (t, J = 11.9 Hz, 1 H), 2.32 (tt, J = 12.0/3.7 Hz, 1 H), 2.43
(t, J = 11.9 Hz, 1 H), 2.57 (dd, J = 11.9/6.8 Hz, 1 H), 2.60 (dd, J = 11.9/
6.8 Hz, 1 H), 2.98 (dm, J = 12.0 Hz, 1 H), 3.11 (dm, J = 11.9 Hz, 1 H)
ppm.75 13C NMR (126 MHz, 1 M NaOD in D2O, 25 °C): δ 32.9, 34.2,
45.9, 48.2, 49.1, 57.9, 183.7 ppm. IR (film): ν ̃ 3421, 2962, 2839, 2810,
1723, 1589 cm−1. HRMS (ESI): [M + H]+ calcd for C7H16N3O2
174.1237, found 174.1236. Purity (qNMR: 1 M NaOD in D2O, 25 °C,
maleic acid, mS = 6.951 mg, mIC = 9.117 mg): 96%.
rac-(3R,5R)-[5-(Hydrazinylmethyl)piperidine-3-carboxylic
Acid]−Hydrogen Chloride−Water (1/3/1) (rac-12·HCl). Accord-
ing to GP1 with rac-31 (85 mg, 0.22 mmol) and a 1 M aqueous HCl
(6.6 mL, 6.6 mmol). rac-12·HCl was obtained as white solid (57 mg;
87%); mp 135 °C (decomposition). 1H NMR (400 MHz, 1 M NaOD
in D2O, 25 °C): δ 1.56−1.65 (m, 1 H), 1.74−1.85 (m, 1 H), 1.87−1.96
(m, 1 H), 2.41 (tt, J = 7.7/4.3 Hz, 1 H), 2.48 (dd, J = 13.1/6.8 Hz, 1 H),
2.66 (dd, J = 12.0/6.7 Hz, 1 H), 2.70 (dd, J = 12.0/7.4 Hz, 1 H), 2.75−
2.92 (m, 3 H) ppm.75 13C NMR (101 MHz, 1 M NaOD in D2O, 25
°C): δ 30.9, 31.2, 41.2, 47.5, 48.0, 56.3, 183.7 ppm. IR (film): ν ̃ 3428,
2958, 2851, 2366, 1719, 1618, 1595, 1560 cm−1. HRMS (ESI): [M +
H]+ calcd for C7H16N3O2 174.1237, found 174.1241. Purity (qNMR: 1
MNaOD in D2O, 25 °C, maleic acid,mS = 6.166 mg, mIC = 5.709 mg):
98%.
rac-(3R,5R)-[5-(2-Hydrazinylethyl)piperidine-3-carboxylic
acid]−Hydrogen Chloride−Water (1/3/1) (rac-13·HCl). Accord-
ing to GP1 with rac-37 (69 mg, 0.17 mmol) and 1 M aqueous HCl (5.3
mL, 5.3 mmol). rac-13·HCl was obtained as white solid (46 mg, 85%);
mp 145 °C (decomposition). 1HNMR (500MHz, 1MNaOD in D2O,
25 °C): δ 1.11 (q, J = 12.3Hz, 1H), 1.29−1.43 (m, 2H), 1.44−1.55 (m,
1 H), 2.02 (d, J = 12.8 Hz, 1 H), 2.11 (t, J = 11.8 Hz, 1 H), 2.30 (tt, J =
12.0/3.7 Hz, 1 H), 2.42 (t, J = 11.9 Hz, 1 H), 2.73 (dd, J = 12.3/7.0 Hz,
1 H), 2.76 (dd, J = 12.1/6.8 Hz, 1 H), 2.94 (dm, J = 12.2 Hz, 1 H), 3.09
(dm, J = 12.2 Hz, 1 H) ppm.75 13C NMR (126 MHz, 1 M NaOD in
D2O, 25 °C): δ 31.5, 33.9, 34.8, 46.2, 48.2, 50.9, 51.1, 184.0 ppm. IR
(film): ν ̃ 3409, 2955, 2802, 2562, 2347, 1723, 1560 cm−1. HRMS
(ESI): [M + H]+ calcd for C8H18N3O2 188.1394, found 188.1393.
Purity (qNMR: 1 MNaOD in D2O, 25 °C, maleic acid,mS = 11.26 mg,
mIC = 8.962 mg): ≥99%.
rac-(3R,5S)-[5-(2-Hydrazinylethyl)piperidine-3-carboxylic
Acid]−Hydrogen Chloride−Water (1/3/1) (rac-14·HCl). Accord-
ing to GP1 with rac-38 (154 mg; 0.384 mmol) and 1 M aqueous HCl
(11.5 mL, 11.5 mmol). rac-14·HCl was obtained as white solid (101
mg, 83%); mp 143 °C (decomposition). 1H NMR (400 MHz, 1 M
NaOD in D2O, 25 °C): δ 1.37−1.53 (m, 2 H), 1.53−1.66 (m, 2 H),
1.86−1.97 (m, 1 H), 2.34−2.51 (m, 2 H), 2.68−2.82 (m, 4 H), 2.85
(dd, J = 13.1/6.4 Hz, 1 H) ppm.75 13CNMR (101 MHz, 1 M NaOD in
D2O, 25 °C): δ 29.6, 31.0, 32.7, 41.3, 47.5, 49.7, 51.5, 184.0 ppm. IR
(film): ν ̃ 3415, 2955, 2850, 2569, 1719, 1571 cm−1. HRMS (EI, 70 eV):
M+ calcd for C8H17N3O2 187.1321, found 187.1332. Purity (qNMR: 1
MNaOD in D2O, 25 °C, maleic acid,mS = 5.076 mg, mIC = 7.986 mg):
≥99%.
rac-(3R,5S)-(5-{[(E)-2-({5-[2-Chloro-4-(trifluoromethyl)-
phenyl]furan-2-yl}methylidene)hydrazin-1-yl]methyl}-
piperidine-3-carboxylic Acid)−Sodium Chloride (1/2) (rac-
16e).54 According to GP4 with rac-11·HCl, 5-[2-chloro-4-
(trifluoromethyl)phenyl]-2-furaldehyde (15e) and 1 M NaOD (20
μL) rac-16e was obtained quantitatively in solution. Besides the major
E-isomer, the Z-isomer is present in 8%. 1H NMR (500 MHz, DMSO-
d6/D2O= 9:1, 25 °C): δ 1.22 (q, J = 12.5 Hz, 1 H), 1.99−2.10 (m, 1H),
2.13 (d, J = 13.5 Hz, 1 H), 2.44−2.60 (m, 2 H), 2.73 (t, J = 12.5 Hz, 1
H), 3.09 (dd, J = 13.5/6.7 Hz, 1 H), 3.14 (dd, J = 13.7/6.2 Hz, 1 H),
3.28 (dd, J = 12.5/4.2 Hz, 1H), 3.35 (dd, J = 12.5/4.0 Hz, 1 H), 6.67 (d,
J = 3.7 Hz, 1 H), 7.41 (d, J = 3.7 Hz, 1 H), 7.56 (s, 1 H), 7.80 (dd, J =
8.5/1.9 Hz, 1 H), 7.92 (s, 1 H), 8.07 (d, J = 8.4 Hz, 1 H) ppm.75,76 13C
NMR (126 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 30.4, 32.7, 39.8,
45.2, 46.0, 50.6, 109.3, 115.5, 123.3 (q, JCF = 272.7 Hz), 123.8, 124.4 (q,
JCF = 4.4 Hz), 127.7 (q, JCF = 4.1 Hz), 127.9, 128.1 (q, JCF = 32.8 Hz),
128.9, 131.6, 146.7, 152.7, 173.9 ppm.76 19F {1H} NMR (376 MHz,
DMSO-d6/D2O= 9:1, 25 °C): δ−61.1 ppm.
76HRMS (ESI): [M+H]+
calcd for C19H20N3O3ClF3 430.1140, found 430.1139.
rac-(3R,5S)-(5-{[(E)-2-[(3-Phenoxyphenyl)methylidene]-
hydrazin-1-yl]methyl}piperidine-3-carboxylic Acid)−Sodium
Chloride (1/2) (rac-16r).54 According to GP4 with rac-11·HCl, 3-
phenoxybenzaldehyde (15r), and 1 M NaOD (20 μL), rac-16r was
obtained quantitatively in solution. Besides the major E-isomer, the Z-
isomer is present in 3%. 1HNMR (500MHz, DMSO-d6/D2O= 9:1, 25
°C): δ 1.19 (q, J = 12.3 Hz, 1 H), 1.97−2.06 (m, 1 H), 2.10 (d, J = 13.6
Hz, 1 H), 2.40−2.59 (m, 2 H), 2.71 (t, J = 12.5 Hz, 1 H), 3.02 (dd, J =
13.4/7.0 Hz, 1 H), 3.07 (dd, J = 13.5/6.2 Hz, 1 H), 3.25 (dd, J = 12.3/
3.9 Hz, 1H), 3.33 (dd, J = 12.6/4.1 Hz, 1 H), 6.87 (ddd, J = 8.2/2.5/1.1
Hz, 1 H), 6.98−7.04 (m, 2 H), 7.09−7.13 (m, 1 H), 7.16 (tt, J = 7.6/1.1
Hz, 1 H), 7.24 (dd, J = 7.9/0.9 Hz, 1 H), 7.35 (t, J = 7.9 Hz, 1 H), 7.39−
7.44 (m, 2H), 7.57 (s, 1 H) ppm.75,76 13CNMR (126MHz, DMSO-d6/
D2O = 9:1, 25 °C): δ 30.5, 32.8, 40.0, 45.2, 46.1, 50.9, 114.2, 117.6,
118.7, 120.7, 123.6, 130.2, 130.3, 133.6, 138.6, 156.6, 157.0, 174.0
ppm.76HRMS (ESI): [M+H]+ calcd for C20H24N3O3 354.1812, found
354.1811.
rac-(3R,5S)-(5-{[(E)-2-{[5-(2-Chlorophenyl)furan-2-yl]-
methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−Sodium Chloride (1/2) (rac-16fv).54 According to GP4 with
rac-11·HCl, 5-(2-chlorophenyl)-2-furaldehyde (15fv), and 1 MNaOD
(20 μL), rac-16fv was obtained quantitatively in solution. Besides the
major E-isomer, the Z-isomer is present in 9%. 1H NMR (500 MHz,
DMSO-d6/D2O = 9:1, 25 °C): δ 1.21 (q, J = 12.5 Hz, 1 H), 2.02−2.09
(m, 1 H), 2.13 (d, J = 13.7 Hz, 1 H), 2.42−2.61 (m, 2 H), 2.73 (t, J =
12.5 Hz, 1 H), 3.07 (dd, J = 13.4/6.9 Hz, 1 H), 3.12 (dd, J = 13.5/6.2
Hz, 1 H), 3.28 (dd, J = 12.6/4.0 Hz, 1H), 3.34 (dd, J = 12.6/4.0 Hz, 1
H), 6.62 (d, J = 3.6 Hz, 1 H), 7.19 (d, J = 3.6 Hz, 1 H), 7.33 (td, J = 7.7/
1.7 Hz, 1 H), 7.45 (td, J = 7.6/1.3 Hz, 1 H), 7.55 (dd, J = 7.2/1.0 Hz, 1
H), 7.56 (s, 1 H), 7.86 (dd, J = 8.0/1.7 Hz, 1 H) ppm.75,76 13C NMR
(126MHz, DMSO-d6/D2O= 9:1, 25 °C): δ 30.4, 32.7, 39.8, 45.1, 46.0,
50.8, 109.2, 113.2, 124.6, 127.5, 127.6, 128.1, 128.7, 128.7, 130.8, 148.1,
151.5, 173.9 ppm.76 HRMS (ESI): [M + H]+ calcd for C18H21N3O3Cl
362.1266, found 362.1265.
rac-(3R,5S)-(5-{[(E)-2-{[5-(3-Chlorophenyl)furan-2-yl]-
methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−SodiumChloride (1/2) (rac-16fw).54According to GP4with
rac-11·HCl, 5-(3-chlorophenyl)-2-furaldehyde (15fw), and 1MNaOD
(20 μL), rac-16fw was obtained quantitatively in solution. Besides the
major E-isomer, the Z-isomer is present in 9%. 1H NMR (500 MHz,
DMSO-d6/D2O = 9:1, 25 °C): δ 1.22 (q, J = 12.5 Hz, 1 H), 1.99−2.09
(m, 1 H), 2.13 (d, J = 13.6 Hz, 1 H), 2.44−2.59 (m, 2 H), 2.74 (t, J =
12.5 Hz, 1 H), 3.07 (dd, J = 13.5/6.9 Hz, 1 H), 3.12 (dd, J = 13.6/6.4
Hz, 1 H), 3.28 (dd, J = 12.7/3.8 Hz, 1H), 3.35 (dd, J = 12.6/4.0 Hz, 1
H), 6.58 (d, J = 3.5 Hz, 1 H), 7.09 (d, J = 3.6 Hz, 1 H), 7.33 (dd, J = 8.1/
2.1 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1 H), 7.55 (s, 1 H), 7.66 (dt, J = 8.0/1.2
Hz, 1 H), 7.74 (t, J = 1.9 Hz, 1 H) ppm.75,76 13C NMR (126 MHz,
DMSO-d6/D2O= 9:1, 25 °C): δ 30.4, 32.7, 39.8, 45.1, 46.0, 50.8, 109.4,
109.7, 121.8, 122.7, 124.9, 127.1, 131.0, 132.0, 133.8, 150.4, 151.9,
173.9 ppm.76 HRMS (ESI): [M + H]+ calcd for C18H21N3O3Cl
362.1266, found 362.1265.
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rac-(3R,5S)-(5-{[(E)-2-{[5-(2,4-Dichlorophenyl)furan-2-yl]-
methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−Sodium Chloride (1/2) (rac-16fy).54 According to GP4 with
rac-11·HCl, 5-(2,4-dichlorophenyl)-2-furaldehyde (15fy), and 1 M
NaOD (20 μL), rac-16fy was obtained quantitatively in solution.
Besides the major E-isomer, the Z-isomer is present in 9%. 1H NMR
(500 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 1.23 (q, J = 12.5 Hz, 1 H),
1.99−2.10 (m, 1 H), 2.14 (d, J = 13.3 Hz, 1 H), 2.45−2.61 (m, 2 H),
2.75 (t, J = 12.4 Hz, 1 H), 3.08 (dd, J = 13.5/6.7 Hz, 1 H), 3.12 (dd, J =
13.6/6.3 Hz, 1 H), 3.28 (dd, J = 12.4/3.9 Hz, 1H), 3.36 (dd, J = 12.6/
4.0 Hz, 1 H), 6.63 (d, J = 3.6 Hz, 1 H), 7.23 (d, J = 3.6 Hz, 1 H), 7.53
(dd, J = 8.6/2.2 Hz, 1 H), 7.55 (s, 1 H), 7.70 (d, J = 2.2 Hz, 1 H), 7.87
(d, J = 8.6 Hz, 1 H) ppm.75,76 13C NMR (126 MHz, DMSO-d6/D2O =
9:1, 25 °C): δ 30.3, 32.7, 39.8, 44.9, 46.0, 50.7, 109.3, 113.7, 124.3,
127.1, 127.9, 128.6, 129.5, 130.2, 132.1, 147.2, 151.8, 173.7 ppm.76
HRMS (ESI): [M + H]+ calcd for C18H20N3O3Cl2 396.0876, found
396.0875.
rac-(3R,5S)-(5-{[(E)-2-({5-[2-(Trifluoromethyl)phenyl]furan-
2-yl}methylidene)hydrazin-1-yl]methyl}piperidine-3-carbox-
ylic Acid)−Sodium Chloride (1/2) (rac-16fz).54 According to GP4
with rac-11·HCl, 5-[2-(trifluoromethyl)phenyl]-2-furaldehyde (15fz),
and 1 M NaOD (20 μL), rac-16fz was obtained quantitatively in
solution. Besides the major E-isomer the Z-isomer is present in 12%. 1H
NMR (500MHz, DMSO-d6/D2O= 9:1, 25 °C): δ 1.21 (q, J = 12.5 Hz,
1 H), 1.97−2.08 (m, 1 H), 2.12 (d, J = 13.6 Hz, 1 H), 2.43−2.59 (m, 2
H), 2.73 (t, J = 12.5 Hz, 1 H), 3.05 (dd, J = 13.4/6.9 Hz, 1 H), 3.10 (dd,
J = 13.5/6.1 Hz, 1 H), 3.27 (dd, J = 12.6/3.9 Hz, 1H), 3.34 (dd, J =
12.5/4.1 Hz, 1 H), 6.61 (d, J = 3.5 Hz, 1 H), 6.83 (d, J = 3.5 Hz, 1 H),
7.54 (s, 1 H), 7.58 (t, J = 7.7Hz, 1H), 7.75 (t, J = 7.7Hz, 1H), 7.82 (d, J
= 7.8Hz, 1 H), 7.85 (d, J = 7.9 Hz, 1H) ppm.75,76 13CNMR (126MHz,
DMSO-d6/D2O= 9:1, 25 °C): δ 30.4, 32.8, 39.8, 45.0, 46.0, 50.8, 108.8,
112.3, 124.0 (q, JCF = 273.4 Hz), 124.6, 124.7 (q, JCF = 30.6 Hz), 126.8
(q, JCF = 5.9 Hz), 128.5, 128.6 (q, JCF = 1.7 Hz), 129.8, 132.8, 158.6,
152.5, 173.8 ppm.76 19F {1H} NMR (376 MHz, DMSO-d6/D2O = 9:1,
25 °C): δ −58.4 ppm.76 HRMS (ESI): [M + H]+ calcd for
C19H21N3O3F3 396.1530, found 396.1528.
rac-(3R,5S)-(5-{[(E)-2-({5-[2-Chloro-5-(trifluoromethyl)-
phenyl]furan-2-yl}methylidene)hydrazin-1-yl]methyl}-
piperidine-3-carboxylic Acid)−Sodium Chloride (1/2) (rac-
16ga).54 According to GP4 with rac-11·HCl, 5-[2-chloro-5-
(trifluoromethyl)phenyl]-2-furaldehyde (15ga), and 1 M NaOD (20
μL), rac-16gawas obtained quantitatively in solution. Besides themajor
E-isomer, the Z-isomer is present in 8%. 1H NMR (500 MHz, DMSO-
d6/D2O= 9:1, 25 °C): δ 1.17 (q, J = 12.5 Hz, 1H), 1.95−2.08 (m, 1 H),
2.12 (d, J = 13.1 Hz, 1 H), 2.30−2.42 (m, 1 H), 2.45−2.59 (m, 1 H),
2.67 (t, J = 12.5 Hz, 1 H), 3.08 (dd, J = 12.4/5.9 Hz, 1 H), 3.12 (dd, J =
12.7/5.3 Hz, 1 H), 3.25 (dd, J = 12.1/2.5 Hz, 1H), 3.31 (dd, J = 12.7/
4.0 Hz, 1 H), 6.66 (d, J = 3.6 Hz, 1 H), 7.36 (d, J = 3.6 Hz, 1 H), 7.55 (s,
1 H), 7.65 (dd, J = 8.4/2.3 Hz, 1 H), 7.80 (d, J = 8.4 Hz, 1 H), 8.13 (d, J
= 2.3 Hz, 1 H) ppm.75,76 13C NMR (126 MHz, DMSO-d6/D2O = 9:1,
25 °C): δ 31.0, 32.7, 40.9, 45.9, 46.2, 50.5, 109.1, 114.8, 123.5 (q, JCF =
4.0 Hz), 123.5, 123.7 (q, JCF = 272.5 Hz), 124.6 (q, JCF = 3.9 Hz), 128.4
(q, JCF = 32.5 Hz), 129.0, 132.2, 132.5, 146.4, 152.5, 173.4 ppm.
76 19F
{1H} NMR (376 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ −61.3 ppm.
76
HRMS (ESI): [M + H]+ calcd for C19H20N3O3ClF3 430.1140, found
430.1139.
rac-(3R,5S)-(5-{[(E)-2-{[5-(4-Chloro-2-nitrophenyl)furan-2-
yl]methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−sodiumChloride (1/2) (rac-16gb).54 According to GP4 with
rac-11·HCl, 5-(4-chloro-2-nitrophenyl)-2-furaldehyde (15gb), and 1
M NaOD (20 μL), rac-16gb was obtained quantitatively in solution.
Besides the major E-isomer, the Z-isomer is present in 13%. 1H NMR
(500 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 1.20 (q, J = 12.6 Hz, 1 H),
1.98−2.07 (m, 1 H), 2.11 (d, J = 13.3 Hz, 1 H), 2.41−2.60 (m, 2 H),
2.71 (t, J = 12.4 Hz, 1 H), 3.04 (dd, J = 13.5/6.9 Hz, 1 H), 3.09 (dd, J =
13.5/6.1 Hz, 1 H), 3.26 (dd, J = 13.1/3.8 Hz, 1H), 3.33 (dd, J = 12.6/
4.2 Hz, 1 H), 6.60 (d, J = 3.6 Hz, 1 H), 6.93 (d, J = 3.5 Hz, 1 H), 7.44 (s,
1 H), 7.78 (dd, J = 8.6/2.1 Hz, 1 H), 7.86 (d, J = 8.5 Hz, 1 H), 8.05 (d, J
= 2.1 Hz, 1 H) ppm.75,76 13C NMR (126 MHz, DMSO-d6/D2O = 9:1,
25 °C): δ 30.5, 32.7, 40.0, 45.3, 46.1, 50.6, 108.8, 112.7, 121.3, 123.5,
123.8, 129.7, 132.4, 132.5, 145.5, 146.6, 153.6, 174.0 ppm.76 HRMS
(ESI): [M + H]+ calcd for C18H20N4O5Cl 407.1117, found 407.1117.
rac-(3R,5S)-(5-{[(E)-2-({5-[3-(Trifluoromethyl)phenyl]furan-
2-yl}methylidene)hydrazin-1-yl]methyl}piperidine-3-carbox-
ylic Acid)−Sodium Chloride (1/2) (rac-16gc).54 According to GP4
with rac-11·HCl, 5-[3-(trifluoromethyl)phenyl]-2-furaldehyde (15gc),
and 1 M NaOD (20 μL), rac-16gc was obtained quantitatively in
solution. Besides the major E-isomer, the Z-isomer is present in 7%. 1H
NMR (500MHz, DMSO-d6/D2O= 9:1, 25 °C): δ 1.21 (q, J = 12.5 Hz,
1 H), 2.00−2.09 (m, 1 H), 2.13 (d, J = 13.2 Hz, 1 H), 2.43−2.60 (m, 2
H), 2.73 (t, J = 12.5 Hz, 1 H), 3.08 (dd, J = 13.5/6.8 Hz, 1 H), 3.12 (dd,
J = 13.6/6.4 Hz, 1 H), 3.28 (dd, J = 12.6/3.9 Hz, 1H), 3.35 (dd, J =
12.6/4.0 Hz, 1 H), 6.60 (d, J = 3.5 Hz, 1 H), 7.19 (d, J = 3.5 Hz, 1 H),
7.56 (s, 1 H), 7.62 (d, J = 7.9 Hz, 1 H), 7.67 (t, J = 8.0 Hz, 1 H), 7.99 (s,
1 H), 8.00 (d, J = 6.6 Hz, 1 H) ppm.75,76 13CNMR (126 MHz, DMSO-
d6/D2O = 9:1, 25 °C): δ 30.5, 32.7, 39.9, 45.2, 46.0, 50.7, 109.7, 109.7,
119.4 (q, JCF = 3.8 Hz), 123.7 (q, JCF = 4.0 Hz), 124.1 (q, JCF = 273.5
Hz), 124.7, 127.0, 129.9 (q, JCF = 32.0 Hz), 130.2, 131.0, 150.4, 152.1,
174.0 ppm.76 19F {1H} NMR (376 MHz, DMSO-d6/D2O = 9:1, 25
°C): δ −61.3 ppm.76 HRMS (ESI): [M + H]+ calcd for C19H21N3O3F3
396.1530, found 396.1528.
rac-(3R,5S)-(5-{[(E)-2-({5-[4-Fluoro-3-(trifluoromethyl)-
phenyl]furan-2-yl}methylidene)hydrazin-1-yl]methyl}-
piperidine-3-carboxylic Acid)−Sodium Chloride (1/2) (rac-
16ge).54 According to GP4 with rac-11·HCl, 5-[4-fluoro-3-
(trifluoromethyl)phenyl]-2-furaldehyde (15ge), and 1 M NaOD (20
μL), rac-16gewas obtained quantitatively in solution. Besides themajor
E-isomer, the Z-isomer is present in 9%. 1H NMR (500 MHz, DMSO-
d6/D2O= 9:1, 25 °C): δ 1.22 (q, J = 12.5 Hz, 1 H), 1.99−2.11 (m, 1H),
2.13 (d, J = 13.6 Hz, 1 H), 2.44−2.60 (m, 2 H), 2.74 (t, J = 12.5 Hz, 1
H), 3.07 (dd, J = 13.5/6.9 Hz, 1 H), 3.12 (dd, J = 13.5/6.3 Hz, 1 H),
3.28 (dd, J = 12.4/2.8 Hz, 1H), 3.35 (dd, J = 12.6/4.0 Hz, 1 H), 6.59 (d,
J = 3.5 Hz, 1 H), 7.14 (d, J = 3.5 Hz, 1 H), 7.52−7.58 (m, 2 H), 7.99−
8.07 (m, 2 H) ppm.75,76 13C NMR (126 MHz, DMSO-d6/D2O = 9:1,
25 °C): δ 30.4, 32.7, 39.8, 45.1, 46.0, 50.7, 109.5, 109.8, 117.4 (qd, JCF =
32.1/13.3 Hz), 118.2 (d, JCF = 21.8 Hz), 121.6 (q, JCF = 4.4 Hz), 122.5
(q, JCF = 274.3 Hz), 124.8, 127.3 (d, JCF = 3.7 Hz), 129.7 (d, JCF = 8.7
Hz), 149.7, 152.0, 157.8 (dq, JCF = 253.9/1.6 Hz), 173.9 ppm.
76 19F
{1H} NMR (376 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ −117.65 (q,
JFF = 12.5 Hz), −60.14 (d, JFF = 12.4 Hz) ppm.
76 HRMS (ESI): [M +
H]+ calcd for C19H20N3O3F4 414.1435, found 414.1434.
rac-(3R,5S)-(5-{[(E)-2-{[5-(Naphthalen-1-yl)furan-2-yl]-
methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−Sodium Chloride (1/2) (rac-16gf).54 According to GP4 with
rac-11·HCl, 5-(naphthalen-1-yl)-2-furaldehyde (15gf), and 1MNaOD
(20 μL), rac-16gf was obtained quantitatively in solution. Besides the
major E-isomer, the Z-isomer is present in 12%. 1H NMR (500 MHz,
DMSO-d6/D2O = 9:1, 25 °C): δ 1.23 (q, J = 12.5 Hz, 1 H), 2.02−2.11
(m, 1 H), 2.14 (d, J = 13.4 Hz, 1 H), 2.46−2.61 (m, 2 H), 2.75 (t, J =
12.5 Hz, 1 H), 3.07 (dd, J = 13.4/6.8 Hz, 1 H), 3.12 (dd, J = 13.5/6.2
Hz, 1 H), 3.29 (dd, J = 12.7/3.5 Hz, 1H), 3.36 (dd, J = 12.4/4.0 Hz, 1
H), 6.69 (d, J = 3.5 Hz, 1 H), 6.98 (d, J = 3.5 Hz, 1 H), 7.56−7.65 (m, 4
H), 7.80 (dd, J = 7.3/1.3 Hz, 1 H), 7.95 (d, J = 8.2 Hz, 1 H), 8.01 (dd, J
= 7.9/1.7 Hz, 1 H), 8.42 (dd, J = 8.6/1.3 Hz, 1 H) ppm.75,76 13C NMR
(126MHz, DMSO-d6/D2O= 9:1, 25 °C): δ 30.4, 32.8, 39.8, 45.1, 46.0,
50.9, 109.4, 111.7, 124.9, 125.3, 125.7, 125.7, 126.3, 127.1, 127.4, 128.6,
128.7, 129.2, 133.7, 151.6, 151.7, 173.8 ppm.76HRMS (ESI): [M+H]+
calcd for C22H24N3O3 378.1812, found 378.1811.
rac-(3R,5S)-(5-{[(E)-2-({5-[3,5-Bis(trifluoromethyl)phenyl]-
furan-2-yl}methylidene)hydrazin-1-yl]methyl}piperidine-3-
carboxylic Acid)−SodiumChloride (1/2) (rac-16gg).54 According
to GP4 with rac-11·HCl, 5-[3,5-bis(trifluoromethyl)phenyl]-2-furalde-
hyde (15gg), and 1 M NaOD (20 μL), rac-16gg was obtained
quantitatively in solution. Besides the major E-isomer, the Z-isomer is
present in 9%. 1H NMR (500 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ
1.22 (q, J = 12.6 Hz, 1 H), 2.02−2.10 (m, 1 H), 2.14 (d, J = 13.3 Hz, 1
H), 2.41−2.63 (m, 2 H), 2.73 (t, J = 12.5 Hz, 1 H), 3.10 (dd, J = 11.9/
5.2 Hz, 1 H), 3.14 (dd, J = 11.9/4.8 Hz, 1 H), 3.28 (dd, J = 12.2/3.7 Hz,
1H), 3.35 (dd, J = 12.5/3.9 Hz, 1H), 6.64 (d, J = 3.6Hz, 1H), 7.42 (d, J
= 3.6 Hz, 1 H), 7.56 (s, 1 H), 7.94 (s, 1 H), 8.30 (s, 2 H) ppm.75,76 13C
NMR (126 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 30.3, 32.5, 39.8,
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45.1, 45.9, 50.5, 109.6, 111.7, 119.9 (q, JCF = 3.8 Hz), 123.2 (q, JCF = 3.5
Hz), 123.2 (q, JCF = 273.1 Hz), 123.9, 131.1 (q, JCF = 33.0 Hz), 132.3,
148.8, 153.0, 173.8 ppm.76 19F {1H} NMR (376 MHz, DMSO-d6/D2O
= 9:1, 25 °C): δ −61.6 ppm.76 HRMS (ESI): [M + H]+ calcd for
C20H20N3O3F6 464.1403, found 464.1403.
rac-(3R,5S)-(5-{[(E)-2-{[5-(2-Bromophenyl)furan-2-yl]-
methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−SodiumChloride (1/2) (rac-16gk).54 According toGP4 with
rac-11·HCl, 5-(2-bromophenyl)-2-furaldehyde (15gk), and 1 M
NaOD (20 μL), rac-16gk was obtained quantitatively in solution.
Besides the major E-isomer, the Z-isomer is present in 9%. 1H NMR
(500 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 1.22 (q, J = 12.5 Hz, 1 H),
2.00−2.10 (m, 1 H), 2.13 (d, J = 13.4 Hz, 1 H), 2.41−2.60 (m, 2 H),
2.74 (t, J = 12.5 Hz, 1 H), 3.07 (dd, J = 13.4/6.8 Hz, 1 H), 3.11 (dd, J =
13.5/6.2 Hz, 1 H), 3.28 (dd, J = 12.6/3.9 Hz, 1H), 3.35 (dd, J = 12.5/
4.1 Hz, 1 H), 6.62 (d, J = 3.6 Hz, 1 H), 7.22 (d, J = 3.5 Hz, 1 H), 7.26
(td, J = 7.7/1.7 Hz, 1 H), 7.49 (td, J = 7.6/1.4 Hz, 1 H), 7.56 (s, 1 H),
7.73 (dd, J = 8.1/1.3 Hz, 1 H), 7.80 (dd, J = 7.9/1.7 Hz, 1 H) ppm.75,76
13CNMR (126 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 30.4, 32.8, 39.8,
45.1, 46.0, 50.8, 109.0, 112.8, 118.6, 124.7, 128.1, 128.5, 129.2, 130.2,
134.2, 149.3, 151.6, 173.9 ppm.76 HRMS (ESI): [M + H]+ calcd for
C18H21N3O3Br 406.0761, found 406.0761.
rac-(3R,5S)-(5-{[(E)-2-{[2-(Naphthalen-2-yl)pyrimidin-5-yl]-
methylidene}hydrazin-1-yl]methyl}piperidine-3-carboxylic
Acid)−Sodium Chloride (1/2) (rac-16ho).54 According to GP4
with rac-11·HCl, 2-(naphthalen-2-yl)pyrimidine-5-carboxaldehyde
(15ho), and 1MNaOD (20 μL), rac-16ho was obtained quantitatively
in solution. Besides the major E-isomer, the Z-isomer is present in 9%.
1HNMR (500 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 1.27 (q, J = 12.8
Hz, 1 H), 2.06−2.22 (m, 2 H), 2.43−2.64 (m, 2 H), 2.76 (t, J = 12.4 Hz,
1 H), 3.16 (dd, J = 13.5/6.8 Hz, 1 H), 3.20 (dd, J = 13.6/6.0 Hz, 1 H),
3.32 (dd, J = 12.5/4.2 Hz, 1H), 3.37 (dd, J = 12.5/4.0 Hz, 1 H), 7.56−
7.65 (m, 3 H), 7.96−8.00 (m, 1 H), 8.05 (d, J = 8.7 Hz, 1 H), 8.07−8.12
(m, 1 H), 8.48 (dd, J = 8.7/1.7 Hz, 1 H), 8.95 (s, 1 H), 9.00 (s, 2 H)
ppm.75,76 13C NMR (126 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 30.3,
32.7, 39.8, 45.0, 46.0, 50.5, 124.5, 126.8, 127.0, 127.5, 127.5, 127.7,
128.4, 128.5, 129.0, 132.8, 134.0, 134.4, 153.4, 161.0, 173.7 ppm.76
HRMS (ESI): [M + H]+ calcd for C22H24N5O2 390.1925, found
390.1923.
rac-(3R,5R)-(5-{2-[(E)-2-({5-[2-Chloro-4-(trifluoromethyl)-
phenyl]furan-2-yl}methylidene)hydrazin-1-yl]ethyl}-
piperidine-3-carboxylic Acid)−Sodium Chloride (1/3) (rac-
18e).54 According to GP4 with rac-13·HCl, 5-[2-chloro-4-
(trifluoromethyl)phenyl]-2-furaldehyde (15e), and 1 M NaOD (30
μL), rac-18e was obtained quantitatively in solution. Besides the major
E-isomer, the Z-isomer is present in 17%. 1HNMR (500MHz, DMSO-
d6/D2O= 9:1, 25 °C): δ 1.10 (q, J = 12.5 Hz, 1H), 1.45−1.60 (m, 2 H),
1.73−1.85 (m, 1H), 2.11 (d, J = 13.3Hz, 1H), 2.30 (tt, J = 12.6/3.8Hz,
1 H), 2.43 (t, J = 12.2 Hz, 1 H), 2.65 (t, J = 12.4 Hz, 1 H), 3.14−3.20
(m, 3 H), 3.28 (dd, J = 12.2/3.6 Hz, 1 H), 6.65 (d, J = 3.6 Hz, 1 H), 7.40
(d, J = 3.6 Hz, 1 H), 7.50 (s, 1 H), 7.80 (d, J = 8.6 Hz, 1 H), 7.92 (s, 1
H), 8.07 (d, J = 8.4 Hz, 1 H) ppm.75,76 13C NMR (126 MHz, DMSO-
d6/D2O = 9:1, 25 °C): δ 31.2, 31.3, 33.0, 41.4, 44.3, 46.1, 47.7, 108.9,
115.5, 122.8, 123.3 (q, JCF = 272.2 Hz), 124.4 (q, JCF = 3.9 Hz), 127.7
(q, JCF = 4.0 Hz), 127.7, 127.94 (q, JCF = 33.14Hz), 128.8, 131.7, 146.4,
153.1, 174.7 ppm.76 19F{1H} NMR (376 MHz, DMSO-d6/D2O = 9:1,
25 °C): δ −61.1 ppm.76 HRMS (ESI): [M + H]+ calcd for
C20H22N3O3ClF3 444.1296, found 444.1296.
rac-(3R,5R)-(5-{2-[(E)-2-{[5-(2,4-Dichlorophenyl)furan-2-yl]-
methylidene}hydrazin-1-yl]ethyl}piperidine-3-carboxylic
Acid)−Sodium Chloride (1/3) (rac-18fy).54 According to GP4 with
rac-13·HCl, 5-(2,4-dichlorophenyl)-2-furaldehyde (15fy), and 1 M
NaOD (30 μL), rac-18fy was obtained quantitatively in solution.
Besides the major E-isomer, the Z-isomer is present in 14%. 1H NMR
(500 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 1.09 (q, J = 12.5 Hz, 1 H),
1.43−1.58 (m, 2 H), 1.72−1.84 (m, 1 H), 2.11 (d, J = 13.3 Hz, 1 H),
2.30 (tt, J = 12.3/3.8Hz, 1H), 2.43 (t, J = 12.1Hz, 1H), 2.65 (t, J = 12.5
Hz, 1 H), 3.11−3.21 (m, 3 H), 3.28 (dd, J = 12.4/4.0 Hz, 1 H), 6.61 (d,
J = 3.5 Hz, 1 H), 7.22 (d, J = 3.5 Hz, 1 H), 7.49 (s, 1 H), 7.52 (dd, J =
8.6/2.3 Hz, 1 H), 7.69 (d, J = 2.3 Hz, 1 H), 7.87 (d, J = 8.6 Hz, 1 H)
ppm.75,76 13C NMR (126 MHz, DMSO-d6/D2O = 9:1, 25 °C): δ 31.3,
31.3, 33.0, 41.4, 44.4, 46.1, 47.7, 108.9, 113.7, 123.3, 127.2, 127.9,
128.5, 129.3, 130.1, 132.0, 146.9, 152.2, 174.7 ppm.76 HRMS (ESI):
[M + H]+ calcd for C19H22N3O3Cl2 410.1033, found 410.1032.
rac-(3R,5S)-[1-(tert-Butyl) 3-Methyl 5-Formylpiperidine-1,3-
dicarboxylate] (rac-20)44 and rac-(3R,5R)-[1-(tert-Butyl) 3-
Methyl 5-Formylpiperidine-1,3-dicarboxylate] (rac-21). 26
(1:1 E-/Z-mixture, 424 mg, 1.49 mmol) was dissolved in THF (15
mL). The solution was cooled to 0 °C, and a 2M aqueousHCl (2.5mL;
5.0 mmol) was added. The mixture was stirred for 2 d, while the
reaction was allowed to reach rt (0 °C → rt). It was quenched with
NaHCO3 (429 mg; 5.11 mmol) and concentrated under reduced
pressure. H2O (20 mL) was added to the residue, and it was extracted
with DCM (5× 20 mL). The combined organic phases were dried over
Na2SO4 and concentrated under reduced pressure. After purification by
flash chromatography (iso-hexanes/EtOAc = 3:1), rac-20 and rac-21
were obtained in 1:1 mixture (according to 1H NMR) as colorless oil
(296 mg, 73%). 1HNMR (400MHz, C2Cl4D2, 80 °C): δ 1.43 (s, 9 H, a
or b), 1.45 (s, 9 H, a or b), 1.59 (dt, J = 13.4/11.9 Hz, 1H, a), 1.94 (ddd,
J = 13.9/9.2/4.6 Hz, 1H, b), 2.14−2.22 (m, 1H, b), 2.32−2.54 (m, 3H,
a and b), 2.59−2.80 (m, 4 H, a and b), 3.31 (dd, J = 13.4/8.5 Hz, 1 H,
a), 3.44 (dd, J = 13.8/4.3Hz, 1H, b), 3.68 (s, 3 H, a or b), 3.69 (s, 3 H, a
or b), 3.79 (dd, J = 13.5/4.3 Hz, 1 H, a), 3.93 (dd, J = 13.7/5.2 Hz, 1 H,
b), 4.22−4.33 (m, 2 H, a and b), 9.63 (d, J = 1 Hz, 1 H, a), 9.68 (s, 1 H,
b) ppm. 13C NMR (101 MHz, C2Cl4D2, 80 °C): δ 25.8 (b), 27.5 (a),
28.4 (a or b), 28.5 (a or b), 38.3 (b), 40.7 (a), 43.3 (b), 43.6 (a), 45.7 (a
or b), 45.8 (a or b), 45.8 (a or b), 47.6 (b), 51.9 (a or b), 52.0 (a or b),
80.4 (a or b), 80.5 (a or b), 154.3 (a or b), 154.4 (a or b), 172.8 (a or b),
173.1 (a or b), 200.7 (a), 201.1 (b) ppm. IR (film): ν ̃ 2977, 2955, 2933,
2871, 1735, 1694 cm−1. HRMS (ESI): [M + H]+ calcd for C13H22NO5
272.1493, found 272.1498.
rac-(3R,5S)-[1-(tert-Butyl) 3-Methyl 5-Hydroxypiperidine-
1,3-dicarboxylate]41 (rac-23). Methyl 5-hydroxynicotinate (22,
309 mg, 1.97 mmol), Rh on Al2O3 (94 mg, 0.046 mmol), and conc
H2SO4 (200mg, 2.03mmol) were suspended inMeOH (10mL) under
Ar. The mixture was hydrogenated (10 bar H2) at 80 °C for 26 h. After
cooling to rt, the Rh on Al2O3 catalyst was filtered off and the solvent
was concentrated in vacuum. The residue was dissolved in dioxane (10
mL) and NEt3 (1.1 mL, 7.8 mmol) and di-tert-butyl dicarbonate (401
mg; 1.80 mmol) were added. The reaction mixture was stirred at rt for 3
h before removing the solvent under vacuum. After purification by flash
chromatography (iso-hexanes/EtOAc = 1:1), rac-23 was obtained as
white, amorphous solid (278 mg; 55%). 1HNMR (400 MHz, C2Cl4D2,
80 °C): δ 1.44 (s, 9 H), 1.55−1.70 (m, 1 H), 2.22 (d, J = 13.4 Hz, 1 H),
2.54 (tt, J = 9.3/4.1 Hz, 1 H), 2.75−2.86 (m, 1 H), 3.05 (d, J = 11.4 Hz,
1 H), 3.65 (tt, J = 8.9/3.9 Hz, 1 H), 3.69 (s, 3 H), 3.89 (d, J = 13.1 Hz, 1
H), 3.96 (d, J = 14.2 Hz, 1 H) ppm.75 13C NMR (101 MHz, C2Cl4D2,
80 °C): δ 28.4, 35.2, 40.0, 45.2, 50.6, 52.0, 65.5, 80.1, 154.5, 173.4 ppm.
IR (KBr): ν ̃ 3463, 2986, 2957, 2936, 2870, 1732, 1673 cm−1. HRMS
(ESI): [M + Na]+ calcd for C12H21NO5Na 282.1312, found 282.1312.
rac-(3R,5R)-[1-(tert-Butyl) 3-Methyl 5-Hydroxypiperidine-
1,3-dicarboxylate] (rac-24). rac-24 was obtained as a side product
from the preparation of rac-23 as a colorless resin (97 mg; 19%). 1H
NMR (400 MHz, C2Cl4D2, 80 °C): δ 1.44 (s, 9 H), 1.67 (br s, 1 H),
1.80 (t, J = 11.9 Hz, 1 H), 2.00 (d, J = 13.3 Hz, 1 H), 2.87 (tt, J = 9.8/4.1
Hz, 1 H), 3.02−3.17 (m, 2 H), 3.67 (s, 3 H), 3.75 (dd, J = 13.7/2.8 Hz,
1 H), 3.94−4.07 (m, 2 H) ppm.75 13C NMR (101 MHz, C2Cl4D2, 80
°C): δ 28.4, 34.0, 36.9, 45.8, 49.9, 51.7, 64.2, 80.1, 155.4, 173.6 ppm. IR
(film): ν ̃ 3445, 2976, 2930, 1735, 1693, 1672 cm−1. HRMS (ESI): [M +
Na]+ calcd for C12H21NO5Na 282.1312, found 282.1313.
rac-(3R)-(1-tert-Butyl 3-Methyl 5-Oxopiperidine-1,3-dicar-
boxylate)42 (25). rac-23 (110 mg; 0.424 mmol) was dissolved in
DCM (5 mL) and Dess−Martin periodinane (232 mg; 0.546 mmol)
was added in portions over 45 min. After 2 h of stirring at rt, another
portion of Dess−Martin periodinane (131 mg, 0.309 mmol) was added
and it was stirred for further 0.5 h. The mixture was concentrated in
vacuum, and after purification by flash chromatography (iso-hexanes/
EtOAc = 3:7) 25 was obtained as a colorless resin (81 mg; 74%). 1H
NMR (400 MHz, C2Cl4D2, 80 °C): δ 1.44 (s, 9 H), 2.58 (dd, J = 16.9/
6.0 Hz, 1 H), 2.70 (dd, J = 16.9/7.3 Hz, 1 H), 3.03 (quin, J = 6.28 Hz, 1
H), 3.71 (s, 3 H), 3.76 (dd, J = 13.6/6.9 Hz, 1 H), 3.82 (dd, J = 13.7/5.0
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Hz, 1 H), 3.94 (d, J = 18.9 Hz, 1 H), 3.99 (d, J = 18.9 Hz, 1 H) ppm. 13C
NMR (101 MHz, C2Cl4D2, 80 °C): δ 28.3, 39.6, 40.1, 44.2, 52.3, 54.3,
80.9, 154.1, 172.4, 203.2 ppm. IR (film): ν ̃ 2978, 2956, 2934, 1737,
1698 cm−1. HRMS (EI, 70 eV): M+ calcd for C12H19NO5 257.1263,
found 257.1268.
rac-(3R)-{1-(tert-Butyl) 3-Methyl 5-[(E)-Methoxymethylene]-
piperidine-1,3-dicarboxylate} and rac-(3R)-1-{(tert-Butyl) 3-
Methyl 5-[(Z)-Methoxymethylene]piperidine-1,3-dicarboxy-
late} (26). (Methoxymethyl)triphenylphosphonium chloride (1.73 g;
4.95 mmol) and potassium tert-butoxide (524 mg; 4.58 mmol) were
suspended in anhydrous THF (10 mL) under Ar. The mixture was
stirred for 30 min at rt, cooled to −78 °C, and then 25 (681 mg, 2.65
mmol), dissolved in anhydrous THF (5 mL), was added and stirred for
further 75 min at −78 °C and 55 min at rt. Then the reaction was
quenched with ammonium chloride (525 mg, 3.71 mmol) and
dissolved in H2O (25 mL). The aqueous phase was extracted with
DCM (5 × 20 mL). The combined organic phases were dried over
Na2SO4 and concentrated under reduced pressure. After purification by
flash chromatography (iso-hexanes/EtOAc = 5:1), 26 was obtained as
colorless oil (432mg; 57%) and as a 1:1mixture of the E- andZ-isomers
according to 1H NMR. 1H NMR (400 MHz, C2Cl4D2, 80 °C): δ 1.43
(s, 9 H, E or Z), 1.43 (s, 9 H, E or Z), 2.10 (t, J = 12.5 Hz, 1 H, E), 2.22
(t, J = 12.2 Hz, 1 H, Z), 2.37 (dd, J = 14.1/4.3 Hz, 1 H, Z), 2.43−2.52
(m, 2 H, E and Z), 2.93 (dd, J = 14.1/4.4 Hz, 1 H, E), 3.01−3.10 (m, 2
H, E and Z), 3.31 (d, J = 14.7 Hz, 1 H, Z), 3.36 (d, J = 14.1 Hz, 1 H, E),
3.55 (s, 3H,E), 3.56 (s, 3H, E orZ), 3.66 (s, 3H, E orZ), 3.66 (s, 3H, E
or Z), 4.04−4.12 (m, 3 H, E and Z), 4.63 (d, J = 14.8 Hz, 1 H, Z), 5.81
(s, 1 H, Z), 5.97 (s, 1 H, E) ppm. 13C NMR (101 MHz, C2Cl4D2, 80
°C): δ 26.3 (E), 28.5 (E or Z), 28.5 (E or Z), 30.5 (Z), 41.5 (E), 42.1
(Z), 42.3 (Z), 45.8 (Z), 46.2 (E), 46.7 (E), 51.6 (E), 51.6 (Z), 59.6 (E),
59.6 (Z), 79.6 (E or Z), 79.7 (E or Z), 109.6 (E or Z), 109.7 (E or Z),
141.9 (Z), 142.6 (E), 154.4 (E or Z), 154.7 (E or Z), 173.2 (E or Z),
173.2 (E or Z) ppm. IR (film): ν ̃ 2976, 2953, 2935, 2844, 1737, 1698
cm−1. HRMS (EI, 70 eV): M+ calcd for C14H23NO5 285.1576, found
285.1577.
rac-(3R,5S)-[1-(tert-Butyl) 3-Methyl 5-(Hydroxymethyl)-
piperidine-1,3-dicarboxylate]44 (rac-27) and rac-(3R,5R)-[1-
(tert-Butyl) 3-Methyl 5-(Hydroxymethyl)piperidine-1,3-dicar-
boxylate]48 (rac-28). rac-20 and rac-21 (in 1:1 mixture, 191 mg,
0.703 mmol) were dissolved in ethanol (5 mL) and cooled to 0 °C.
Sodium borohydride (80 mg; 2.1 mmol) was added to the solution, and
it was stirred for 1 h. The reaction was quenched with ammonium
chloride (202 mg, 3.78 mmol), dissolved in H2O (25 mL), and it was
extracted with DCM (5 × 20 mL). The combined organic phases were
dried over Na2SO4 and concentrated under reduced pressure. After
purification by flash chromatography (iso-hexanes/EtOAc = 2:1), rac-
27 and rac-28 were obtained in a 1:1 mixture (according to 1H NMR)
as colorless oil (145mg, 76%). 1HNMR (400MHz, C2Cl4D2, 80 °C): δ
1.25−1.36 (m, 1 H, a), 1.44 (s, 9 H, a or b), 1.44 (s, 9 H, a or b), 1.62−
1.76 (m, 2 H, a and b), 1.86−1.99 (m, 2 H, b), 2.11 (dtt, J = 13.1/3.6/
1.7 Hz, 1 H, a), 2.35−2.51 (m, 2 H, a), 2.58 (tt, J = 8.4/4.4 Hz, 1 H, b),
2.72 (dd, J = 13.2/11.3 Hz, 1 H, a), 3.31 (dd, J = 13.5/3.7 Hz, 1 H, b),
3.38−3.51 (m, 6 H, a and b), 3.66 (s, 3 H, a or b), 3.67 (s, 3 H, a or b),
3.72 (dd, J = 13.5/4.4 Hz, 1 H, b), 4.09−4.16 (m, 1 H, a), 4.22−4.30
(m, 1 H, a) ppm.75 13CNMR (101MHz, C2Cl4D2, 80 °C): δ 28.4 (a or
b), 28.5 (a or b), 28.5 (b), 30.4 (a), 35.2 (b), 38.0 (a or b), 38.1 (a or b),
41.3 (a), 45.3 (b), 45.9 (a or b), 46.0 (a or b), 46.7 (a), 51.7 (a), 51.7
(b), 63.2 (a), 65.1 (b), 79.8 (a or b), 79.9 (a or b), 154.6 (a or b), 155.0
(a or b), 173.4 (a or b), 173.5 (a or b) ppm. IR (film): ν ̃ 3450, 2976,
2932, 2868, 1736, 1691, 1672 cm−1. HRMS (EI, 70 eV): M+ calcd for
C13H23NO5 273.1576, found 273.1576.
rac - (3R , 5S ) - [1 - ( te r t -Buty l ) 3 -Methyl 5- { [1 - ( te r t -
Butoxycarbonyl)hydrazinyl]methyl}piperidine-1,3-dicarboxy-
late] (rac-30). rac-27 and rac-28 (in 1:1 mixture, 464 mg, 1.70 mmol),
N-(tert-butoxycarbonyl)aminophthalimide47 (29, 710 mg, 2.71 mmol),
and triphenylphosphine (1.06 g, 3.94 mmol) were dissolved in
anhydrous THF (20 mL) under Ar. The solution was cooled to 0 °C,
and diisopropyl azodicarboxylate (1.0 mL, 4.8 mmol) was added
dropwise over 30 min under stirring. After additional 75 min of stirring,
the reaction mixture was concentrated under reduced pressure. The
crude intermediate was purified by flash chromatography (iso-hexanes/
EtOAc = 3:1), and the resulting residue was dissolved in THF (20 mL)
and cooled to 0 °C. Methylhydrazine (0.50 mL, 9.6 mmol) was added,
and after 110 min of stirring, another portion of methylhydrazine (0.10
mL, 1.9 mmol) was added. The reaction mixture was stirred for further
10 min at 0 °C and then concentrated under reduced pressure. After
purification by flash chromatography (iso-hexanes/EtOAc = 1:1), rac-
30 was obtained as colorless oil (249 mg; 38%). 1H NMR (400 MHz,
C2Cl4D2, 80 °C): δ 1.15−1.31 (m, 1 H), 1.44 (s, 9 H), 1.46 (s, 9 H),
1.82−1.95 (m, 1 H), 2.02−2.09 (m, 1 H), 2.31 (dd, J = 13.2/11.5 Hz, 1
H), 2.45 (tt, J = 11.8/4.0 Hz, 1 H), 2.65 (dd, J = 13.2/11.5 Hz, 1 H),
3.20 (dd, J = 14.0/6.1 Hz, 1 H), 3.27 (dd, J = 14.0/7.4 Hz, 1 H), 3.67 (s,
3 H), 3.91 (br s, 2 H), 4.06 (dt, J = 13.2/1.8 Hz, 1 H), 4.31 (dt, J = 13.2
Hz, 1 H) ppm.75 13C NMR (101 MHz, C2Cl4D2, 80 °C): δ 28.4, 28.5,
31.9, 34.9, 41.6, 45.9, 47.8, 51.6, 53.7, 79.8, 80.7, 154.4, 156.7, 173.3
ppm. IR (film): ν ̃ 3334, 2975, 2931, 1736, 1693, 1631 cm−1. HRMS (EI,
70 eV): M+ calcd for C18H33N3O6 387.2369, found 387.2369.
rac - (3R , 5R ) - [1 - ( te r t -Buty l ) 3 -Methyl 5- { [1 - ( te r t -
Butoxycarbonyl)hydrazinyl]methyl}piperidine-1,3-dicarboxy-
late] (rac-31). rac-31 was obtained as additional product in the
synthesis of rac-30 as colorless oil (282 mg; 43%). 1HNMR (400MHz,
C2Cl4D2, 80 °C): δ 1.43 (s, 9 H), 1.45 (s, 9 H), 1.53−1.64 (m, 1 H),
1.85 (ddd, J = 12.7/8.0/4.3Hz, 1H), 2.15−2.25 (m, 1H), 2.69 (ddt, J =
11.3/8.1/4.6 Hz, 1H), 3.13−3.22 (m, 2H), 3.36−3.45 (m, 2H), 3.50−
3.69 (m, 5 H), 3.98 (br s, 2 H) ppm.75 13C NMR (101 MHz, C2Cl4D2,
80 °C): δ 28.4, 28.4, 29.0, 31.7, 38.1, 45.6, 46.8, 51.5, 52.1, 79.6, 80.6,
154.5, 156.7, 173.6 ppm. IR (film): ν ̃ 3334, 3224, 2976, 2932, 2868,
1736, 1694 cm−1. HRMS (EI, 70 eV): M+ calcd for C18H33N3O6
387.2369, found 387.2379.
rac-(3R,5S)-{1-[(tert-Butoxy)carbonyl] 5-({1-[(tert-Butoxy)-
carbonyl]hydrazinyl}methyl)piperidine-3-carboxylic Acid}
(rac-32). rac-30 (316 mg, 0.816 mmol) was dissolved in MeOH (10
mL), cooled to 0 °C, and a 1M aqueousNaOH (3.0mL, 3.0mmol) was
added. The mixture was stirred for 15 h, while the reaction was allowed
to reach rt (0 °C → rt). Then it was concentrated under reduced
pressure, diluted with H2O (30 mL), washed with DCM (3 × 20 mL),
and acidified with phosphoric acid (85%, 0.25 mL, 3.7 mmol). The
aqueous phase was extracted with DCM (5 × 20 mL). The combined
organic phases were dried over Na2SO4 and concentrated under
reduced pressure. rac-32 was obtained as colorless resin (313 mg,
quant). 1H NMR (400 MHz, C2Cl4D2, 80 °C): δ 1.34−1.42 (m, 1 H),
1.54 (s, 9 H), 1.56 (s, 9 H), 1.92−2.07 (m, 1 H), 2.20 (dm, J = 13.3 Hz,
1 H), 2.42 (dd, J = 13.2/11.5 Hz, 1 H), 2.59 (tt, J = 11.7/3.9 Hz, 1 H),
2.78 (dd, J = 13.2/11.5 Hz, 1 H), 3.31 (dd, J = 14.0/6.2 Hz, 1 H), 3.38
(dd, J = 14.0/7.2 Hz, 1 H), 4.18 (dm, J = 13.2 Hz, 1 H), 4.44 (dm, J =
13.1 Hz, 1 H) ppm.75 13C NMR (101 MHz, C2Cl4D2, 80 °C): δ 28.4,
28.5, 31.8, 34.9, 41.0, 45.7, 47.7, 53.7, 80.0, 80.9, 154.5, 156.8, 175.2
ppm. IR (film): ν ̃ 3434, 2979, 2934, 1729, 1697 cm−1. HRMS (ESI):
[M + H]+ calcd for C17H32N3O6 374.2286, found 374.2290.
r a c - ( 3R , 5R ) - { 1 - ( t e r t - Bu t y l ) 3 -Me thy l 5 - [ (E ) - 2 -
Methoxyethenyl]piperidine-1,3-dicarboxylate} and rac-
(3R,5R)-{1-(tert-Butyl) 3-Methyl 5-[(Z)-2-Methoxyethenyl]-
piperidine-1,3-dicarboxylate} (rac-33). (Methoxymethyl)-
triphenylphosphonium chloride (2.85 g; 8.16 mmol) and potassium
tert-butoxide (856 mg; 7.48 mmol) were suspended in anhydrous THF
(23 mL) under Ar. The mixture was stirred at rt for 30 min, cooled to 0
°C, and then rac-20 and rac-21 (in 1:1 mixture, 1.15 g, 4.25 mmol),
dissolved in anhydrous THF (10 mL), were added. It was stirred for
further 80min at 0 °C and 20min at rt. Then the reaction was quenched
with ammonium chloride (905 mg, 16.9 mmol), dissolved in H2O (30
mL), iso-hexane (15mL) was added, the phases were separated, and the
aqueous phase was further extracted with DCM (4 × 25 mL). The
combined organic phases were dried over Na2SO4 and concentrated
under reduced pressure. After purification by flash chromatography on
silica gel (EtOAc/iso-hexane = 1:5), rac-33was obtained as colorless oil
(614 mg; 48%) and as 1:0.43 mixture of the E- and Z-isomer according
to 1HNMR. 1HNMR (400 MHz, C2Cl4D2, 80 °C): δ 1.25−1.39 (m, 1
H + 0.43× 1H, E andZ), 1.54 (s, 0.43× 9H,Z), 1.54 (s, 9 H, E), 2.00−
2.15 (m, 2 H + 0.43× 1H, E and Z), 2.28−2.38 (m, 1 H + 0.43× 1H, E
andZ), 2.40−2.58 (m, 1H + 0.43× 2H, E andZ), 2.60−2.70 (m, 1H +
0.43 × 1 H, E and Z), 3.48 (s, 3 H, E), 3.56 (s, 0.43 × 3 H, Z), 3.65 (s,
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0.43 × 3 H, Z), 3.66 (s, 3 H, E), 3.96−4.05 (m, 1 H + 0.43 × 1 H, E and
Z), 4.07 (dd, J = 8.2/6.3Hz, 0.43× 1H,Z), 4.21−4.32 (m, 1H + 0.43×
1 H, E and Z), 4.57 (dd, J = 12.7/7.5 Hz, 1 H, E), 5.88 (dd, J = 6.3/1.1
Hz, 0.43 × 1 H, Z), 6.32 (dd, J = 12.7/0.8 Hz, 1 H, E) ppm. 13C NMR
(101 MHz, C2Cl4D2, 60 °C): δ 28.4 (E), 28.4 (Z), 31.7 (Z), 34.2 (Z),
34.7 (E), 35.0 (E), 41.4 (Z), 41.5 (E), 45.4 (E), 45.4 (Z), 50.0 (E), 50.0
(Z), 51.6 (Z), 51.7 (E), 56.1 (E), 59.7 (Z), 79.6 (Z), 79.7 (E), 104.2
(E), 106.8 (Z), 147.4 (Z), 148.1 (E), 154.4 (E), 154.5 (Z), 173.4 (E),
173.5 (Z) ppm. IR (film): ν ̃ 2976, 2952, 2935, 2861, 1737, 1694, 1655
cm−1. HRMS (ESI): [M + H]+ calcd for C15H26NO5 300.1806, found
300.1806.
r a c - ( 3R , 5S ) - { 1 - ( t e r t - Bu t y l ) 3 -Me thy l 5 - [ (E ) - 2 -
Methoxyethenyl]piperidine-1,3-dicarboxylate} and rac-
(3R,5S)-{1-(tert-Butyl) 3-Methyl 5-[(Z)-2-Methoxyethenyl]-
piperidine-1,3-dicarboxylate} (rac-34). rac-34 was obtained as
additional product in the synthesis of rac-33 as colorless oil (417 mg,
33%) and as 1:0.27 mixture of the E- and Z-isomer according to 1H
NMR. 1HNMR (400MHz, C2Cl4D2, 80 °C): δ 1.43 (s, 0.27 × 9 H, Z),
1.43 (s, 9 H, E), 1.59 (ddd, J = 13.1/8.0/4.5 Hz, 1 H, E), 1.74 (ddd, J =
12.9/6.7/4.4 Hz, 0.27× 1 H, Z), 1.89 (ddd, J = 12.8/8.3/4.3 Hz, 0.27×
1 H, Z), 1.99 (ddd, J = 13.2/7.0/4.2 Hz, 1 H, E), 2.42 (qt, J = 7.7/4.0
Hz, 1 H, E), 2.54−2.70 (m, 1 H + 0.27 × 2 H, E and Z), 2.79−2.90 (m,
0.27× 1H, Z), 3.06 (dd, J = 13.0/7.4 Hz, 1H, E), 3.26−3.32 (m, 0.27×
1 H, Z), 3.40−3.54 (m, 5 H + 0.27 × 2 H, E and Z), 3.57 (s, 0.27 × 3 H,
Z), 3.59−3.76 (m, 4 H + 0.27× 4 H, E and Z), 4.24 (dd, J = 8.0/6.3 Hz,
0.27 × 1 H, Z), 4.65 (dd, J = 12.7/7.6 Hz, 1 H, E), 5.87 (dd, J = 6.3/1.3
Hz, 0.27 × 1 H, Z), 6.34 (dd, J = 12.8/1.0 Hz, 1 H, E) ppm. 13C NMR
(101 MHz, C2Cl4D2, 60 °C): δ 28.4 (E), 28.4 (Z), 28.9 (Z), 31.7 (E),
32.5 (Z), 33.4 (E), 38.3 (E), 38.3 (Z), 45.2 (E), 45.2 (Z), 49.3 (E), 49.3
(Z), 51.6 (E), 51.6 (Z), 56.1 (E), 59.7 (Z), 79.3 (Z), 79.4 (E), 104.0
(E), 106.5 (Z), 147.0 (Z), 148.1 (E), 154.4 (E), 154.7 (Z), 173.6 (E),
173.9 (Z) ppm. IR (film): ν ̃ 2975, 2951, 2933, 2860, 1736, 1694, 1654
cm−1. HRMS (ESI): [M + H]+ calcd for C15H26NO5 300.1806, found
300.1808.
rac-(3R,5R)-[1-(tert-Butyl) 3-Methyl 5-(2-Oxoethyl)-
piperidine-1,3-dicarboxylate] (rac-35). According to GP2 with
rac-33 (568mg; 1.90 mmol) and 2M aqueous HCl (3.5 mL, 7.0 mmol)
and a reaction time of 7 h, rac-35 was obtained as a colorless oil (435
mg, 80%). 1HNMR (400MHz, C2Cl4D2, 80 °C): δ 1.28 (q, J = 12.4Hz,
1 H), 1.45 (s, 9 H), 1.97−2.09 (m, 1 H), 2.15 (dtt, J = 13.1/3.7/1.8 Hz,
1 H), 2.22−2.38 (m, 3 H), 2.50 (tt, J = 11.7/4.0 Hz, 1 H), 2.69 (dd, J =
13.2/11.5 Hz, 1 H), 3.67 (s, 3 H), 4.07 (dm, J = 13.0 Hz, 1 H), 4.29
(dm, J = 13.4 Hz, 1 H), 9.74 (t, J = 1.8 Hz, 1 H) ppm. 13C NMR (101
MHz, C2Cl4D2, 80 °C): δ 28.5, 30.4, 33.8, 41.5, 45.7, 47.4, 49.0, 51.7,
80.1, 154.4, 173.0, 200.0 ppm. IR (film): ν ̃ 2977, 2953, 2933, 2863,
2724, 1733, 1693 cm−1. HRMS (ESI): [M + H]+ calcd for C14H24NO5
286.1649, found 286.1656.
rac-(3R,5S)-[1-(tert-Butyl) 3-Methyl 5-(2-Oxoethyl)-
piperidine-1,3-dicarboxylate] (rac-36). According to GP2 with
rac-34 (326mg, 1.09 mmol) and 2M aqueous HCl (2.0 mL, 4.0 mmol)
and a reaction time of 8.5 h, rac-36 was obtained as a colorless oil (272
mg, 88%). 1HNMR (400MHz, C2Cl4D2, 120 °C): δ 1.43 (s, 9 H), 1.61
(ddd, J = 13.6/6.1/4.4 Hz, 1 H), 1.99 (ddd, J = 13.6/8.2/3.8 Hz, 1 H),
2.24−2.44 (m, 3 H), 2.58 (tt, J = 8.1/4.4 Hz, 1 H), 3.19 (dd, J = 13.4/
5.9 Hz, 1 H), 3.43 (dd, J = 13.3/3.3 Hz, 1 H), 3.54 (dd, J = 13.5/7.1 Hz,
1H), 3.60−3.67 (m, 4H), 9.74 (t, J = 1.7Hz, 1H) ppm. 13CNMR (101
MHz, C2Cl4D2, 80 °C): δ 27.5, 28.4, 31.9, 38.2, 45.5, 45.9, 48.1, 51.7,
79.8, 154.5, 173.2, 200.4 ppm. IR (film): ν ̃ 2976, 2952, 2932, 2868,
2723, 1731, 1693 cm−1. HRMS (ESI): [M + H]+ calcd for C14H24NO5
286.1649, found 286.1655.
rac-(3R,5R)-{1-(tert-Butyl) 3-Methyl 5-[2-({[(tert-Butoxy)-
carbonyl]amino}amino)ethyl]piperidine-1,3-dicarboxylate}
(rac-37). According to GP3 with rac-35 (86 mg, 0.30 mmol), tert-butyl
carbazate (66 mg, 0.49 mmol), AcOH (0.043 mL, 0.75 mmol) and
NaBH3CN (81 mg, 1.2 mmol, added in three portions). rac-37 was
obtained as a colorless oil (90mg; 74%). 1HNMR (400MHz, C2Cl4D2,
80 °C): δ 1.18 (q, J = 12.3 Hz, 1 H), 1.26−1.38 (m, 2 H), 1.44 (s, 9 H),
1.44 (s, 9 H), 1.50−1.58 (m, 1 H), 2.12 (dtt, J = 12.6/3.4/1.8 Hz, 1 H),
2.24 (dd, J = 12.9/11.8 Hz, 1 H), 2.43 (tt, J = 11.8/4.0 Hz, 1 H), 2.66
(dd, J = 12.9/11.8 Hz, 1 H), 2.85 (dd, J = 12.7/6.9 Hz, 1 H), 2.89 (dd, J
= 12.8/7.5 Hz, 1 H), 3.66 (s, 3 H), 4.06 (dm, J = 13.1 Hz, 1 H), 4.27
(dm, J = 13.1Hz, 1H) ppm.75 13CNMR (101MHz, C2Cl4D2, 80 °C): δ
28.4, 28.5, 31.9, 33.5, 34.2, 41.7, 45.8, 49.3, 49.6, 51.6, 79.7, 80.4, 154.5,
156.6, 173.4 ppm. IR (film): ν ̃ 3329, 2976, 2930, 2868, 1736, 1696
cm−1. HRMS (ESI): [M + H]+ calcd for C19H36N3O6 402.2599, found
402.2599.
rac-(3R,5S)-{1-(tert-Butyl) 3-Methyl 5-[2-({[(tert-Butoxy)-
carbonyl]amino}amino)ethyl]piperidine-1,3-dicarboxylate}
(rac-38). According to GP3 with rac-36 (115 mg, 0.403 mmol), tert-
butyl carbazate (89 mg, 0.66 mmol), AcOH (0.057 mL, 1.0 mmol), and
NaBH3CN (112 mg, 1.69 mmol, added in three portions), rac-38 was
obtained as a colorless oil (125 mg; 77%). 1H NMR (400 MHz,
C2Cl4D2, 120 °C): δ 1.29−1.40 (m, 2 H), 1.43 (s, 9 H), 1.44 (s, 9 H),
1.51−1.61 (m, 1 H), 1.80−1.90 (m, 1 H), 1.95 (ddd, J = 12.6/7.7/4.2
Hz, 1 H), 2.52−2.63 (m, 1 H), 2.81−2.94 (m, 2 H), 3.14 (dd, J = 13.2/
6.6 Hz, 1 H), 3.40 (dd, J = 13.2/3.7 Hz, 1 H), 3.55 (dd, J = 13.4/6.6 Hz,
1 H), 3.58 (dd, J = 13.5/5.1 Hz, 1 H), 3.65 (s, 3 H), 5.94 (br s, 1 H)
ppm.75 13C NMR (101 MHz, C2Cl4D2, 80 °C): δ 28.4, 28.5, 30.1, 30.8,
32.4, 38.2, 45.6, 48.4, 49.9, 51.6, 79.5, 80.3, 154.6, 156.6, 173.6 ppm. IR
(film): ν ̃ 3320, 2976, 2930, 2861, 1735, 1796 cm−1. HRMS (ESI): [M +
H]+ calcd for C19H36N3O6 402.2599, found 402.2603.
Aldehydes. Synthetic protocols and detailed analytical data for
aldehydes are provided in the Supporting Information.
MS Binding Experiments: mGAT1 Membrane Preparation.
Membrane preparations of HEK293 cells stably expressing mGAT155
were prepared and applied as previously described.35,51,77
Library Screening. Library screening experiments were basically
performed as reported35,51 except for varying hydrazine and aldehyde
concentrations and buffer composition: Quadruplicate samples in a
total volume of 250 μL in 1.2 mL polysterene 96-deep-well plates
(Sarstedt) were employed. The incubation buffer contained 12.5 mM
Na2HPO4·2H2O, 12.5 mM NaH2PO4·H2O, 1 M NaCl, and 200 μM
sodium L-ascorbate, and the pH was adjusted to 7.1 with 2 M NaOH.
Solutions were added as 10-fold concentrated stock solutions, and all
samples contained 1% DMSO (final concentration). Aldehydes were
applied in a final concentration of 1.0 μM per sample (with each
aldehyde library representing a mixture of eight different aldehydes)
and hydrazines (rac-11, rac-12, rac-13, or rac-14, applied as
hydrochlorides)49 were applied in 200 μM. Directly after combining
the hydrazine and aldehydes, the mGAT1 membrane preparation was
added, which started the first incubation period of 4 h at 37 °C in a
shaking water bath (for library generation). Then MS marker 6 was
added in a concentration of 20 nM (final concentration in the sample),
starting the second incubation period of 40 min at 37 °C. Total binding
was determined with analogously constituted samples lacking any
inhibitor and nonspecific binding was determined in the presence of
100 mM GABA. All experiments additionally obtained matrix blanks,
zero samples, and matrix standards. The incubation was terminated by
vacuum filtration (96-well filter plate, Acroprep, glass fiber, 1.0 μm, 350
μL; Pall). After five washing steps with ice-cold aqueous 1 M NaCl, the
filter plates were dried at 50 °C for 60 min and cooled to room
temperature. The marker 6 was subsequently liberated by elution with
MeOH, and the eluate was collected in a 96-deep-well plate. To each
sample (except the matrix blanks) 200 μL of 1 nM [2H10]NO711 in
MeOH was added as internal standard. For calibration, blank matrix
was supplemented with 200 μL of methanolic calibration standards
with 20 pM, 50 pM, 100 pM, 200 pM, 500 pM, 1.0 nM, 2.5 nM, and 5.0
nM NO711, respectively (these samples were employed for generating
calibration curves for marker quantitation). All samples were dried to
completeness at 50 °C for 16 h and subsequently reconstituted in 200
μL of 10 mM ammonium formate buffer (pH 7.0) containing 5%
MeOH. Quantification was performed by LC-ESI-MS/MS. As a
control, analogous samples were employed in the library screening
experiments for characterizing specific binding of pure aldehyde
libraries and pure hydrazines (rac-11, rac-12, rac-13, or rac-14, applied
as hydrochlorides),49 respectively.
Deconvolution Experiments. The deconvolution experiments
were analogously performed as the library screening experiments (as
described above), but instead of a mixture of eight aldehydes, single
aldehydes (1.0 μM per sample) were applied.
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Competition Experiments for Establishing Binding Affinities
of Hydrazones. Full-scaleMS binding experiments were performed as
previously described38,77 by applying pure hydrazones54 and the
incubation buffer as described under “Library screening”.
Saturation Experiments for Investigation of Test Com-
pounds’ Mode of Interaction. MS based saturation experiments
with NO711 as reporter ligand (concentration range: 2.5−480 nM)
addressing mGAT1 were performed as previously described.38,77 Pure
hydrazones54 and tiagabine were added in the desired concentrations to
the binding samples before incubation was started by addition of the
mGAT1 membrane preparation. All other conditions (e.g., incubation
buffer, filtration, and washing of binding samples, drying of eluates, and
reconstitution of samples) were exactly the same as described under
“Library screening”.
LC-ESI-MS/MS. Quantification by LC-ESI-MS/MS was performed
on an API 3200 or 3200 Q TRAP triple-quadrupole mass spectrometer
(AB Sciex). The injection volume was always 30 μL, and the LC
conditions were exactly as described previously.38 Detailed instrument
settings of the mass spectrometers are specified in the Supporting
Information.
Data Analysis in mGAT1MS Binding Assays. Data analysis was
performed as previously described.35,38,51,77 Binding affinities for test
compounds are expressed as pKi values (with Ki values calculated
according to Cheng and Prussoff,78 taking into account that the
investigated test compounds and NO711 may not address the same
binding site, the Ki values could be considered as apparent Ki values).
Affinities (Kd) for NO711 and densities of binding sites (Bmax) in the
absence or presence of test compounds were calculated from saturation
isotherms. Bmax values are given in [pmol/(mg protein)], Kd values in
[nM]. All results represent means ± SEM, determined in at least three
separate experiments. To distinguish between competitive and
noncompetitive binding interactions between test compounds and
the reporter ligand NO711, a Schild-like coefficient was calculated
according to Hulme and Trevethick58 with coefficient = [log
(Kd_NO711_app/Kd_NO711 − 1)higher concentrated test compound − log-
(Kd_NO711_app/Kd_NO711 −1)lower concentrated test compound]/[log (higher
concentration test compound) − log (lower concentration test
compound)]
GABA Uptake Assays. [3H]GABA uptake assays were performed
as previously described,55 except that 200 μM sodium L-ascorbate was
added to all samples as antioxidant.
MS Transport Assays: Competitive MS Transport Assays.
Competitive MS Transport Assays were performed as reported,64,65
except that sodium L-ascorbate (200 μM) was added to all samples
(including controls) as antioxidant.
Saturation Experiments for Investigation of Test Com-
pound’s Mode of Interaction by Means of MS Transport
Assays. Saturation experiments by means ofMS Transport Assays with
COS cells stably expressing hGAT1 were performed as previously
described,64,65 except that sodium L-ascorbate (200 μM) was added to
all samples as antioxidant. Pure hydrazones rac-16gf and rac-16gg and
tiagabine (5), respectively, were added in the desired concentrations to
the samples containing the COS-hGAT1 cells, and after preincubation
for 25 min, the addition of (2H6)GABA started the uptake. Vmax and Km
values in the absence or presence of test compound were calculated
from saturation isotherms. Vmax values are given in [amol/cell·min], Km
values in [μM]. All results represent means± SEM, determined in three
separate experiments.
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Simon, Á. Major human γ-aminobutyrate transporter: in silico
prediction of substrate efficacy. Biochem. Biophys. Res. Commun. 2007,
364, 952−958.
(32) Wein, T.; Wanner, K. T. Generation of a 3D model for human
GABA transporter hGAT-1 usingmolecular modeling and investigation
of the binding of GABA. J. Mol. Model. 2010, 16, 155−161.
(33) Skovstrup, S.; Taboureau, O.; Braüner-Osborne, H.; Jørgensen,
F. S. Homology modelling of the GABA transporter and analysis of
tiagabine binding. ChemMedChem 2010, 5, 986−1000.
(34) Wein, T.; Petrera, M.; Allmendinger, L.; Höfner, G.; Pabel, J.;
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A B S T R A C T
The γ-aminobutyric acid (GABA) transporter mGAT4 represents a promising drug target for the treatment of
epilepsy and other neurological disorders; however, the lack of highly potent and selective inhibitors for mGAT4
still retards its pharmacological elucidation. Herein, the generation and screening of pseudostatic combinatorial
hydrazone libraries at the murine GABA transporter mGAT4 for the search of novel GABA uptake inhibitors is
described. The hydrazone libraries contained more than 1100 compounds derived from nipecotic acid deriva-
tives substituted at the 5-position instead, as common, at the 1-position of the core structure. Two hits were
found and evaluated, which display potencies in the lower micromolar range at mGAT4 and its human
equivalent hGAT3. These compounds possess a lipophilic moiety derived from a biphenyl residue attached to the
5-position of the hydrophilic nipecotic acid moiety via a three-atom spacer. Thus, the novel structures with
potencies close to that of the bench mark mGAT4 inhibitor (S)-SNAP-5114 add new insights into the struc-
ture–activity relationship of mGAT4 inhibitors and could provide a promising starting point for the development
of new mGAT4 inhibitors with even higher potencies.
1. Introduction
Worldwide, about 50 million people suffer from epilepsy making
this disease one of the most prevalent neurological disorders globally1
associated with a high economic burden.2,3 The principal inhibitory
neurotransmitter in the CNS is γ-aminobutyric acid (GABA; 1; Fig. 1)
and an impaired GABAergic neurotransmission has been demonstrated
to play a dominant role in the pathophysiology of epilepsy.4–7 For
treatment, reduced GABAergic neurotransmission can be adjusted by
agonists of GABA receptors, by inhibition of catabolic enzymes or by
targeting GABA transport proteins.8 Four subtypes of membrane bound
GABA transporters (GATs) from the solute carrier 6 (SLC6) gene family
are known that are designated as mGAT1, mGAT2, mGAT3 and mGAT4
when expressed in mice; due to inconsistent nomenclature in depen-
dence on the species from which the transporters are cloned, for all
other species, and also adopted by the Human Genome Organization
(HUGO), they are termed as GAT1 (≙ mGAT1), BGT1 (≙ mGAT2),
GAT2 (≙ mGAT3) and GAT3 (≙ mGAT4).9,10 Amongst the four different
subtypes, mGAT1 and mGAT4 are predominately found in the mam-
malian brain closely to GABAergic synapses and remove GABA from the
synaptic cleft by utilizing a sodium- and chloride-dependent trans-
port.11–13 mGAT1 is mainly located on presynaptic neurons mediating
neuronal GABA uptake, whereas mGAT4 is mainly located on astrocytes
mediating glial GABA uptake, while mGAT2 and mGAT3 are weakly
expressed in most parts of the brain.14–16mGAT1 is a well-known target
for achieving anticonvulsant effects and several potent and selective
mGAT1 inhibitors such as tiagabine (2) and structurally related com-
pounds have been developed.17–20 Tiagabine (2) was approved as add-
on treatment of partial-onset seizures and is the only GAT inhibitor in
clinical use up to now21,22; main drawbacks, however, are its side ef-
fects including dizziness, asthenia, nervousness, tremor, diarrhea, and
depression.23,24 Conversely, for mGAT4 as well as for the other GABA
transporter subtypes (mGAT2 and mGAT3) there is a lack of highly
potent inhibitors that could be employed as pharmacological tools for
elucidating the therapeutic potential of inhibitors of these GAT sub-
types. Hence, the functional role of the other GABA transporter sub-
types still has to be elucidated in more detail, although particularly
mGAT2 and mGAT4 are already considered as promising drug targets
for the treatment of epilepsy and other neurological disorders such as
anxiety and pain.9,12,13 In the more recent years several efforts have
been undertaken to synthesize and evaluate potential ligands of dif-
ferent GAT subtypes25–30; thereby, compounds could be identified with
selectivities for mGAT2–mGAT4, although their potencies are re-
markably lower than those of potent mGAT1 inhibitors. The compound
(S)-SNAP-5114 (3) represented the first prototypic inhibitor with
moderate potency at and selectivity for mGAT431 and chemically more
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stable carba analogs of this trityloxy derivative 3 could be synthesized
later, of which DDPM-1457 (4) displays similar potency.32 Most of the
potent and selective GAT inhibitors with selectivities for either mGAT1
or mGAT4 are typically derivatives of small cyclic amino acids such as
nipecotic acid (5), of which the hydrophilic amino acid moiety is sub-
stituted with lipophilic aromatic residues attached to the amino group
(i.e. the 1-position of the piperidine moiety) via a linker. Notably, ni-
pecotic acid (5) itself displays already reasonable potency at different
GAT subtypes; however, it is nearly inactive in vivo due to limited
blood–brain barrier permeability as a direct consequence of its high
polarity.33 Besides, a series of isatin derivatives including compound 6
was more recently reported representing a new class of mGAT4 in-
hibitors structurally distinctly different from aforementioned nipecotic
acid (5) derivatives.34
Herein, we describe the screening of hydrazone libraries, generated
by dynamic combinatorial chemistry (DCC), at mGAT4 with the aim of
exploring novel structures as potential GABA uptake inhibitors.
2. Results and discussion
2.1. Structures of hydrazone libraries
Most recently, we generated and screened hydrazone libraries at
mGAT1 for exploring an uncommon substitution pattern of nipecotic
acid (5) derivatives as means of obtaining novel bioactive compounds.
Based on in silico studies the 5-position of the nipecotic acid (5) core
structure instead of the common 1-position was substituted with aro-
matic residues attached to it via a spacer. In order to enable a vast and
easy to perform structural variation of the lipophilic moiety library
generation and screening was performed according to an established
procedure.35,36 This proven procedure combines the formation of
combinatorial hydrazone libraries with the read-out of their binding
affinities towards mGAT1 by means of mass spectrometry based binding
assays (MS Binding Assays). This approach is described in detail else-
where (as well as the syntheses of hydrazines rac-7–rac-11 and the
compilation of aldehyde libraries 12, see below).37,38 Despite being
possibly prone to hydrolysis, the hydrazone function has proven to
represent a well-suited linker with sufficient stability also in presence of
the biological target material; it allowed the identification of new
highly potent inhibitors for the GABA transporter mGAT1 bearing a
hydrazone function in the spacer as already demonstrated, pre-
viously.35,36
Considering that the nipecotic acid (5) moiety is also present as
parent structure in prototypic mGAT4 inhibitors such as (S)-SNAP-5114
(3), the aforementioned combinatorial hydrazone libraries containing
the same nipecotic acid (5) derivatives, bearing an extraordinary sub-
stitution pattern and a vast diversity of lipophilic residues, were utilized
for a new screening campaign for mGAT4 inhibitors as described
herein. As in the mentioned previous approaches, hydrazone libraries
were generated by reacting hydrophilic building blocks possessing a
hydrazine function with lipophilic building blocks equipped with an
aldehyde function. The hydrazine function was attached to the 5-posi-
tion of nipecotic acid (5) directly (rac-7) or via a spacer containing one
(rac-8 and rac-9) or two C-atoms (rac-10 and rac-11) and the linker
residue was either cis- (rac-7, rac-8 and rac-10) or trans-oriented (rac-9
and rac-11) with respect to the carboxylic acid function in 3-position of
the piperidine ring (note that commercially available, achiral methyl 5-
hydroxynicotinate was used as starting material for the syntheses of all
hydrazines, the latter of which were accordingly obtained as race-
mates37). By reaction with appropriate aldehydes 12 these nipecotic
acid (5) derived hydrazines were converted into the corresponding
hydrazones with a three (rac-13), four (rac-14 and rac-15) and five
Fig. 1. Structures of GABA and selected GABA uptake inhibitors.
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atom spacer (rac-16 and rac-17; Scheme 1). As pattern for the lipophilic
moiety a total of 224 mostly aromatic aldehydes grouped in 28 alde-
hyde libraries was employed (Fig. 2) and combined separately with all
five hydrazines, rac-7–rac-11. As these 140 libraries comprise more
than 1,100 compounds their screening at mGAT4 could be expected to
reveal new insights into the structure–activity relationship and to yield
potentially new scaffolds for mGAT4 inhibitors.
2.2. Generation and screening of hydrazone libraries
In contrast to the screening at mGAT1, which is based on MS
Binding Assays using LC-MS/MS quantification of the non-labelled
GAT1-selective inhibitor NO711 as reporter ligand, binding assays for
screening at mGAT4 are, due to the lack of ligands with sufficient af-
finity, up to now not available. Accordingly, in this present approach
we tried to combine combinatorial generation of pseudostatic hy-
drazone libraries with the [3H]GABA uptake assay routinely used in our
group (described in detail by Kragler et al. 39,40). As this functional
assay is based on intact HEK cells stably expressing mGAT4 (in contrast
to the MS based screening at mGAT1, for which membrane fragments
were utilized), library generation and screening had to be decoupled,
due to the conditions required for in situ library generation that would
severely impair viability of the cells. Therefore, combinatorial hy-
drazone libraries were generated by preincubating the concentrated
mixture of a single hydrazine (from a 10mM stock solution in phos-
phate buffer) with each aldehyde library containing eight individual
aldehydes (each in a concentration of 100 µM in a stock solution in
DMSO) for 30–40min. The hydrazine was used in large excess com-
pared to aldehydes (5mM hydrazine versus 400 µM total aldehyde
concentration during preincubation) in order to speed up hydrazone
formation and most of all to achieve a constant library composition
even if a thermodynamic equilibrium were operating; that way, the
dynamic combinatorial libraries were rendered pseudostatic (i.e. forced
to a fixed composition). To prove that these conditions appeared ap-
propriate to guarantee quantitative hydrazone formation, control ex-
periments were carried out: Therefore, hydrazone formation was ex-
emplarily performed with all five hydrazines, rac-7–rac-11, which were
individually reacted with aldehyde 12w. This aldehyde, 12w, had been
demonstrated in previous approaches to be comparatively slower re-
acting than other evaluated aldehydes (in experiments performed under
identical conditions, i.e. solvent composition and concentrations), when
preparing the libraries for the screening experiments.35,37 When the
progress of the reactions was monitored by 1H NMR, the signal of the
aldehyde proton of 12w was found to completely (for reactions with
rac-7–rac-9) or nearly completely (rac-10 and rac-11) disappear within
10min after mixing the individual building blocks (note that the al-
dehyde was observed to be in equilibrium with the geminal diol of its
hydrate form, the latter of which also disappeared during hydrazone
formation). Within the same time, the 1H NMR signal resulting from the
formed hydrazone grew to full intensity indicating an almost quanti-
tative to quantitative hydrazone formation within 10min and even
more in the set time period for library generation (30–40min).
The libraries that were formed according to the abovementioned
procedure are termed “cis-C0”, “cis-C1”, “trans-C1”, “cis-C2” and “trans-
C2” for hydrazones derived from rac-13, rac-14, rac-15, rac-16 and rac-
17, respectively, throughout this paper to indicate their relative con-
figurations and different spacer lengths (Fig. 3).
As we aimed to screen for compounds with low micromolar or
submicromolar potency, the original pseudostatic hydrazone libraries
were diluted to a final concentration of 1 µM (1 µM for each hydrazone)
and studied for their inhibitory potencies in [3H]GABA uptake assays
for mGAT4. Libraries were considered active, if they reduced remaining
[3H]GABA uptake below 50%. Given the large number of compounds
included in the library screening, we decided to use this single, strict
“activity criterion” (i.e. reduction of remaining GABA uptake below
50% at a concentration of 1 µM of each library component) in order to
screen exclusively for the most active compounds. The results of the
screening process, i.e. the percentage of remaining [3H]GABA uptake in
the presence of each of the 140 hydrazone libraries, are summarized in
Table 1.
The hydrazone libraries showed a broad range of inhibitory po-
tencies, but only two fulfilled the “activity criterion” by reducing re-
maining [3H]GABA uptake below 50% (by mean values of three re-
plicates), that were cis-C0 hydrazone library 9 and cis-C0 hydrazone
library 24 with remaining [3H]GABA uptake of 45% for each.
Interestingly, both “active” libraries are derived from hydrazone rac-13
and thus represent the compounds with the shortest spacer lengths (i.e.
three atoms) of all analogs. Notably, the hydrazines rac-7–rac-11, when
tested in pure form without prior preincubation with an aldehyde li-
brary, did not show any remarkable activity in concentrations of
100 µM.
After the initial screening step, the two libraries found to be “active”
were subjected to deconvolution experiments in order to identify their
most active components. The deconvolution experiments were per-
formed in the same way as the screening experiments except that only a
single hydrazone was generated and applied by employing only a single
aldehyde instead of a library representing a mixture of eight com-
pounds. The results from [3H]GABA uptake assays obtained for in-
dividual components of cis-C0 hydrazone libraries 9 and 24 are sum-
marized in Table 2. None of the 16 hydrazones from the two most
“active” libraries reduced remaining [3H]GABA uptake below 50%.
Hence, the inhibitory potencies observed for both libraries in the initial
screening appear to be the result of additive effects rather than due to a
single component with submicromolar potency (and besides additive
effects, inevitable variations associated with the application of a func-
tional biological test system based on living cells, which on their own
have only minor effects, could cumulatively cause a degree of scattering
that may also be an explanation for these discrepancies). However, the
two most active hydrazones from deconvolution, i.e. rac-13bq and rac-
13bt, still reduced remaining [3H]GABA uptake to a remarkable extent
with mean values of 69% and 72%, respectively. These two “active”
hydrazones were both contained in cis-C0 hydrazone library 9, while
surprisingly none of the individual components of library 24 reduced
uptake substantially. Being the most active compounds and hence re-
presenting the hits from these screening and deconvolution experi-
ments, the two hydrazones rac-13bq and rac-13bt were subjected to
further analysis in order to establish their inhibitory potencies (pIC50)
and subtype selectivities.
Scheme 1. Condensation of nipecotic acid derived
hydrazines rac-7–rac-11 with diverse aldehydes 12 to
afford hydrazones with general structures rac-
13–rac-17 (each hydrazine and hydrazone, respec-
tively, was obtained as racemate as indicated in this
scheme; for the sake of simplicity, only one en-
antiomer is depicted in the following schemes and
figures).
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2.3. Hit verification
For hit verification, the two most active hydrazones, rac-13bq and
rac-13bt, were each separately synthesized in pure form. To this end,
hydrazine rac-7 was reacted with aldehydes 12bq and 12bt, respec-
tively, yielding corresponding hydrazones rac-13bq and rac-13bt as
shown in Table 3.
In order to demonstrate that these hydrazones, rac-13bq and rac-
13bt (synthesized in pure form and without excessive hydrazine as
applied during the screening experiments), show sufficient hydrolytic
stability for the subsequent full-scale GABA uptake assays, we per-
formed control experiments. To this end, the hydrazones were diluted
Fig. 2. Libraries consisting of aldehydes 12a–12hp.
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in the incubation buffer (containing millimolar concentrations of salts,
glucose and tris(hydroxymethyl)aminomethane; pH=7.2),40 to which
GABA (1) was added, and the solution was monitored by 1H NMR at
37 °C over 2.5 h (corresponding 1H NMR spectra of hydrazone rac-13bq
are exemplarily shown in Fig. 4). During the kinetic experiments no
degradation of the hydrazones could be observed and both rac-13bq
and rac-13bt appeared stabile at 37 °C over the observation period
(2.5 h). Accordingly, it may be concluded that the incubation buffer as
well as the presence of GABA (1), as to be utilized during the corre-
sponding GABA uptake assays, does not affect the hydrazone stability,
even when the hydrazones were applied in pure form and without ex-
cessive hydrazine (as it is the case during screening experiments to
render hydrazone libraries pseudostatic).
Both hydrazones were then tested for their inhibitory potencies at
mGAT4 as well as at the other three GABA transporter subtypes
(mGAT1–mGAT3) in order to determine their subtype selectivities.
Therefore, full-scale [3H]GABA uptake assays were performed using
HEK cells stably expressing mGAT1–mGAT439,40; the data from which
were used to generate the respective concentration-inhibition curves
and calculation of IC50 values. In order to confirm potencies and to
establish IC50 values also at the human equivalent of this GABA trans-
porter subtype, both compounds were additionally characterized at
hGAT3 in competitive MS based GABA transport experiments (MS
Transport Assays)41,42 utilizing COS cells stably expressing hGAT3. The
results obtained in these experiments are summarized (as pIC50 values)
in Table 4. For hydrazone rac-13bq pIC50 values of 5.27 at mGAT4 and
5.56 at hGAT3 and for rac-13bt of 4.99 at mGAT4 and 5.03 at hGAT3,
respectively, were established. Notably, the pIC50 values of rac-13bq
and rac-13bt at hGAT3 are close to that of bench mark mGAT4/hGAT3
inhibitor (S)-SNAP-5114 (3), while the pIC50 values at mGAT4 are
somewhat lower for the hydrazones as compared to 3 (with the nominal
difference amounting to 0.38–0.66 log units). In this context it is worth
mentioning that the hydrazones are, in contrast to (S)-SNAP-5114 (3),
racemic, providing the possibility that the corresponding eutomers
could be even a bit more potent. Furthermore, the inhibitory potencies
of the two hydrazones, rac-13bq and rac-13bt, at both mGAT4 and
hGAT3 appear nominally slightly superior (or at least similarly, i.e. for
rac-13bt at hGAT3) than those of isatin derivative 6 as a yet published
example of a non-nipecotic acid (5) derived GAT inhibitor. Thus, the
hydrazones rac-13bq and rac-13bt represent novel mGAT4 and hGAT3
inhibitors, respectively, with promising potencies in the lower micro-
molar range. Thereby, the inhibitory potency of rac-13bq at mGAT4
and hGAT3 appears to be slightly superior to that of rac-13bt.
The inhibitory potency of hydrazone rac-13bt at mGAT1 and
mGAT2 appears to be too low to reduce [3H]GABA uptake to 50% or
below, even at a concentration of 100 µM. Hence, no pIC50 value could
be determined using 100 µM as the highest test concentration, but it
may be concluded that the pIC50 values of rac-13bt at these two
transporters are likely to be lower than 4.0. Thus, both hydrazones, rac-
13bq and rac-13bt, are at least one order of magnitude more potent
towards mGAT4 than towards mGAT1 and mGAT2, respectively, in-
dicating a reasonable subtype selectivity over the latter two GAT sub-
types. Conversely, for both hydrazones rac-13bq and rac-13bt pIC50
values at mGAT3 are similar to those at mGAT4 indicating a poor
subtype selectivity for mGAT4 over mGAT3. This is, however, a pro-
blem frequently observed for other mGAT4 inhibitors reported in lit-
erature.27,32,40,42 For both hydrazones, rac-13bq and rac-13bt, the li-
pophilic domains are derived from a biphenyl moiety; while a biphenyl
moiety is well known as a lipophilic domain of mGAT1 inhibitors,36,43 it
is to our knowledge unprecedented for mGAT4 inhibitors with high
potencies (pIC50≥5).
Fig. 3. Example for the conversion of aldehyde library 3 with hydrazine rac-7 into cis-C0 hydrazone library 3.
T.J. Hauke et al.
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3. Conclusion
In summary, the generation and screening of combinatorial hy-
drazone libraries derived from 5-substituted nipecotic acid (5) deriva-
tives at mGAT4 is described herein. The hydrazone libraries were ren-
dered pseudostatic and contained more than 1,100 individual
compounds with varying spacer lengths and lipophilic moieties. The
generated libraries were screened in a functional assay for their in-
hibitory potencies at mGAT4, i.e. in [3H]GABA uptake experiments
using HEK cells stably expressing this target. With hydrazones rac-13bq
and rac-13bt two hits were obtained from the screening and deconvo-
lution experiments. Hit verification revealed a promising potency at
mGAT4 of these two compounds only slightly inferior to that of best
prototypic mGAT4 inhibitors known so far. These compounds, rac-13bq
and rac-13bt, possess a novel structural scaffold for this kind of
bioactive compounds, comprising a 5-substitution instead of the
common 1-substitution of the nipecotic acid (5) moiety, as well as bi-
phenyl residues as lipophilic domaines. There is still a lack of highly
potent and selective mGAT4 inhibitors that would allow to elucidate
the pharmacological role of this GABA transporter subtype, which is
thought to be a promising drug target. The two hydrazones described
herein represent new structural motifs for mGAT4 inhibitors, which
could serve as useful starting points for further exploring structure–-
activity relationship of mGAT4 inhibitors and facilitate the rational
design of new ligands with higher potencies at this molecular target.
4. Experimental section
4.1. Chemistry
4.1.1. General methods
NMR spectroscopy was performed on an Avance III HD Bruker
BioSpin spectrometer (Bruker; 1H NMR: 500MHz, 13C NMR: 126MHz,
19F NMR: 376MHz) equipped with a CryoProbeTM Prodigy broadband
probe head; the spectra were processed with the NMR software
MestReNova, version 12.0 (Mestrelab Research S.L.). Chemical shifts
were referenced to DMSO solvent signals (1H NMR: 2.53 ppm; 13C
NMR: 39.13 ppm). High-resolution mass spectrometry (ESI) was per-
formed with Thermo Finnigan LTQ FT Ultra mass spectrometer
(ThermoFischer Scientific). Syntheses of hydrazines rac-7–rac-11,
which were applied as hydrochlorides, and compilation of libraries
containing aldehydes 12a–12hp are described elsewhere.37,38 For hit
verification individual hydrazones were synthesized in sealed 1.5mL
tubes under Ar. Reaction progress (determined by integration of the
remaining signal of the aldehyde proton) was monitored by 1H NMR.
All NMR and HRMS measurements as well as the GABA uptake assays
were performed using the 10mM hydrazone solutions without further
purification or drying.
4.1.2. Synthesized compounds
4.1.2.1. rac-(3R,5S)-{5-[(E)-2-({4′-Chloro-4-fluoro-[1,1′-biphenyl]-2-yl}
methylidene)hydrazin-1-yl]piperidine-3-carboxylic acid}–sodium chloride
(1/2), (rac-13bq). To DMSO‑d6 (850 µL) a 200mM stock solution of
rac-7 in D2O (50 µL, 0.010mmol), a 1M solution of NaOD in D2O
(20 µL, 0.020mmol) and D2O (30 µL) were added to reach a total
volume of 950 µL. The reaction was started by the addition of a 200mM
stock solution of 4′chloro 4 fluoro [1,1′biphenyl] 2carbaldehyde (12bq)
in DMSO‑d6 (50 µL, 0.010mmol). The mixture was sonicated for 5min
and stored at rt over night to obtain rac-13bq in solution (remaining
aldehyde≤2%).
1H NMR (500MHz, DMSO‑d6/D2O=9:1, 25 °C): δ=1.36 (q,
J=12.2 Hz, 1H), 2.18 (d, J=12.7 Hz, 1H), 2.35–2.46 (m, 1H),
Table 1
Screening of cis-C0 (rac-13), cis-C1 (rac-14), trans-C1 (rac-15), cis-C2 (rac-16)
and trans-C2 hydrazone libraries (rac-17) at mGAT4.
library remaining [3H]GABA uptake [%]a
cis-C0 cis-C1 trans-C1 cis-C2 trans-C2
library 1 122 ± 4 113 ± 0.4 107 ± 10 113 ± 29 122 ± 18
library 2 118 ± 20 81 ± 8 113 ± 16 106 ± 20 125 ± 11
library 3 113 ± 4 80 ± 34 102 ± 10 90 ± 5 98 ± 8
library 4 118 ± 8 97 ± 12 112 ± 8 95 ± 18 106 ± 13
library 5 116 ± 4 75 ± 2 133 ± 27 95 ± 10 100 ± 8
library 6 100 ± 13 66 ± 12 110 ± 8 89 ± 8 97 ± 14
library 7 87 ± 15 61 ± 6 105 ± 5 92 ± 16 61 ± 19
library 8 88 ± 9 88 ± 12 114 ± 1 84 ± 8 89 ± 15
library 9 45 ± 6 76 ± 3 99 ± 28 102 ± 27 89 ± 14
library 10 72 ± 22 55 ± 3 106 ± 11 91 ± 10 112 ± 8
library 11 109 ± 2 71 ± 7 101 ± 11 82 ± 18 66 ± 5
library 12 112 ± 13 75 ± 10 126 ± 34 86 ± 13 106 ± 2
library 13 90 ± 8 78 ± 18 123 ± 14 97 ± 18 98 ± 9
library 14 83 ± 8 91 ± 0.4 123 ± 21 85 ± 6 85 ± 17
library 15 89 ± 15 80 ± 6 112 ± 6 82 ± 5 92 ± 6
library 16 129 ± 6 92 ± 5 108 ± 14 87 ± 19 87 ± 15
library 17 64 ± 8 82 ± 20 111 ± 19 71 ± 14 79 ± 8
library 18 80 ± 7 78 ± 19 107 ± 11 90 ± 5 74 ± 25
library 19 88 ± 6 81 ± 4 123 ± 12 85 ± 16 86 ± 14
library 20 91 ± 16 56 ± 4 107 ± 7 84 ± 13 63 ± 4
library 21 93 ± 10 67 ± 3 92 ± 4 93 ± 5 58 ± 15
library 22 98 ± 10 92 ± 9 99 ± 17 103 ± 7 67 ± 6
library 23 105 ± 12 65 ± 5 109 ± 29 77 ± 18 73 ± 15
library 24 45 ± 6 64 ± 3 109 ± 6 60 ± 11 61 ± 12
library 25 94 ± 7 82 ± 16 110 ± 20 105 ± 16 83 ± 9
library 26 82 ± 12 75 ± 12 118 ± 17 109 ± 19 72 ± 17
library 27 86 ± 4 71 ± 12 108 ± 42 85 ± 3 57 ± 2
library 28 78 ± 11 64 ± 3 101 ± 16 92 ± 13 67 ± 16
only hydrazineb 116 ± 8 92 ± 13 86 ± 6 102 ± 19 85 ± 10
a Percentage of remaining [3H]GABA uptake in the presence of corre-
sponding pseudostatic hydrazone libraries containing eight components each in
a concentration of 1 µM; data represent means ± SD of three replicates. The
limit for further analysis of a hydrazone library was defined as 50% remaining
[3H]GABA uptake (libraries considered “active” are highlighted in bold letters).
b Pure hydrazines rac-7, rac-8, rac-9, rac-10 and rac-11, respectively, were
applied in a concentration of 100 µM for control.
Table 2
Deconvolution of cis-C0 hydrazone libraries (rac-13) considered “active” at
mGAT4.
library cis-C0 hydrazone remaining [3H]GABA uptake [%]a
library 9 rac-13bm 90 ± 4
rac-13bn 96 ± 11
rac-13bo 83 ± 18
rac-13 bp 84 ± 5
rac-13bq 69 ± 1
rac-13br 92 ± 11
rac-13bs 89 ± 5
rac-13bt 72 ± 7
library 24 rac-13gc 95 ± 5
rac-13gd 96 ± 4
rac-13ge 88 ± 8
rac-13gf 102 ± 7
rac-13gg 86 ± 4
rac-13gh 85 ± 6
rac-13gi 92 ± 8
rac-13gj 93 ± 6
a Percentage of remaining [3H]GABA uptake in the presence of individual
cis-C0 hydrazones in a concentration of 1 µM; data represent means ± SD of
three replicates. Values of hydrazones chosen for further analysis are high-
lighted in bold letters.
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2.47–2.59 (m, 1H), 2.63 (t, J=12.3 Hz, 1H), 3.25 (dd, J=12.5/
4.1 Hz, 1H), 3.30 (dd, J=11.7/4.2 Hz, 1H), 3.36 (tt, J=11.0/4.0 Hz,
1H), 7.17 (td, J=8.4/2.7 Hz, 1H), 7.25–7.35 (m, 3H), 7.50–7.53 (m,
3H), 7.58 (dd, J=10.6/2.7 Hz, 1H) ppm. 13C NMR (126MHz,
DMSO‑d6/D2O=9:1, 25 °C): δ=32.45, 40.50, 45.92, 47.27, 52.71,
110.02 (d, JCF=23.0 Hz), 114.60 (d, JCF=25.4 Hz), 128.48, 131.41,
132.32 (d, JCF=9.0 Hz), 132.37, 133.81, 134.70 (d, JCF=2.7 Hz),
135.34 (d, JCF=8.0 Hz), 137.52, 161.77 (d, JCF=243.2 Hz),
174.07 ppm. 19F {1H} NMR (376MHz, DMSO‑d6/D2O=9:1, 25 °C):
δ=-114.33 ppm. HRMS (ESI): [M+H]+ calcd. for C19H20N3O2ClF,
376.1223; found: 376.1224.
Besides the major E-isomer the Z-isomer was present in 8% ac-
cording to 1H NMR; in addition to the signals listed for the E-isomer
NMR spectra showed signals of low intensity corresponding to the Z-
isomer. Peaks for the protons of OH and NH groups disappeared due to
deuterium exchange and corresponding signals were not detectable in
the 1H NMR spectrum.
4.1.2.2. rac-(3R,5S)-{5-[(E)-2-[(2-{[1,1′-Biphenyl]-4-yl}phenyl)
methylidene]hydrazin-1-yl]piperidine-3-carboxylic acid}–sodium chloride
(1/2), (rac-13bt). To DMSO‑d6 (850 µL) a 200mM stock solution of
rac-7 in D2O (50 µL, 0.010mmol), a 1M solution of NaOD in D2O
(20 µL, 0.020mmol) and D2O (30 µL) were added to reach a total
volume of 950 µL. The reaction was started by the addition of a 200mM
stock solution of 2-{[1,1′biphenyl] 4yl}benzaldehyde (12bt) in
DMSO‑d6 (50 µL, 0.010mmol). The mixture was sonicated for 5min
and stored at rt over night to obtain rac-13bt in solution (remaining
aldehyde≤7%).
1H NMR (500MHz, DMSO‑d6/D2O=9:1, 25 °C): δ=1.39 (q,
J=12.3 Hz, 1H), 2.22 (d, J=13.2 Hz, 1H), 2.44–2.61 (m, 2H), 2.68 (t,
J=12.4 Hz, 1H), 3.26–3.44 (m, 3H), 7.29–7.33 (m, 1H), 7.37–7.40 (m,
2H), 7.40–7.43 (m, 3H), 7.50–7.53 (m, 2H), 7.70 (s, 1H), 7.72–7.75 (m,
2H), 7.76–7.80 (m, 2H), 7.88–7.93 (m, 1H) ppm. 13C NMR (126MHz,
DMSO‑d6/D2O=9:1, 25 °C): δ=32.18, 39.81, 45.40, 47.02, 52.45,
124.71, 126.61, 126.68, 127.62, 127.68, 127.95, 129.13, 130.14,
130.15, 132.72, 136.36, 138.69, 139.03, 139.40, 139.54, 173.76 ppm.
HRMS (ESI): [M+H]+ calcd. for C25H26N3O2, 400.2020; found:
400.2020.
Besides the major E-isomer the Z-isomer was present in 10% ac-
cording to 1H NMR; in addition to the signals listed for the E-isomer
NMR spectra showed signals of low intensity corresponding to the Z-
isomer. Peaks for the protons of OH and NH groups disappeared due to
deuterium exchange and corresponding signals were not detectable in
the 1H NMR spectrum.
4.1.3. Monitoring of hydrazone formation for library generation by 1H
NMR
NMR samples were prepared by mixing 300 µL of a 10mM stock
solution of the corresponding hydrazine in phosphate buffer (1M NaCl,
12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 200 µM sodium L-ascorbate in
H2O; pH=7.1) with 300 µL of an 800 µM stock solution of aldehyde
12w in DMSO‑d6 directly in the NMR tube (resulting in an initial
concentration of 5mM hydrazine and 400 µM aldehyde after mixing).
The NMR kinetic experiments were performed at 25 °C using a
standard proton pulse sequence with water suppression by excitation
sculpting provided by the Bruker TopSpin pulse program library; the
spectra were recorded with 32 transients and a relaxation delay of 1 s.
The first NMR spectrum was measured 5min after sample preparation
and a 5min time increment was chosen for further measurements.35
4.1.4. Monitoring of hydrazone stability in incubation buffer by 1H NMR
For NMR sample preparation, to 480 µL “Krebs” buffer (119mM
NaCl, 2.5mM CaCl2, 1.2mM MgSO4, 1.2 mM KH2PO4, 4.7mM KCl,
11mM glucose, 25mM tris(hydroxymethyl)aminomethane;
pH=7.2)40 60 µL of a solution of 20mM sodium L-ascorbate and
400 µM GABA (1) in H2O and 60 µL of a 10mM solution of the corre-
sponding in DMSO‑d6/D2O (= 9:1) were added. The monitoring was
started after the addition of the hydrazone to the NMR tube.
The NMR kinetic experiments were performed at 37 °C using a
standard proton pulse sequence with water suppression by excitation
sculpting provided by the Bruker TopSpin pulse program library; the
spectra were recorded with 64 transients and a relaxation delay of 1 s.
Table 3
Syntheses of cis-C0 hydrazones rac-13bq and rac-13bt in pure form.a
entry aldehyde R1 R2 hydrazoneb yield
1 12bq -F -Cl rac-13bq nearly quant.c
2 12bt -H -phenyl rac-13bt nearly quant.c
a Hydrazine rac-7 was applied as hydrochloride and stoichiometric amounts of NaOD were used to neutralize the introduced HCl.
b Besides the major E-isomer minor amounts (≤10%) of the Z-isomer were formed.
c The reaction was performed in deuterated solvents in order to be able to monitor reaction progress by 1H NMR. The hydrazones were used from this stock
solution for all further experiments without additional drying and purification.
Fig. 4. Excerpts of 1H NMR spectra (∼6–10 ppm, displaying hydrazone proton*
and aromatic region) of hydrazone rac-13bq diluted 1:10 to 1mM in Krebs
puffer (pH=7.2), to which 2mM sodium L-ascorbate and 40 µM GABA (1)
were added. The spectra were recorded 5min (1), 30min (2), 60min (3) and
150min (4) after sample preparation at 37 °C.
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The first NMR spectrum was measured 5min after sample preparation
and a 5min time increment was chosen for further measurements.37
4.2. Biological evaluation
4.2.1. Cells expressing GABA transporters
HEK cells stably expressing mGAT1–mGAT4 were prepared and
processed as described in reference40 and COS cells stably expressing
hGAT3 as in reference.42
4.2.2. Library generation and screening
For library generation a 10mM stock solution of the corresponding
hydrazine in phosphate buffer (1M NaCl, 12.5 mM Na2HPO4, 12.5mM
NaH2PO4, 200 µM sodium L-ascorbate in H2O; pH=7.1) was mixed 1:1
with a library stock solution in DMSO containing eight individual al-
dehydes each in a concentration of 100 µM; after vortexing the mixture
was kept at room temperature for 30–40min to allow quantitative
hydrazone library formation. To the thus preincubated mixture (20 µL)
a 20mM solution of sodium L-ascorbate in H2O (10 µL) and Krebs buffer
(2.5 mM CaCl2, 1.2 mM MgSO4, 1.2mM KH2PO4, 4.7 mM KCl, 11mM
glucose, 25mM Tris, 119mM NaCl, pH 7.2; 70 µL) were then added to
obtain solutions of hydrazones (10 µM) and sodium L-ascorbate (2mM)
10-fold concentrated compared to the intended final assay concentra-
tions.
The uptake assays for library screening were performed in triplicate
samples in a total volume of 250 µL Krebs buffer containing 1% DMSO
in the 96-well plate format basically as described for full-scale experi-
ments40 except that 200 µM sodium L-ascorbate was added to all sam-
ples and that the test compounds (i.e. hydrazone libraries) were added
only in a single concentration (1 µM for each library component with
remaining excessive hydrazine). In short, an aliquot of the suspension
of HEK cells stably expressing mGAT4 was equilibrated with the hy-
drazone libraries (added from the aforementioned preincubated and
diluted solution additionally containing sodium L-ascorbate; 25 µL) in a
shaking water bath at 37 °C for 25min. Then a solution of [3H]GABA
(8 nM final assay concentration) and unlabelled GABA (32 nM final
assay concentration) in Krebs buffer was added (25 µL) and it was
further incubated for 4min. The incubation was terminated by filtration
under reduced pressure. After rinsing with a cold 0.9% NaCl solution
the filters were transferred to a 96-well plate. Rotiszint Eco Plus (Roth)
was added (200mL per well) and the radioactivity was determined in a
MicroBeta liquid scintillation counter (Perkin Elmer LAS). Non-specific
uptake was defined in the presence of 1mM GABA accordingly and was
subtracted from total uptake to obtain specific uptake.
4.2.3. Deconvolution experiments
The deconvolution experiments were analogously performed as the
experiments with the libraries but employing single aldehydes (100 µM
per sample) instead of a mixture of eight aldehydes during preincuba-
tion for library generation; the test compounds’ resulting assay con-
centration was 1 µM.
4.2.4. [3H]GABA uptake assays
[3H]GABA uptake assays were performed as reported40 except that
sodium L-ascorbate (200 µM) was added to all samples as antioxidant.
4.2.5. MS Transport assays
Competitive MS Transport Assays were performed as reported42
except that sodium L-ascorbate (200 µM) was added to all samples as
antioxidant.
4.2.6. Data analysis
Data analysis was performed as reported.40,42 The results of
screening and deconvolution experiments are given as percentages of
remaining specific [3H]GABA uptake in the presence of corresponding
test compounds (either hydrazone libraries or single hydrazones)
compared to specific [3H]GABA uptake in absence of test compounds;
data represent means ± SD of three replicates. Inhibitory potencies of
test compounds from full-scale experiments with mGAT1–mGAT4
([3H]GABA uptake assays) and hGAT3 (MS Transport Assays) are given
as pIC50 values; IC50 values were determined by non-linear regression
using Prism 6 (GraphPad Software). The results are expressed as
means ± SEM of at least three separate experiments, each carried out
with triplicate samples.
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